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1DEMENTIA
The number of people with dementia worldwide is projected to triple in the coming thirty 
years, from 47 to 135 million.1 This amplification is mainly driven by population ageing; an 
increase in the number and proportion of older people.2 Dementia is a clinical diagnosis 
characterised by cognitive impairment that interferes with daily functioning.3 It has major 
impact on society at the micro- and macro-level. People with dementia have severely 
impaired quality of life, and face increasing disability and reduced life expectancy.4,5 The 
functional dependence associated with dementia leads to an increased burden on (in)
formal caregiving.6 The community as a whole is affected by costs of health- and social 
care, and loss in productivity, mainly due to informal care.5 The combined annual costs are 
estimated at almost 700 billion euros worldwide.5 Therefore, the G8 countries have agreed 
to take global action to reduce the dementia prevalence and burden, and have identified 
dementia prevention as a major public health priority.7
The two main subtypes of dementia are Alzheimer’s disease and vascular dementia.8 The 
first is neuropathologically characterized by beta-amyloid depositions (“plaques”) and 
hyperphosporylated tau (“tangles”), and the second by cerebrovascular lesions. It was 
long presumed that the two diseases occurred exclusive of one another. However, in the 
last decades it became apparent that the majority of persons with dementia have both 
neurodegenerative and cerebrovascular pathology.9 They also share common risk factors.10 
The most influential risk factor for dementia is age, with around 80% of persons with 
dementia being 75 years or older.11 Yet, more noteworthy are the potentially modifiable 
risk factors; midlife hypertension, diabetes, midlife obesity, physical inactivity, depression, 
smoking, hyperlipidaemia and low educational attainment.10,12 Up to a third of dementia 
cases may be attributable to these modifiable risk factors.10 
DEMENTIA PREVENTION TRIALS
The window of opportunity for interventions aimed at preventing dementia is large. It has 
been estimated, that if modifiable risk factors could be reduced by 10%, this could lead to 
a reduction in the prevalence of Alzheimer’s disease of 8% within forty years.10 This would 
sum up to 8.8 million people in whom dementia could be prevented. Initially, randomised 
controlled trials (RCTs) only included cognitive impairment and dementia as secondary 
outcome measures.13 In the last three years, the first trials with cognition or dementia as 
primary outcome have been published. The Finnish Geriatric Intervention Study to Prevent 
Cognitive Impairment and Disability (FINGER) and Multidomain Alzheimer Preventive Trial 
(MAPT) showed that a multi-domain intervention targeting several dementia risk factors 
could potentially have a beneficial effect on cognition within 2-3 years in an at risk 
population.14,15 The Prevention of Dementia by Intensive Vascular Care (preDIVA; box 1) trial, 
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however, did not show a beneficial effect on prevention of dementia within 6-8 years, in 
a general population aged 70-78 years.16 Researchers from these three trials united their 
efforts in the design and execution of the Healthy Ageing Through Internet Counselling in the 
Elderly (HATICE; box 1).17 This thesis is based on post hoc analyses in the preDIVA trial and 
two sub-studies in the HATICE trial.
Box 1 - Description of the preDIVA and HATICE trial
Prevention of Dementia by Intensive Vascular Care (preDIVA) is a Dutch cluster-
randomised controlled trial (RCT), which ran from 2006-2016.16 The trial studied 
the eﬀect of nurse-led vascular care during 6-8 years on incident all-cause dementia. Participants 
randomised to the intervention group had four-monthly visits to a practice nurse during which 
lifestyle and medical advice was given regarding blood pressure, cholesterol, weight, smoking, 
physical activity and diet. Participants in the control group received standard care. For the trial 
community-dwelling people aged 70-78 years, without dementia, were recruited at baseline. 
Every two years all participants visited a trial nurse, during which primary and secondary outcome 
measures were assessed, including cardiovascular risk parameters and cognition. After 6-8 years 
an independent outcome adjudication committee validated all possible dementia cases based 
on clinically available data.
Healthy Ageing Through Internet Counselling in the Elderly (HATICE), is an 
international RCT which ran from 2015-2018 on the eﬀect of an internet 
intervention for cardiovascular self-management to reduce the risk of 
cardiovascular disease and dementia.17 For HATICE, people aged 65 years and 
older at increased cardiovascular risk were recruited to participate in the Netherlands, Finland 
and France. Intervention participants gained access to an interactive internet platform with 
remote support by a coach and several other functionalities to facilitate self-management, such 
as the ability to enter measurements and set goals.18 The control group gained access to a 
platform with static information. After 18 months the eﬀect of the intervention on a composite 
score containing systolic BP, low-density lipoprotein cholesterol and body-mass index, was 
assessed.
BLOOD PRESSURE AND COGNITION
Though the main result of the preDIVA trial was neutral, a significant effect of the intervention 
was seen among participants with untreated hypertension at baseline who were adherent 
to the intervention.16 This suggests that older people with hypertension could be a good 
target population for preventive interventions and that BP-lowering interventions might 
be paramount. Because of the high prevalence of hypertension and its effective and 
widely implemented treatment, it is also a feasible target. In this thesis, I therefore focus on 
prevention of dementia through blood pressure (BP) management. 
There is a clear association between a high BP in midlife and an increased risk of dementia 
in late life.10 A high BP may cause microvascular dysfunction and damage leading to 
cerebrovascular lesions and, in turn, cognitive decline.19 With BP in late life this relation is 
11
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less straightforward. The association between mean BP in late life and dementia may follow 
a J-shaped curve, meaning that both a high and low BP are associated with an increased risk 
(Figure 1).20 Trials that assessed the effect of BP-lowering interventions on incident dementia 
are suggestive of a beneficial effect, but have not been conclusive yet.21 Furthermore, 
results from observational studies have suggested that, beside a BP lowering effect, specific 
antihypertensive medication (AHM) classes might also have a class-specific beneficial effect 
on dementia.22 The adverse relation with a low BP in people in late life, might be because 
an already ongoing process of neurodegeneration causes autonomic dysregulation or 
because problems with cerebral blood flow regulation cause cerebral hypoperfusion.23 
Figure 1 - Conceptual illustration of the relation between different blood pressure (BP) measures over 
time (A) and the (possible) association between these BP measures in late life and dementia (B). The 
solid line in figure 1B. represents a relation that is confirmed in observational studies and the dotted 
line a hypothesized relation. The relation between mean BP (green line) and risk of dementia follows 
a J-shaped curve, indicating that both higher and lower BP levels are associated with an increased risk 
of dementia.20 A declining trend (trend line) in BP is associated with an increased risk of dementia.25 
Such an association has not been established for increasing trend in BP in late life, but it is likely that 
also steep increases are unfavourable. A higher BP variability is hypothesized to be associated with an 
increased risk of dementia.26 
12
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There is limited available evidence on the effect of AHM deprescription (that is, decrease 
or discontinue AHM).23 One relatively small trial showed that discontinuation of AHM was 
safe, but did not have a beneficial effect on cognition within 16 weeks.24 In addition, there 
is evidence suggesting that not only mean BP is of prognostic value, but also changes over 
time, such as a declining BP or BP variability (Figure 1).25,26 BP variability is associated with 
cardiovascular disease and mortality and may also cause cognitive deficits due to cerebral 
small vessel disease (SVD).27 It is important to clarify the relation between BP in late life and 
dementia, as most prevention trials target older populations, and lower may not always be 
better.
METHODOLOGICAL CHALLENGES
Dementia prevention trials face methodological challenges in at least four stages of 
the study design: selection and recruitment of the target population, adherence to the 
intervention and selection of a suitable outcome measure. The lack of a beneficial effect 
of the preDIVA intervention may be (partially) attributable to the unselected, population-
based recruitment strategy, including participants with a relatively low or average baseline 
risk. It is conceivable that targeting a high-risk population would yield a larger window of 
opportunity for dementia prevention. Also, the optimal age range for the target population 
is unclear; dementia incidence is higher at older ages, but with increasing age the effect 
of the intervention might also diminish.28 External validity of trial results is, among other 
factors, dependent on recruitment methods.  Understanding people’s reasons for deciding 
to participate or not has the potential to improve recruitment and external validity of 
study findings. After recruitment of the study population, the next challenge, for non-
pharmacological prevention trials in particular, is adherence to the intervention. It is difficult 
to instigate a lifestyle improvement, but it is even more strenuous to make a lifestyle 
change sustainable.29 Finally, very few trials have the opportunity to select dementia as 
primary outcome, as it requires a long intervention duration and a large study population 
to demonstrate an effect. Ongoing and future trials will, therefore, often have intermediate 
outcome measures. A good intermediate outcome measure needs to be sensitive to an 
intervention effect and it should be reliable to generalise an effect on the intermediate 
outcome measure to an effect on incident dementia. Intermediate outcome measures that 
are currently used are cognition and measures of cardiovascular risk. Another proposed 
intermediate outcome measure is cerebral SVD, a radiological marker of damage to the 
small cerebral vasculature.30 
13
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1AIM AND OUTLINE OF THE THESIS
This thesis is focused on the prevention of dementia through BP management. 
In part I of this thesis we aim to unravel the complex relation between BP in late life and 
incident dementia. First of all, by updating the literature on the preventive effect of BP-
lowering interventions on incident dementia, with a systematic review and meta-analysis 
(chapter two). In chapter three we assess whether there is a class-specific effect of AHM 
in the prevention of dementia within the preDIVA study population. Within this study 
population we also assess whether BP variability is associated with incident dementia 
(chapter four). In chapter five we present the results of semi-structured interviews with 
Dutch general practitioners to describe how they deal with the ambiguity in evidence 
regarding AHM (de)prescription in older people, in daily clinical practice. 
In part II of this thesis we tackle some of the previously mentioned methodological 
challenges in dementia prevention trials. In chapter six we investigate whether the preDIVA 
intervention was more effective among participants with a high modifiable dementia risk 
score, to assess whether such a risk score might be useful to select trial participants. In 
two sub-studies among HATICE participants we studied reasons for participating in HATICE 
(chapter seven) and factors that influence initial and sustained engagement with the 
intervention (chapter eight). In chapter nine we assess whether it is possible to intervene 
in the progression of cerebral SVD, with a systematic review and meta-analysis on the 
preventive effect of AHM, to see if it might be eligible as intermediate outcome measure 
for future trials.
In chapter ten we provide a general discussion of the presented results. We discuss how 
the different studies are interlinked, what they add to current literature and what their 
implications are on clinical practice and future research. Chapter eleven of this thesis 
provides an overall summary.
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ABSTRACT
Our objective was to study the preventive effect of lowering blood pressure (BP) by 
medication and/or lifestyle changes on incident all-cause dementia, Alzheimer’s disease 
and vascular dementia. In this systematic review we included randomized controlled trials 
with a BP-lowering intervention. Of the nine included trials seven assessed the effect of 
antihypertensive medication and two of a lifestyle or combined intervention. In the 
intervention arm, 1041 out of 29029 (3.6%) participants were diagnosed with dementia 
compared to 1090 out of 28653 (3.8%) controls during a median follow-up of 3.9 years 
[range 2-10], resulting in a pooled risk ratio (RR) of 0.93 (95% confidence interval [CI] 
0.84-1.02; I2 16%). Three trials specified dementia subtypes, with no significant effect on 
Alzheimer’s disease or vascular dementia. To conclude, lowering BP by medication and/
or lifestyle changes did not lead to a significantly reduced risk of dementia. This appeared 
independent of dementia subtype.
17
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INTRODUCTION
The number of people diagnosed with dementia worldwide is anticipated to triple between 
2015 and 2050, due to an increasingly ageing population.2 Up to a third of Alzheimer’s disease 
cases are attributable to potentially modifiable risk factors, with (midlife) hypertension 
accounting for 5%.10 The high prevalence of hypertension and the widely implemented 
and relatively inexpensive blood pressure (BP)-lowering interventions render it suitable as 
prevention target.31,32 
In spite of the potential of BP-lowering interventions to prevent dementia, such a preventive 
effect has not been convincingly documented.21,33 In two meta-analyses, published in 
200821 and 200933, there was a suggestion of a preventive effect of lowering BP on incident 
dementia with, respectively, a hazard ratio of 0.87 (95% confidence interval [CI] 0.76-1.00) 
and an odds ratio of 0.89 (95% CI 0.74-1.07). These previous meta-analyses confined their 
scope to the effect of antihypertensive medication or to participants without a history 
of cerebrovascular disease. Lifestyle changes are an important aspect of BP-lowering 
interventions in current clinical guidelines and can lead to substantial BP reductions.31,34 In 
addition, two large trials with lifestyle interventions have recently been published.16,35
Our primary aim was to study the preventive effect of lowering BP by medication and/
or lifestyle changes, on incident all-cause dementia. Our secondary aim was to study the 
preventive effect on the dementia subtypes Alzheimer’s disease and vascular dementia.
METHODS
This systematic review was performed following the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement and the protocol was registered in Prospero 
(CRD42017056875).36,37 
Data Sources and Searches
We searched MEDLINE, EMBASE, PsycInfo, the Cochrane Library, the Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), Web of Science, clinicaltrials.gov and World 
Health Organization international clinical trials register platform up to August 29th 2017. 
The search included related terms for randomized controlled trial (RCT), dementia and 
BP-lowering interventions, including specific antihypertensive drugs and lifestyle changes 
(Supplementary Appendix S1: full search strategy). The reference lists of the included 
articles and systematic reviews of interest were additionally searched for potentially eligible 
studies. 
18
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Study Selection
Two authors (T.v.M. and L.A.v.V. or E.M.F.S.) independently assessed all articles, first based on 
their titles and abstracts and then based on their full text. Disagreement was resolved by 
consulting a third author (E.R.). We included studies that matched the following criteria: RCT; 
BP-lowering intervention with medication and/or a lifestyle changes; incident dementia 
according to internationally accepted criteria as primary or secondary outcome; and at least 
200 participants. An intervention was considered BP-lowering if it was generally accepted in 
allopathic medicine and if the (reported) goal of the intervention was to reduce BP or if BP 
at baseline and follow-up (or change during follow-up) were reported. Studies with multi-
domain interventions (that is, also including other intervention targets such as cholesterol) 
were also included, as long as BP was one of the targets of the intervention. No restriction 
was applied on the control condition or to whether BP-lowering concerned primary or 
secondary cardiovascular prevention (that is, we included study populations with and 
without a history of cardiovascular disease). We excluded studies with solely institutionalized 
patients (such as nursing home residents), as they consist of a multi-morbid population 
that is substantially different from the general or hospital-based population. Only articles 
published in English were included. For our secondary aim, the definition of Alzheimer’s 
disease and vascular dementia used in the individual trials was adopted.
Data Extraction and Quality Assessment
Data from the included trials were extracted independently by two authors (T.v.M. and 
E.M.F.S.) following a predefined data extraction form including study characteristics, 
baseline characteristics, content of the intervention and control group, dementia incidence, 
mortality incidence and funding sources. Risk of bias was assessed with the Cochrane risk 
of bias assessment 38 and quality of evidence following the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) approach.39 Authors from the included 
trials were contacted in case data necessary for meta-analysis were not published. 
Data Synthesis and Analysis
Data on incident dementia, Alzheimer’s disease and vascular dementia were pooled into 
risk ratios (RR) according to the DerSimonian-Laird random effects model.40 Statistical 
heterogeneity between the studies was assessed with I2 statistic and risk of publication 
bias with a funnel plot.40 We performed subgroup analyses on population characteristics 
by pooling trials that only included people aged at least 70 years, with a history of stroke 
and with type 2 diabetes, and a subgroup analysis on the nature of the intervention 
(pharmacological versus lifestyle intervention). With meta-regression analysis we assessed 
the influence of duration of the intervention, mean age at baseline, difference in systolic 
19
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BP (SBP) at follow-up between the intervention and control group, SBP at baseline and 
follow-up in the intervention group and decrease of SBP during follow-up. If SBP at baseline, 
follow-up or decrease during follow-up was not documented, it  was either calculated 
based on the data that was available (for example, decrease calculated by subtracting 
SBP at baseline from SBP at follow-up) or data reported in the (primary) publication of the 
entire trial population was used. A class-specific protective effect is hypothesized for several 
antihypertensive drug classes aside from their potentially protective effect through BP-
lowering.41 To compare the effect of different classes of antihypertensive medication we 
used pairwise meta-analysis. For this analysis we defined class according  the drug used 
as (primary) intervention, and did not take off-label or additional drug use into account. 
Originally, we intended to perform a network meta-analysis, but the number of trials with 
different classes of antihypertensive medication was deemed too low and trials were only 
placebo-controlled, rendering indirect treatment comparisons unreliable. We included a 
description of competing risk analyses performed in the individual trials and a pooled RR on 
mortality, to assess the potential influence of mortality as competing risk for dementia. As 
BP-lowering is effective in reducing the risk of mortality,31 the number of participants at risk 
of dementia and their mean age might inadvertently be higher in the intervention group, 
thereby attenuating potential effects on dementia. If mortality rates were only reported 
from the entire trial population and not separate for the subset with information on 
dementia, this data was used. All data were analysed using R studio (version 3.4.3; Boston, 
Massachusetts, United States of America) package meta for the statistical analysis.42 
RESULTS
We identified 5164 individual articles, of which 179 were included based on title and abstract 
(Figure 1). After careful reviewing of the full text, 17 articles reporting on nine individual 
trials were included for meta-analysis.16,21,35,43-48 One trial was excluded because the authors 
could not provide separate data on dementia.49 
Quality assessment
Table S1 in the online supplement shows the risk of bias assessment. Overall the risk of 
bias was low, with the exception of the Prevention of Dementia by Intensive Vascular care 
(preDIVA) and Look Action for Health in Diabetes (Look AHEAD) trial, that had a high risk of 
performance bias, as participants and personnel were not blinded due to the nature of 
the intervention (a lifestyle or combined intervention).16,35 In the Prevention Regimen for 
Effectively Avoiding Second Strokes (PRoFESS) trial the sponsor was involved in the study 
design, collection, analysis and interpretation of the data, creating risk of bias.48 The sponsor 
was however not involved in the decision to submit the paper for publication. Additional 
20
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data on dementia incidence was supplied by authors from the Action in Diabetes and 
Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) trial.47 In the 
funnel plot (Supplementary Figure S1) the Systolic Hypertension in Europe (Syst-Eur) trial was 
considered an outlier, with a relative high standard error and low risk ratio of 0.47.44 Aside 
from this there was no pattern indicative of publication bias. The GRADE level of evidence 
was assessed as high. 
Figure 1 - Flowchart of study selection
Study characteristics
Among the different trials, three included people aged at least 70 years, two trials were 
conducted in patients with a history of stroke and two among people with type 2 diabetes 
(Table 1). In all trials mean age at baseline was at least 60 years and in four trials participants 
had a mean baseline SBP more than 160 mmHg (Table 2). Seven trials assessed the effect 
of antihypertensive medication and two of a lifestyle or combined intervention. Four trials 
studied the effect of a multi-domain intervention which also targeted for example cholesterol 
or physical activity.16,35,47,48 Median intervention duration was 3.9 years [range 2-10]. Two 
studies had an observational extended follow-up of 1.5 years after the intervention period 
ended (to 3.9 and 11.4 years after baseline).35,44 
21
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Primary analyses
Dementia was the primary outcome measure in the preDIVA trial,16 while the other trials 
included it as secondary outcome. In total, 1041 out of 29029 participants (3.6%) were 
diagnosed with incident dementia in the intervention group and 1090 out of 28653 (3.8%) 
in the control group, resulting in a pooled RR of 0.93 (95% CI 0.84-1.02; I2 16%; Figure 2). 
Figure 2 - Forest plot on the effect of BP-lowering interventions on incident all-cause dementia
RR indicates risk ratio; CI, confidence interval.
Figure 3 - Effect of blood pressure lowering treatment on Alzheimer’s disease (A) and vascular 
dementia (B)
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Figure 4 - Meta-regression assessing the influence of duration (A), age (B) and difference in systolic 
BP between treatment arms at follow-up (C) on the effect of BP-lowering interventions to prevent 
dementia
SBP indicates systolic blood pressure; FU, follow-up; interv., intervention.
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Dementia incidence rates ranged between 1.6 cases/1000 persons/year in the two studies 
with (relatively young) diabetes patients and 36.4 cases/1000 persons/year in the trial with 
people ≥80 years (Supplementary Table S2).21,35,47 Excluding the Syst-Eur trial as outlier from 
the meta-analysis resulted in a RR of 0.96 (95% CI 0.88-1.04; I2 0%). Three trials registered 
the subtype of dementia.16,21,44 BP-lowering interventions did not significantly reduce the 
number of incident Alzheimer’s disease cases (RR 0.80; 95% CI 0.53-1.20; I2 71%; Figure 3A) 
or vascular dementia cases (RR 0.83; 95% CI 0.57-1.21; I2 0%; Figure 3B). 
Subgroup and sensitivity analyses
Subgroup analyses showed no effect in populations with solely participants aged ≥70 years 
(RR 0.94; 95% CI 0.84-1.10; I2 0%), with history of a stroke (RR 0.96; 95% CI 0.86-1.07; I2 0%), 
or with diabetes (RR 1.02; 95% CI 0.74-1.41; I2 9%; Supplementary Figure S2). No differences 
were noticeable in the subset of trials with a purely pharmacological intervention (RR 0.92; 
95% CI 0.80-1.04; I2 37%) or with a (combined) lifestyle intervention  (RR 0.94; 95% CI 0.76-
1.18; I2 0%; Supplementary Figure S3). Meta-regression showed no influence of duration 
of intervention (beta 0.00, p-value 0.67), mean age at baseline (beta 0.00, p-value 0.90), 
or contrast in SBP at follow-up between the intervention and control group (beta -0.01, 
p-value 0.30) (Figure 4). Also mean SBP at baseline or follow-up or decline in SBP during 
follow-up in the intervention group did not influence the result (Supplementary Figure S4). 
Pairwise meta-analyses showed no beneficial effect of specific classes of antihypertensive 
medication (Supplementary Table S3), apart from the result of the Syst-Eur trial (RR 0.47; 
95% CI 0.28-0.78), which was the only trial on the effect of calcium channel blockers.44 In one 
trial that assessed a multi-domain intervention including lifestyle changes, a competing risk 
analysis was performed, showing no significant effect of the intervention on dementia or 
mortality.16 In total, 2721 out of 32148 patients (8.5%) died in the intervention group and 
2863 out of 31797 (9.0%) in the control group, which resulted in a RR on mortality of 0.93 
(95% CI 0.87-0.99; I2 31%; Supplementary Figure S5). 
DISCUSSION
Our meta-analysis could not confirm that lowering BP with medication and/or lifestyle 
changes leads to a significant reduction of incident all-cause dementia, Alzheimer’s disease 
or vascular dementia. The results were not significantly influenced by the presence of a 
history of stroke, diabetes, age, duration of the intervention or SBP. Only one trial performed 
a competing risk analysis.
Our neutral result is in line with two previous systematic reviews; broadening the scope 
to primary and secondary cardiovascular prevention, and including lifestyle changes 
in addition to use of antihypertensive medication, did not have any apparent effect on 
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the overall estimate.21,33 Nevertheless, all three point estimates of the meta-analyses are 
consistently in favour of strategies aimed at BP-lowering. Our update of the literature, and 
thereby increased number of participants, reduces the likelihood that the absence of a 
significant effect is due to a power problem. 
The present findings may be explained by the fact that participants in the included trials 
had a mean age of 64-84 years, while the strong association between a high BP and the risk 
of dementia is mainly evident from observational studies with hypertension at midlife (35-
64 years).10 Whether BP-lowering at midlife can prevent dementia later in life is difficult to 
demonstrate unequivocally, due to the long time lag between risk exposure and treatment 
on the one hand and disease occurrence on the other. It would be valuable if RCTs with BP-
lowering interventions in this age group were to include an observational extended follow-
up with dementia as outcome.28 As hypertension is but one of many risk factors for all-
cause dementia,10 with a modest potential effect, it might be interesting to see if treatment 
of multiple risk factors alerts a more substantial risk reduction. Observational studies have 
suggested that in older adults a lower BP may even be harmful for cognitive function,20 
although there are no clinical trials to support this.23 In our meta-regression analyses we 
did not find clues for a potentially harmful effect of BP-lowering at older ages or with lower 
SBP. It will be interesting to see if this is supported by the Systolic Blood Pressure Intervention 
Trial memory and cognition in decreased hypertension (SPRINT-MIND), a trial that compares 
intensive to standard BP control (target SBP of ≤120 versus ≤140 mmHg).50 The results of 
this trial are, however, not likely to change the lack of beneficial effect we found in our 
meta-analysis (Supplementary Appendix S2).
The relatively short follow-up of most studies, is another potential explanation for the 
absence of a clear protective effect.51 It can be argued that less than five years may be too 
short to assess the effect of BP-lowering on dementia, as it intervenes in a relative slow 
causal pathway with hypertension leading to atherosclerosis, cerebrovascular lesions and 
ultimately dementia.51 Our meta-regression did not show a stronger effect in trials with 
a longer intervention duration. However, the two trials with an intervention duration >5 
years were the two trials with a lifestyle or combined intervention and reached a relative 
small contrast in BP between the intervention and control group, which could have also 
limited their beneficial effect.16,35 This limits our ability to conclude whether BP-lowering 
interventions are effective in reducing the risk of dementia on the long term. 
Finally, the absence of a protective effect on incident dementia might be (partially) explained 
by the competing risk of death. The differential effect on mortality in the BP-lowering group, 
introduces an imbalance in the number of survivors who are still at risk of dementia and 
potentially also an age imbalance, while increasing age is the most important risk factor for 
dementia. Given the fact that the confidence interval only just overlapped one, even a small 
effect on mortality could have contributed to the overall neutral effect in our meta-analysis. 
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When analysing the results of an individual trial, it is possible to account for competing risks 
by performing a competing risk analysis.52 However, in the included studies only one trial 
performed such an analysis, with, in contrast to the pooled effect, no significant effect on 
mortality.16 Within a meta-analysis with aggregated data it is not yet possible to perform an 
accurate competing risk analysis. We could therefore not refute the possibility of a type II 
error due to competing risk of death.
An important strength of our systematic review is the large number of included participants, 
with data on almost 60 thousand participants including 2131 incident cases of dementia. 
Overall, our meta-analysis showed consistent results with low statistical heterogeneity 
and high level of evidence. It is relatively new to address the influence of competing risk 
of death in a systematic review of dementia prevention trials, which might be crucial to 
substantiate an effect. By including both interventions with antihypertensive medication 
as well as lifestyle changes, we assessed the effect of a wide range of BP reductions, which 
appeared to be lower in trials with lifestyle changes. This could also be interpreted as a 
limitation, because the anticipated effect on dementia risk reduction would be smaller with 
smaller BP reductions. However, our meta-regression did not show a significant effect of 
the degree of BP reduction. Another disadvantage of the inclusion of lifestyle interventions 
is that participants could not be blinded for the intervention, which could create a risk of 
performance bias. A second potential limitation is the large differences in study population 
across the trials, reflected in the wide variety in dementia incidence rates. Nonetheless, 
no apparent benefit or harm of specific population characteristics was apparent in our 
subgroup analyses, particularly not according to age, which is the most important driver for 
the wide range in dementia incidence rates. 
To conclude, we could not show that BP-lowering interventions, including antihypertensive 
medication and/or lifestyle changes, in people over 60 years old reduce the risk of incident 
all-cause dementia. This appears independent of dementia subtype and the level of BP 
reduction. As few trials had an intervention duration longer than 5 years, a long-term effect 
could not yet be refuted. No trials assessing the effect of lowering BP on incident dementia 
were performed in midlife populations. A potential type II error due to the competing risk of 
death is conceivable and we recommend future RCTs to include such an analysis.
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SUPPLEMENTARY MATERIAL
Appendix S1. Search strategy
(((((“Dementia”[Mesh] OR dement*[tiab] OR alzheimer*[tiab]))) AND ((((((“Antihypertensive 
Agents”[Mesh] OR “Antihypertensive Agents” [Pharmacological Action]  OR “Hypertension/
drug therapy”[Mesh] OR “Hypertension/prevention and control”[Mesh] OR “Hypertension/
therapeutic use”[Mesh] OR “Hypertension/therapy”[Mesh] OR “Hypertension/diet therapy”[Mesh] 
OR “Hypertension/drug effects”[Mesh] OR “Nutrition Therapy”[Mesh] OR “Diet, Food, and 
Nutrition”[Mesh] OR “Diet”[Mesh] OR “Alcohol Drinking”[Mesh] OR “Exercise”[Mesh] OR “Exercise 
Therapy”[Mesh] OR “Exercise Movement Techniques”[Mesh] OR “Sports”[Mesh] OR “Physical 
Fitness”[Mesh] OR “Body Weight”[MeSH] OR “Life Style”[Mesh] OR “Tobacco Use”[Mesh] OR 
“Tobacco Use Cessation”[Mesh] OR “Smoking Cessation”[MeSH] OR exercis*[tiab] OR aerobic*[tiab] 
OR physical activit*[tiab] OR sport*[tiab] OR physical fitness*[tiab] OR diet*[tiab] OR nutrition*[tiab] 
OR nutrient*[tiab] OR food[tiab] OR feeding[tiab] OR weigh*[tiab] OR overweigh*[tiab] OR 
obes*[tiab] OR smok*[tiab] OR life style*[tiab] OR lifestyle*[tiab]))) OR (((pharmacolog*[tiab] OR 
nonpharmacolog*[tiab] OR non-pharmacolog*[tiab]) AND (intervention*[tiab] OR treatment*[tiab] 
OR therap*[tiab] OR management[tiab] OR strateg*[tiab])))) OR ((“Sodium Potassium Chloride 
Symporter Inhibitors”[Mesh] OR “Sodium Potassium Chloride Symporter Inhibitors” [Pharmacological 
Action] OR “Bumetanide”[Mesh] OR “Ethacrynic Acid”[Mesh] OR “Furosemide”[Mesh] OR “torsemide” 
[Supplementary Concept] OR “Sodium Chloride Symporter Inhibitors”[Mesh] OR “Sodium 
Chloride Symporter Inhibitors” [Pharmacological Action] OR “Hydrochlorothiazide”[Mesh] OR 
“Chlorothiazide”[Mesh] OR “Bendroflumethiazide”[Mesh] OR “Xipamide”[Mesh] OR “Indapamide”[Mesh] 
OR “Chlorthalidone”[Mesh] OR “Metolazone”[Mesh] OR “Diuretics, Potassium Sparing”[Mesh] OR 
“Amiloride”[Mesh] OR “Triamterene”[Mesh] OR “Dihydropyridines”[Mesh] OR “Amlodipine”[Mesh] OR 
“cilnidipine” [Supplementary Concept] OR “Felodipine”[Mesh] OR “Isradipine”[Mesh] OR “lercanidipine” 
[Supplementary Concept] OR “Nicardipine”[Mesh] OR “Nifedipine”[Mesh] OR “Nimodipine”[Mesh] OR 
“Nitrendipine”[Mesh] OR “mepirodipine” [Supplementary Concept] OR “lacidipine” [Supplementary 
Concept] OR “aranidipine” [Supplementary Concept] OR “azelnidipine” [Supplementary Concept] 
OR “benidipine hydrochloride” [Supplementary Concept] OR “clevidipine” [Supplementary 
Concept] OR “darodipine” [Supplementary Concept] OR “efonidipine” [Supplementary Concept] OR 
“manidipine” [Supplementary Concept] OR “niguldipine” [Supplementary Concept] OR “nilvadipine” 
[Supplementary Concept] OR “Nisoldipine”[Mesh] OR “Nitrendipine”[Mesh] OR “oxodipine” 
[Supplementary Concept] OR “pranidipine” [Supplementary Concept] OR “Diltiazem”[Mesh] OR 
“Verapamil”[Mesh] OR “Angiotensin-Converting Enzyme Inhibitors”[Mesh] OR “Captopril”[Mesh] OR 
“Enalapril”[Mesh] OR “Fosinopril”[Mesh] OR “Lisinopril”[Mesh] OR “Perindopril”[Mesh] OR “quinapril” 
[Supplementary Concept] OR “Ramipril”[Mesh] OR “trandolapril” [Supplementary Concept] OR 
“benazepril” [Supplementary Concept] OR “zofenopril” [Supplementary Concept] OR “imidapril” 
[Supplementary Concept] OR “Cilazapril”[Mesh] OR “Angiotensin Receptor Antagonists”[Mesh] OR 
“candesartan” [Supplementary Concept] OR “eprosartan” [Supplementary Concept] OR “irbesartan” 
[Supplementary Concept] OR “Losartan”[Mesh] OR “olmesartan” [Supplementary Concept] OR 
“telmisartan” [Supplementary Concept] OR “Valsartan”[Mesh] OR “azilsartan” [Supplementary 
Concept] OR “fimasartan” [Supplementary Concept] OR “Atenolol”[Mesh] OR “Metoprolol”[Mesh] 
OR “Nadolol”[Mesh] OR “Nebivolol”[Mesh] OR “Oxprenolol”[Mesh] OR “Pindolol”[Mesh] OR 
“Propranolol”[Mesh] OR “Timolol”[Mesh] OR “Bisoprolol”[Mesh] OR “Acebutolol”[Mesh] OR 
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“Celiprolol”[Mesh] OR “esmolol” [Supplementary Concept] OR “Sotalol”[Mesh] OR “Doxazosin”[Mesh] 
OR “Phentolamine”[Mesh] OR “Indoramin”[Mesh] OR “Phenoxybenzamine”[Mesh] OR “Prazosin”[Mesh] 
OR “Terazosin” [Supplementary Concept] OR “Ketanserin”[Mesh] OR “urapidil” [Supplementary 
Concept] OR “Phentolamine”[Mesh] OR “carvedilol” [Supplementary Concept] OR “Labetalol”[Mesh] 
OR “Hydralazine”[Mesh] OR “Minoxidil”[Mesh] OR “aliskiren” [Supplementary Concept] OR 
“Mineralocorticoid Receptor Antagonists”[Mesh] OR “eplerenone” [Supplementary Concept] OR 
“Spironolactone”[Mesh] OR “Clonidine”[Mesh] OR “Guanabenz”[Mesh] OR “Guanfacine”[Mesh] 
OR “Methyldopa”[Mesh] OR “moxonidine” [Supplementary Concept] OR “Guanethidine”[Mesh] 
OR “Mecamylamine”[Mesh] OR “Magnesium Sulfate”[Mesh] OR antihypertensive[tiab] OR anti-
hypertensive[tiab] OR beta-blocker*[tiab] OR betablocker*[tiab] OR angiotensin*[tiab] OR loop 
diuretic*[tiab] OR bumetanide[tiab] ethacrynic acid[tiab] OR furosemide[tiab] OR torsemide[tiab] 
OR thiazide diuretic*[tiab] OR epitizide[tiab] OR hydrochlorothiazide[tiab] OR chlorothiazide[tiab] 
OR bendroflumethiazide[tiab] OR xipamide[tiab] OR indapamide[tiab] OR chlorthalidone[tiab] OR 
metolazone[tiab] OR amiloride[tiab] OR triamterene[tiab] OR amlodipine[tiab] OR cilnidipine[tiab] OR 
felodipine[tiab] OR isradipine[tiab] OR lercanidipine[tiab] OR levamlodipine[tiab] OR nicardipine[tiab] 
OR nifedipine[tiab] OR nimodipine[tiab] OR nitrendipine[tiab] OR barnidipine[tiab] OR lacidipine[tiab] 
OR aranidipine[tiab] OR azelnidipine[tiab] OR benidipine[tiab] OR clevidipine[tiab] OR darodipine[tiab] 
OR efonidipine[tiab] OR manidipine[tiab] OR niguldipine[tiab] OR nilvadipine[tiab] OR nisoldipine[tiab] 
OR nitrendipine[tiab] OR oxodipine[tiab] OR pranidipine[tiab] OR diltiazem[tiab] OR verapamil[tiab] 
OR ACE-inhibitor*[tiab] OR captopril[tiab] OR enalapril[tiab] OR fosinopril[tiab] OR lisinopril[tiab] 
OR perindopril[tiab] OR quinapril[tiab] OR ramipril[tiab] OR trandolapril[tiab] OR benazepril[tiab] 
OR zofenopril[tiab] OR imidapril[tiab] OR cilazapril[tiab] OR candesartan[tiab] OR eprosartan[tiab] 
OR irbesartan[tiab] OR losartan[tiab] OR olmesartan[tiab] OR telmisartan[tiab] OR valsartan[tiab] 
OR azilsartan[tiab] OR fimasartan[tiab] OR atenolol[tiab] OR metoprolol[tiab] OR nadolol[tiab] 
OR nebivolol[tiab] OR oxprenolol[tiab] OR pindolol[tiab] OR propranolol[tiab] OR timolol[tiab] 
OR bisoprolol[tiab] OR acebutolol[tiab] OR celiprolol[tiab] OR esmolol[tiab] OR sotalol[tiab] 
OR doxazosin[tiab] OR phentolamine[tiab] OR indoramin[tiab] OR phenoxybenzamine[tiab] 
OR prazosin[tiab] OR terazosin[tiab] OR tolazolin[tiab] OR ketanserin[tiab] OR urapidil[tiab] OR 
fentolamin[tiab] OR carvedilol[tiab] OR labetalol[tiab] OR hydralazine[tiab] OR minoxidil[tiab] OR 
aliskiren[tiab] OR eplerenone[tiab] OR spironolactone[tiab] OR clonidine[tiab] OR guanabenz[tiab] 
OR guanfacine[tiab] OR methyldopa[tiab] OR moxonidine[tiab] OR guanethidine[tiab] OR 
mecamylamine[tiab] OR magnesium sulfate[tiab])))) AND ((“Blood Pressure”[Mesh] OR “Blood Pressure 
Determination”[Mesh] OR “Blood Flow Velocity”[Mesh] OR “Hypertension”[Mesh] OR “Cardiovascular 
Diseases”[Mesh]  OR “Cardiovascular Physiological Processes”[Mesh] OR antihypertens*[tiab] OR anti-
hypertens*[tiab] OR blood pressur*[tiab] OR systolic[tiab] OR diastolic[tiab] OR blood flow[tiab] OR 
(blood[tiab] AND  lower*[tiab]) OR hypertens*[tiab] OR vascular[tiab] OR cardiovascular[tiab]))) AND 
(((“Randomized Controlled Trial” [Publication Type] OR “Random Allocation”[Mesh] OR “Double-Blind 
Method”[Mesh] OR “Single-Blind Method”[Mesh] OR “Placebos”[Mesh] OR “Meta-Analysis” [Publication 
Type] OR “Clinical Trials as Topic”[MeSH Terms] OR “Randomized Controlled Trials as Topic”[Mesh] OR 
“Controlled Clinical Trial” [Publication Type] OR random*[tiab] OR trial*[tiab] OR RCT[tiab] OR RCTs[tiab] 
OR systematic review[tiab] OR meta-anal*[tiab] OR metaanal*[tiab]))) NOT ((“Animals”[Mesh] OR 
animal*[tiab] OR rat[tiab] OR rats[tiab] OR mouse[tiab] OR mice[tiab] OR dog[tiab] OR dogs[tiab]) NOT 
“Humans”[Mesh])
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Appendix S2. Potential influence of SPRINT-MIND
Systolic Blood Pressure Intervention Trial memory and cognition in decreased hypertension 
(SPRINT-MIND) will study if intensive blood pressure lowering leads to a lower risk of 
dementia over five years follow-up.50 As this is an important and influential trial, we wanted 
to assess its potential influence on our meta-analysis. 
In the SPRINT trial 4678 participants were included in the control group and 4683 participants 
in the intervention group, with a mean age at baseline of 68 years. For this analysis we 
estimated an incidence rate of 10.3 cases per 1000 person years in the control group, which 
was found in the Medical Research Council Cognitive Function and Ageing Study (MRC 
CFAS) cohort aged 70-74 years.53 This would result to an estimated 241 dementia cases in 
the control group. In this meta-analysis we included the nine studies included in our original 
meta-analysis and additionally included three hypothetical results of SPRINT-MIND trial. To 
assess the potential range in pooled estimates we used the following two hypothetical 
results: 50% and 0% risk reduction. This led to a range in pooled estimates from 0.84 (95% 
confidence interval [95% CI] 0.70-1.00, I2 77%) with 50% risk reduction to 0.94 (95% CI 0.87-
1.03, I2 9%) with 0% risk reduction.
Table S1 - Cochrane risk of bias assessment
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Table S3 - Pairwise meta-analysis of specific classes of antihypertensive medication
No. of trials No. cases/ participants* RR (95% CI) p-value I2
Diuretics 2 163 / 4052 0.89 (0.72-1.09) 0.25 0%
Calcium channel blocker 1 21 / 1485 0.47 (0.28-0.78) <0.01 N.A.**
Angiotensin receptor blocker 2 470 / 11101 1.01 (0.89-1.14) 0.88 0%
Ace-inhibitor and diuretic 2 232 / 8620 0.91 (0.77-1.09) 0.30 0%
* Number of cases represent the number of dementia cases and total number of participants in the intervention group. 
**Statistical heterogeneity could not be assessed on the analysis on calcium channel blockers as this was based on one 
trial. N.A. indicates not applicable.
Table S4 - Funders of the included trials
Trial Funder
SHEP43 The National Heart, Lung, and Blood Institute; the National Institute on Aging
Syst-Eur44 Bayer AG; Merck Sharpe; Dohme
SCOPE45 AstraZeneca
PROGRESS46 Servier; the Health Research Council of New Zealand; the National Health and Medical 
Research Council of Australia 
ADVANCE47 Servier; National Health and Medical Research Council of Australia
HYVET-COG21 The British Heart Foundation; Servier; imperial college
PROFESS48 Boehringer Ingelheim; Bayer-Schering Pharma; GlaxoSmithKline
PreDIVA16 Dutch Ministry of Health, Welfare and Sport; Dutch Innovation Fund; Netherlands 
Organisation for Health Research and Development
Look AHEAD35 National Institutes of Health (and additional non-commercial funding)
Figure S1 - Funnel plot to assess publication bias
Risk of publication bias is higher if the funnel plot is assymetrical. When for example smaller studies with non-significant 
effects are not published this will cause a gap in the bottom righ corner of the graph. Overall, we do not see a assymetrical 
funnel plot, however the outlying result from the Syst-Eur trial is notable. 
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Figure S2 - Subgroup analyses on population characteristics
Figure S3 - Subgroup analyses on type of intervention 
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Figure S4 - Meta-regression assessing the influence of systolic blood pressure on the effect of blood 
pressure lowering treatment to prevent dementia 
Data on SBP was gathered from the primary publication in the PRoFESS and PROGRESS trial.54,55 SBP indicates systolic 
blood pressure; FU, follow-up.
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Figure S5 - Forest plot on the effect of antihypertensive treatment on mortality 
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ABSTRACT
Objective Use of antihypertensive medication (AHM) is potentially associated with 
a reduced risk of dementia. Both calcium channel blockers (CCBs) and 
angiotensin receptor blockers (ARBs) are suggested to have a more 
pronounced protective effect. We aimed to study the association between 
different classes of AHM and dementia in older people. 
Methods A subgroup of community-dwelling older people using AHM included in the 
‘Prevention of Dementia by Intensive Vascular Care’ (preDIVA) randomized 
controlled trial was studied. Incident dementia rates in participants with 
different AHM classes (mono- and combination therapy) were compared to 
dementia rates in participants with any other AHM. 
Results At baseline, 1951 participants (55.3%) used AHM (mean age, 74.4 year [SD 
2.5]; mean systolic blood pressure, 156.4 mmHg [SD 21.5]). 986 participants 
(50.5%) used beta-blockers, 798 diuretics (40.9%), 623 angiotensin 
converting enzyme inhibitors (31.9%), 522 CCBs (26.8%), and 402 ARBs 
(20.6%). After 6.7 years (interquartile range 6.0-7.3) of follow-up, 136 
participants (7.0%) developed dementia. Both use of CCBs (hazard ratio [HR] 
0.56, 95% confidence interval [95% CI] 0.36-0.87) and ARBs (HR 0.60, 95% CI 
0.37-0.98) were independently associated with a decreased risk of dementia. 
The association of CCBs with dementia was most apparent in participants 
without a history of cardiovascular disease  (HR 0.38, 95% CI 0.18-0.81) and 
with uncontrolled hypertension (HR 0.26, 95% CI 0.11-0.61). Systolic blood 
pressure was not significantly lower in participants using CCBs or ARBs.
Conclusion Both use of CCBs and ARBs are independently associated with a decreased 
risk of dementia in older people. 
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INTRODUCTION
Dementia, to date, affects an estimated 36 million people worldwide.56 Due to demographic 
changes this number will increase dramatically over the next decades.56 Up to 30% of 
Alzheimer’s disease is attributable to potentially modifiable, mostly vascular risk factors, 
with midlife hypertension accounting for 5%.10 The high prevalence and readily available 
treatments render hypertension a suitable target for dementia prevention strategies.57  
Despite the epidemiological evidence for hypertension as important risk factor for 
dementia, trials studying the effect of antihypertensive medication (AHM) on the incidence 
of dementia are inconclusive, showing small reductions at best.21 Other mechanisms than 
blood pressure (BP) reduction alone might be responsible for part of the protective effect, 
explaining variability in effect from trials using different AHM classes.22 Particularly, calcium 
channel blockers (CCBs) and angiotensin receptor blockers (ARBs) are suggested to have an 
additional protective effect on incident dementia.22,58 This neuroprotective effect might be 
related to changes in Alzheimer’s disease pathology, for example, plaques and tangles.59 In 
observational studies, the protective effect of other AHM classes has also been suggested.60
We aimed to study the association between different classes of AHM and incident, all-cause 
dementia in older people using AHM. We hypothesized an advantage of CCBs and ARBs 
additional to their BP-lowering effect. 
METHODS
The current study is based on data from the ‘Prevention of Dementia by Intensive Vascular 
care’ trial.61 In this multi-site, randomized controlled trial, 3526 community-dwelling older 
people aged 70-78 years received either intensive vascular care or standard care. During 
6-8 years of follow-up the incidence of the primary endpoint of all-cause dementia was 
assessed. The trial was registered at International Standard Randomized Controlled Trial 
Number  registry (ISRCTN29711771). The study protocol and primary outcome have been 
described in detail elsewhere.61,62 The study was approved by the medical ethics committee 
of the Academic Medical Center and all participants gave written informed consent.
Data collection
At baseline and during follow-up, data on medication use and medical history was collected 
every 2 years with use of the electronic health records. We identified five different classes 
of AHM (β-blockers, diuretics, angiotensin converting enzyme (ACE) inhibitors, CCBs and 
ARBs) (supplementary Table 1). Data on education, smoking, and physical activity, defined 
according to WHO standards, were self-reported.63 BP, body-mass index, and low-density 
lipoprotein cholesterol were measured using standardized protocols.61 The mini-mental 
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state examination (MMSE) was used to measure cognition.64 For the definition of dementia 
the criteria of the Diagnostic and Statistical Manual of Mental Disorders IV were used.3 
The diagnosis of dementia  was evaluated by an independent outcome adjudication 
committee.61 To minimise the risk of false-positive dementia diagnoses, all diagnoses were 
reevaluated with the treating physician after one year.61  
Statistical analysis
All analyses were restricted to participants using AHM at baseline, to limit the influence of 
selective dropout that may have occurred after baseline. We compared use of the different 
AHM classes, including mono- and combination therapy, to any other AHM (without use of 
the class of interest during follow-up). A Cox proportional hazards regression model was used 
to analyse the association with dementia incidence rate. The number of days from baseline 
to the diagnosis of dementia, time of death, or final follow-up visit was used in the model. 
Crude analyses (model 1) were followed by analyses adjusted for history of cardiovascular 
disease (CVD; including myocardial infarction, stroke, and/or transient ischemic attack 
[TIA]) and type two diabetes mellitus (model 2), as these are guiding in clinical practice 
and were significantly different at baseline (Table 1).65 In additional analyses we adjusted 
for randomization group and for the number of AHM classes to account for the severity of 
hypertension, as the Dutch cardiovascular risk management guideline recommends general 
practitioners to add multiple low-dose AHM classes when treatment effect is insufficient.65 
The proportional hazards assumption was tested visually and numerically, using Schoenfeld 
residuals.66 The subclasses dihydropyridine and nondihydropyridine CCBs were individually 
assessed, as nondihydropyridine CCBs were previously identified as being associated with a 
reduced dementia risk.67 To account for the overlap between different AHM classes, that is, 
participants that use multiple AHM classes, we combined all AHM classes into one model. 
As the diagnosis of dementia is often delayed 68 , we included an additional sensitivity 
analyses with a different operationalization of time-to-onset of dementia. The date of 
onset dementia was estimated by the midpoint between the last date seen well, defined 
as the last visit with a MMSE of at least 24, and the diagnosis of dementia. A competing risk 
analysis according to the cause-specific hazard method was used and the subdistribution 
hazard ratio was calculated, to account for the competing event of mortality before the 
possible development of dementia.69 We performed subgroup analyses in participants 
with or without a history of CVD and with controlled or uncontrolled hypertension at 
baseline (defined as a systolic BP ≥155 mmHg; the median systolic BP at baseline), to assess 
the association in high versus low risk participants. A third subgroup analysis included 
participants with mono- or combination therapy. To assess whether participants with 
different AHM classes had a different BP at baseline and during follow-up, BP was compared 
using an independent t-test. Because few data were missing (supplementary Table 2), no 
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imputation was performed. We executed the analyses with R studio version 3.2, using the 
survival package.
RESULTS
In total, 1951 (55.3%) out of 3526 included participants used AHM at baseline [mean age, 
74.4 year (SD 2.5)]. Mean systolic BP at baseline was 156.4 mmHg (SD 21.5). 906 (46.4%) 
participants used one class of AHM (monotherapy) (supplementary Table 3). Combining 
mono- and combination therapy, 986 participants (50.5%) used β-blockers, 798 diuretics 
(40.9%), 623 ACE-inhibitors (31.9%), 522 CCBs (26.8%), 402 ARBs (20.6%), and 32 other AHM 
(1.6%; Table1). 
After a median of 6.7 years (interquartile range [IQR]; 6.0-7.3) of follow-up, 136 participants 
(7.0%) using AHM developed all-cause dementia. The incidence rate of dementia was 11.3 
per 1000 person-years. Both the use of CCBs and ARBs was associated with a decreased 
risk of dementia compared to the use of other AHM [model 2; hazard ratio 0.56, 95% 
confidence interval (CI) 0.36-0.87; hazard ratio 0.60, 95% CI 0.37-0.98; respectively; Table 2 
and Fig. 1a and 1b]. Comparable hazard ratios were found with additional adjustment for 
randomization group or for the number of AHM classes; however, in the latter the results 
were no longer significant (supplementary Table 4). The association with dementia was 
present in participants using dihydropyridine CCBs [n=17 dementia cases (4.3%); model 
1; hazard ratio 0.49, 95% CI 0.29-0.82], but not in participants using nondihydropyridine 
CCBs [n=9 dementia cases (7.8%); model 1; hazard ratio 1.00, 95% CI 0.50-2.00]. The use of 
CCBs and/or ARBs at baseline was associated with a lower incidence of dementia (model 
2; hazard ratio 0.48, 95% CI 0.33-0.71). Comparable results were found when combining all 
AHM classes into one model (supplementary Table 5). Also using time-to-onset defined as 
the date halfway between the last visit with a MMSE score of at least 24 and dementia gave 
comparable results (supplementary Table 6). When accounting for mortality (n=377) as 
competing event, CCBs and ARBs remained independently associated with a decreased risk 
of dementia (model 2; subdistribution hazard ratio 0.59, 95% CI 0.38-0.92; subdistribution 
hazard ratio 0.60, 95% CI 0.37-0.98; respectively; supplementary Table 7). In participants 
using ARBs, the association with dementia appeared comparable between the different 
subgroups, whereas in participants using CCB this was stronger in participants without 
a history of CVD (model 1; hazard ratio 0.38, 95% CI 0.18-0.81) and in participants with 
uncontrolled hypertension (model 1; hazard ratio 0.26, 95% CI 0.11-0.61; supplementary 
Table 7). Participants with uncontrolled hypertension were on average older (respectively, 
74.5 and 74.2 year, P <0.01) and included fewer participants with a history of CVD 
(respectively, 43.0% and 55.6%, P <0.01). During follow-up BP was not significantly different 
for CCB or ARB users compared to other AHM, except for a lower diastolic BP at baseline in 
CCB users (supplementary Figure 1).
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Figure 1 - Cumulative dementia incidence in participants using calcium channel blockers (A) or 
angiotensin receptor blocker (B) versus any other antihypertensive medication 
Data are restricted to 7 year follow-up because of the low numbers of participants at risk of dementia in the 7-8 year 
follow-up period. CCB indicates calcium channel blockers; non-CCB AHM, any other antihypertensive medicine than a 
calcium channel blocker; ARB, angiotensin receptor blocker; non-ARB AHM, any other antihypertensive medicine than a 
angiotensin receptor blocker.
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Table 2 - Cox proportional hazards regression comparing incident dementia rates in participant with 
different classes of antihypertensive medication (AHM) to participants with any other AHM
Dementia cases (%)
Model 1 Model 2
HR (95% CI) HR (95% CI)
β-blocker 69 / 963 (7.2%) 0.90 (0.63-1.29) 0.92 (0.64-1.32)
Diuretic 54 / 784 (6.9%) 0.82 (0.57-1.18) 0.81 (0.56-1.17)
ACE-inhibitor 43 / 600 (7.2%) 1.05 (0.72-1.51) 1.01 (0.69-1.48)
CCB 26 / 512 (5.1%) 0.56 (0.36-0.86) 0.56 (0.36-0.87)
ARB 20 / 389 (5.1%) 0.63 (0.39-1.02) 0.60 (0.37-0.98)
Model 1: unadjusted. Model 2: adjustment for history of cardiovascular disease and diabetes mellitus. The dementia cases 
(percentages) represent the number of participants with incident dementia from the participants using the AHM class of 
interest. HR indicates hazard ratio; CI, confidence interval; ACE, angiotensin converting enzyme; CCB, calcium channel 
blocker; ARB, angiotensin receptor blocker.
DISCUSSION
In this study, in patients using AHM, both the use of CCBs and ARBs was independently 
associated with a reduced risk of incident, all-cause dementia. The association was strongest 
for CCBs and in CCB users without a history of CVD or with uncontrolled hypertension. 
In our study, 5.1% of participants using CCBs or ARBs developed dementia, in comparison 
to 6.7% (n=233) in the complete preDIVA study population (with and without AHM).61 
The association of CCBs and ARBs with a lower dementia incidence risk is in accordance 
with previous studies.44,58 However, with regard to other AHM classes inconsistencies have 
been reported in observational studies, including a protective effect of diuretics and ACE 
inhibitors.60 These discrepancies may be partially explained by variances in population and 
methodology, among others in comparator groups, that is, users of different classes of AHM 
versus nonusers, another AHM class or matched controls.58 In our analysis, we chose to 
compare the AHM class of interest with any other AHM, as both groups are comparable 
with regard to their indication for AHM. In the future, AHM class preference might be aided 
by a possible effect on cognition.
No significant differences in BP were observed between the different AHM classes, except 
for a lower diastolic BP in participants with CCBs, suggesting that the protective effect 
is independent from the BP-lowering effect. There are several hypotheses about the 
neuroprotective effect of CCBs and ARBs. CCBs regulate calcium influx which may prevent 
neuronal cell death, inhibit the production of amyloid β and neurofibrillary tangles, and 
improve cerebrovascular perfusion by relaxing vascular smooth muscle cells.59 Particularly 
dihydropyridine CCBs, which can effectively penetrate the blood-brain barrier, might be able 
to exert these direct effects on the brain.70 The protective effect of ARBs might be related 
to improvement of the cerebral blood flow, restoration of cortical and cerebrovascular 
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angiotensin-1 and -4 receptors, decreased levels of amyloid β 1-42 in the brain, and an anti-
inflammatory effect.59 
We found a strong association between CCBs and dementia in participants without a 
history of CVD, a difference not previously studied in most trials or observational studies.44,71 
A possible explanation for this increased benefit in older people without a history of CVD 
could be related to less pronounced vascular lesions and, therefore, more brain reserve and 
capacity for functional resilience to cognitive decline. The additional benefit also appears 
to be more pronounced for participants with uncontrolled hypertension at baseline. The 
found association in participants with uncontrolled hypertension is supported by results 
from the ‘Systolic Hypertension in Europe’ trial, in which only patients with a systolic BP of 
at least 160 mmHg were included.44 However, it might also have been influenced by a lower 
percentage of participants with a history of CVD. Owing to small numbers in the subgroup 
analyses, we could not adjust for this. The subgroup analysis suggests that CCBs have 
neuroprotective effects even when their BP lowering effect is inadequate. Our results from 
the subgroup analyses, however, should be interpreted with caution, as they are based on 
a small number of dementia cases.  
Our study has strengths and limitations. An important limitation of our study is the fact that 
in clinical practice AHM is not prescribed at random, which may have led to confounding by 
indication. We adjusted for history of CVD and diabetes mellitus, but could not adjust for all 
possible confounders, due to a relative small number of dementia cases in each class of AHM. 
In 2006, Dutch guidelines recommended prescribing diuretics for patients without a history 
of CVD and β-blockers for patients with a history of myocardial infarction.65 ACE inhibitors, 
ARBs, and CCBs were third choice AHM classes, for patients not responding sufficiently to 
diuretics and β-blockers. The association of ARBs and CCBs with a lower risk of dementia, 
might, therefore, be because of a selection of therapy-resistant patients with a high risk of 
CVD. However, the comparable results in the subgroup analysis comparing monotherapy 
with combination therapy mitigates this fear. The absolute number of dementia cases per 
AHM class was low limiting further analyses. Another limitation is the overlap between AHM 
classes, because many participants use multiple AHM classes. Nevertheless, the influence of 
this overlap on our primary analysis appeared limited, as comparable results were found in a 
sensitivity analysis in which all AHM classes were incorporated into one model. Information 
on medication history or dosage of AHM was not available, which prohibited further dose-
response analyses. A strength of our study is the high follow-up rate (97.9%; n=1911), 
long follow-up period, and thorough outcome assessment, providing reliable information 
on incident dementia status.61 Additionally, we studied a large sample of participants 
that is representative of the general Dutch population of 70-78 years using AHM.72 Our 
annualized incidence rate of dementia was comparable to other studies with a similar study 
populations.67,73 Finally, the analysis in which use of CCBs was combined with use of ARBs, 
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showed an even stronger association with dementia, indicating that the separate analyses 
may even be underestimations due to the presence of CCBs or ARBs in the comparator 
group. Further randomized controlled trials will be needed to provide clear answers about 
the effect of CCBs and/or ARBs on dementia. 
In conclusion, both CCBs and ARBs are independently associated with a lower incidence 
of all-cause dementia compared with the use of other AHM. CCBs are associated with the 
lowest risk of dementia and this is mainly driven by dihydropyridine CCBs. Especially people 
without a history of CVD and with uncontrolled hypertension seem to benefit from CCB use. 
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SUPPLEMENTARY MATERIAL
Supplementary table 1 - A list of the different classes of antihypertensive medication and their ATC 
codes.
Class of antihypertensive medication ATC codes
Beta-blockers C07A, C07B, C07C, C07D, C07E, C07F
Diuretics C03A, C03B, C03C, C03D, C03E, C03X
Angiotensin converting enzyme inhibitor C09A, C09B
Calcium channel blocker C08C, C08D, C08E, C08G
Angiotensin receptor blocker C09C, C09D
Other C02A, C02B, C02C, C02D, C02K, C02L, C02N, C09X
ATC indicates Anatomical Therapeutic Chemical.
Supplementary table 2 - Number of participants with missing data for each variable of interest.
Variables Participants with missing data (number, %)
Included in analyses
Antihypertensive medicationa 5 (0.1%)
Dementia 40 (2.1%)
History of CVD 24 (1.2%)
Diabetes mellitus 0 (0.0%)
Included in baseline table
Age 0 (0.0%)
Gender 0 (0.0%)
Blood pressure 0 (0.0%)
Smoking 3 (0.2%)
Physical activity 41 (2.1%)
LDL 201 (10.3%)
BMI 1 (0.1%)
aPercentage calculated is based on all participants included in the analyses (n=1951). CVD indicates cardiovascular 
disease; LDL, low-density lipoprotein; BMI, body-mass index.
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Supplementary table 3 - Medication use at baseline in participants with different classes of 
antihypertensive medication. 
Beta-blocker
N= 986
Diuretic 
N=798
ACE-inhibitor
N=611
CCB
N=522
ARB
N=402
Number of AHM classes
1 304 (30.8) 185 (23.2) 173 (28.3) 107 (20.5) 131 (32.6)
2 398 (40.4) 364 (45.6) 239 (39.1) 204 (39.1) 160 (39.8)
3 222 (22.5) 186 (23.3) 154 (25.2) 153 (29.3) 84 (20.9)
≥4 62 (6.3) 63 (7.9) 45 (7.4) 58 (11.1) 27 (6.7)
AHM classes
Beta-blocker 986 (100) 367 (46.0) 256 (41.9) 231 (44.3) 156 (38.8)
Diuretics 367 (37.2) 798 (100) 245 (40.1) 173 (33.1) 124 (30.8)
ACE-inhibitor 256 (26.0) 245 (30.7) 611 (100) 163 (31.2) 14 (3.5)
CCB 231 (23.4) 173 (21.7) 158 (25.9) 522 (100) 109 (27.1)
ARB 156 (15.8) 124 (15.5) 14 (2.3) 109 (20.9) 402 (100)
Cholesterol lowering med. 541 (54.9) 364 (45.6) 347 (56.8) 207 (51.7) 188 (46.8)
Antithrombotic medication 589 (59.7) 354 (44.4) 323 (52.9) 285 (54.6) 179 (44.5)
Individual participants can be represented in different classes of AHM when they use combination therapy. Data are 
presented as numbers (percentage). ACE indicates angiotensin converting enzyme; CCB, calcium channel blocker; ARB, 
angiotensin receptor blocker; AHM, antihypertensive medication; med., medication.
Supplementary table 4 - Analysis adjusted for randomisation group and the number of 
antihypertensive medication classes 
Model 2 + randomisation Model 2 + nr. of AHM
HR (95% CI) HR (95% CI)
Beta-blocker 0.91 (0.63-1.32) 1.12 (0.76-1.64)
Diuretic 0.81 (0.56-1.17) 1.03 (0.68-1.56)
ACE-inhibitor 1.01 (0.69-1.48) 1.16 (0.78-1.72)
CCB 0.56 (0.36-0.87) 0.65 (0.40-1.05)
ARB 0.60 (0.37-0.98) 0.66 (0.40-1.09)
Cox proportional hazards regression comparing incident dementia rates in participants with different classes of 
antihypertensive medication (AHM) to participants with any other AHM. Data are presented for model 2 (adjusted for 
history of cardiovascular disease and diabetes), with additional adjustment for randomisation group (intensive vascular 
care or standard care) and number of antihypertensive medicine classes. Nr. indicates number, AHM, antihypertensive 
medicine; HR, hazard ratio; CI, confidence interval; ACE, angiotensin converting enzyme; CCB, calcium channel blocker; 
ARB, angiotensin receptor blocker.
49
Antihypertensive classes and dementia
3
Supplementary table 5 - Sensitivity analysis including all antihypertensive medication classes in one 
model
Model 1
HR (95% CI)
Beta-blocker 0.89 (0.56-1.39)
Diuretic 0.72 (0.47-1.10)
ACE-inhibitor 0.87 (0.55-1.39)
CCB 0.54 (0.31-0.92)
ARB 0.54 (0.29-0.98)
Cox proportional hazards regression comparing incident dementia rates in participant with different classes of 
antihypertensive medication (AHM) (combined into one model). HR indicates hazard ratio; CI, confidence interval; ACE, 
angiotensin converting enzyme; CCB, calcium channel blocker; ARB, angiotensin receptor blocker.
Supplementary table 6 - Sensitivity analysis with an alternative operationalization of dementia onset 
Model 1 Model 2
HR (95% CI) HR (95% CI)
Beta-blocker 0.92 (0.65-1.31) 0.95 (0.66-1.36)
Diuretic 0.89 (0.62-1.28) 0.87 (0.60-1.26)
ACE-inhibitor 1.04 (0.72-1.50) 0.99 (0.68-1.45)
CCB 0.58 (0.38-0.89) 0.58 (0.38-0.90)
ARB 0.63 (0.39-1.02) 0.59 (0.36-0.97)
Cox proportional hazards regression comparing time-to-onset of dementia in participants with different classes of 
antihypertensive medication (AHM) to participants with any other AHM. Time-to-onset of dementia is defined as 
the midpoint between the last visit with a MMSE ≥24 and the diagnosis of dementia. Model 1: unadjusted. Model 2: 
adjustment for history of cardiovascular disease and diabetes mellitus. HR indicates hazard ratio; CI, confidence interval; 
ACE, angiotensin converting enzyme; CCB, calcium channel blocker; ARB, angiotensin receptor blocker.
Supplementary table 7 - Competing risk analysis for the use of calcium channel blockers or 
angiotensin receptor blockers and dementia.
Dementia-free 
survival
CSHR (95% CI)
Mortality 
CSHR 
(95% CI)
Dementia
CSHR 
(95% CI)
Dementia
SHR 
(95% CI)
CCB 0.98 (0.87-1.10) 0.93 (0.73-1.18) 0.56 (0.36-0.87) 0.59 (0.38-0.92)
ARB 1.15 (1.01-1.31) 0.89 (0.68-1.16) 0.60 (0.37-0.98) 0.60 (0.37-0.98)
Analyses are adjusted for history of cardiovascular disease and diabetes mellitus (model 2). CSHR indicates cause 
specific hazard ratio, an estimate for the direct effect of CCB or ARB on survival, mortality or dementia. SHR indicates 
subdistribution hazard ratio, an estimate for the risk of dementia while accounting for mortality as competing event. CI 
indicates confidence interval; CCB, calcium channel blocker; ARB, angiotensin receptor blocker.
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Supplementary figure 1 - Blood pressure during follow-up in participants using calcium channel 
blockers (A) or angiotensin receptor blockers (B).
Data is presented as mean (confidence interval). The blue line represents participants using calcium channel blockers (A) 
or angiotensin-2 receptor blockers (B). The red line represents participants using any other antihypertensive medication. 
CCB indicates calcium channel blockers; non-CCB AHM, any other antihypertensive medicine than a calcium channel 
blocker; ARB, angiotensin-2 receptor blocker; non-ARB AHM, any other antihypertensive medicine than a angiotensin-2 
receptor blocker.
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ABSTRACT
Background High visit-to-visit variability (VVV) in blood pressure (BP)  is associated with 
cerebrovascular lesions on neuroimaging. 
Objectives Our primary objective was to investigate whether VVV is associated with 
incident all-cause dementia. As a secondary objective, we studied the 
association of VVV with cognitive decline and cardiovascular disease (CVD). 
Methods We included community-dwelling people (age 70-78 year) from the 
‘Prevention of Dementia by Intensive Vascular Care’ (preDIVA) trial with three 
to five 2-yearly blood pressure measurements during 6-8 years follow-up. 
VVV was defined using coefficient of variation (CV; SD/mean × 100). Cognitive 
decline was assessed using the Mini-Mental State Examination (MMSE). 
Incident CVD was defined as myocardial infarction or stroke. We used a 
Cox proportional hazard regression and mixed-effects model adjusted for 
sociodemographic factors and cardiovascular risk factors. 
Results In 2305 participants (aged 74.2±2.5) mean systolic BP over all available visits 
was 150.1 mmHg (SD 13.6), yielding a CV of 9.0. After 6.4 years (SD 0.8) follow-
up, 110 (4.8%) participants developed dementia and 140 (6.1%) CVD. Higher 
VVV was not associated with increased risk of dementia (hazard ratio [HR] 
1.00 per point CV increase; 95% confidence interval [CI] 0.96-1.05), although 
the highest quartile of VVV was associated with stronger decline in MMSE (β 
-0.09, 95% CI -0.17 to -0.01). Higher VVV was associated with incident CVD 
(HR 1.07; 95% CI 1.04-1.11). 
Conclusion In our study among older people, high VVV is not associated with incident 
all-cause dementia. It is associated with decline in MMSE and incident CVD. 
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INTRODUCTION
Blood pressure (BP) and dementia are intricately linked. At older age, both a high systolic 
BP (SBP), low diastolic BP (DBP) and decreasing BP over time appear to be associated with 
an increased risk for dementia.74,75 Recent studies have suggested that a high visit-to-visit 
variability (VVV) in BP might also be associated with an increased risk of cognitive decline 
and dementia.76-78 BP variability can be measured over a short period (minutes to hours) 
or with longer intervals, i.e., visit-to-visit.76 VVV is a relative new construct that is often 
available in clinical practice. It is associated with an increased risk of cardiovascular disease 
(CVD) and mortality possibly due to increased arterial stiffness and/or poor adherence to 
antihypertensive treatment causing both a high VVV and an increased risk of CVD.27 The 
increased occurrence of cerebrovascular lesions on neuroimaging in persons with high 
VVV might contribute to decreased cognitive functioning and ultimately dementia.76,78,79 
The association between VVV and cognitive impairment has been established in several 
studies.26,77 Until now only one study assessed the association with incident dementia and 
found a positive association.78  
In this study we investigated whether VVV is associated with an increased risk of all-cause 
dementia in community-dwelling older people. Secondarily we assessed the association of 
VVV with cognitive decline and CVD. 
METHODS
Study population and procedures
We performed our post-hoc analyses on data from the ‘Prevention of Dementia by Intensive 
Vascular Care’ (preDIVA) trial (ISRCTN29711771).61 In short, this was a multisite, cluster-
randomized, open-label trial on the effect of intensive vascular care on incident dementia. 
The intervention consisted of four-monthly visits to a practice nurse. During these visits, 
cardiovascular risk factors were assessed and lifestyle advice and drug treatment was 
provided conforming to national guidelines. The guidelines did not include management 
of VVV. Participants in the control condition received care as usual. For the current analyses, 
we considered the trial population as a single-cohort. All community-dwelling older people 
(aged 70 to 78 years) registered to the participating primary care practices, were invited to 
participate.62 The only exclusion criteria were a diagnosis of dementia or a disorder likely 
to hinder successful long-term follow-up. Intervention and follow-up were 6-8 years. The 
medical ethics committee of the Academic Medical Center (AMC) in Amsterdam approved 
the study and all participants gave written informed consent. 
At baseline and after two, four, and six years, all participants visited the study nurse for an in-
person assessment during which BP and other values were measured. Participants recruited 
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early in the trial had a fifth visit after 7-8 years follow-up.61 Only participants who completed 
three or more visits were included in the current analyses, as BP measurements at three 
separate visits were deemed as a minimum requirement for reliable determination of VVV. 
The BP measurements were performed in sitting position, using an automated BP monitor 
(M6, OMRON Healthcare Co., Ltd., Kyoto, Japan).80 BP was measured twice at the same arm 
during each visit. For each visit, the mean BP of the two measurements was calculated 
and per visit one BP value, i.e., the mean, was used to calculate VVV. Data on demographic 
characteristics, cardiovascular history, diabetes mellitus, medication use, and smoking 
habits were self-reported and cross-referenced with electronic health records. Weight and 
length were measured in order to calculate body mass index (BMI), and a blood-sample was 
obtained for measurement of the low-density lipoprotein (LDL) cholesterol. 
Definition of visit-to-visit blood pressure variability
There are several measures for  VVV, including Standard Deviation (SD), Coefficient of 
Variation (CV; calculated as SD divided by mean BP over all available visits, times 100), 
variation independent of mean (VIM; a transformation of SD uncorrelated to mean BP), 
average real variability (ARV; the average of absolute differences between successive 
measurements) and delta BP (maximum BP minus minimum BP) 81. The main difference 
between these measures is the extent to which they depend on mean and absolute BP, 
and the influence of order of the BP measurements. For our analysis, we deemed CV most 
appropriate as our primary VVV parameter, as it is independent from mean BP and allows 
our results to be compared to other studies, which mostly used CV.78,82 Secondary analyses 
were conducted using the other VVV measures. Our primary analyses were executed with 
VVV based on SBP, but in secondary analyses we used VVV based on DBP.78,82 To assess 
the influence of minimum and maximum SBP we divided participants in four mutually 
exclusive categories: stable normotension (maximum ≤140 mmHg), episodic moderate 
hypertension (minimum SBP ≤140 mmHg and maximum SBP 140-179 mmHg), episodic 
severe hypertension (minimum SBP ≤140 mmHg and maximum SBP ≥180 mmHg), and 
stable hypertension (all SBP >140 mmHg).82
Outcomes
Participants were referred to their general practitioner to evaluate the possibility of a cognitive 
disorder in case of cognitive complaints, a decline in Mini-Mental State Examination (MMSE) 
of ≥3 points since baseline or ≥2 point since the preceding visit, or with a MMSE of ≤24.61 In 
case participants dropped-out from the trial information was retrieved on dementia status 
by contacting the participant, a relative, or the general practitioner. The primary outcome 
measure all-cause dementia was diagnosed according to the criteria of the Diagnostic and 
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Statistical Manual of Mental Disorders IV (DSM-IV).3 An independent outcome adjudication 
committee blinded to treatment allocation assessed all possible and probable dementia 
cases based on available clinical data. Diagnosis of dementia was re-evaluated after one 
year, to minimize the risk of false-positive diagnoses. The committee also classified dementia 
cases into Alzheimer’s disease, vascular dementia, and other dementia types. Cognitive 
functioning was measured at each visit using the MMSE.64 CVD was defined as incident 
myocardial infarction or stroke, and included both morbidity and mortality. CVD morbidity 
was self-reported, cross-referenced with electronic health records, and CVD mortality was 
based on data from death certificates. In the first four years of follow-up, TIA and stroke were 
collected as a combined outcome. Stroke diagnosed in the first four years was therefore not 
included in the analyses. 
Statistical analysis
We assessed the association between VVV and dementia using a Cox proportional hazards 
regression model. The number of days from baseline to date of diagnosis, final follow-up 
visit, or time of death was used as timescale. VVV was assessed both as continuous variable 
and divided into quartiles to investigate a possible non-linear relationship. We first assessed 
the unadjusted association (model 1). In a second model we adjusted for sex, age, and 
low educational level defined as no education or primary education only. In model three, 
we additionally adjusted for obesity, defined as BMI ≥30 kg/m², LDL cholesterol, smoking, 
and diabetes mellitus. These covariates were considered potential confounders as they 
are known to be independently associated with an increased risk of dementia 10. Data is 
presented based on model three, unless indicated otherwise. The proportional hazards 
assumption was assessed visually using log-minus-log plots and Schoenfeld residuals.66 We 
analyzed the relation between VVV and changes in MMSE over time with a linear mixed-
effects model. For this analysis, we used VVV divided into quartiles and the lowest quartile 
was used as reference group. Different models were fitted, but a mixed model with the VVV 
quartiles, time (visits), and their interaction as fixed effects was deemed most appropriate as 
we were interested in the association between VVV and changes in cognition over time. To 
assess the association of VVV, as continuous variable and divided into quartiles, with CVD, 
we used a Cox proportional hazards regression model. Because mortality is a competing 
risk for dementia and is associated with a high VVV, it could lead to a type II error with 
respect to a possible association between VVV and dementia. Therefore, we conducted 
a competing risk analysis according to the cause-specific hazard method and calculated 
the subdistribution hazard ratio (HR).69 The following predefined subgroup analyses were 
performed, including intervention versus control group, antihypertensive medication use 
at baseline, change in antihypertensive medication use (i.e., started or stopped) during 
follow-up, history of CVD (including myocardial infarction and stroke) at baseline, and 
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number of BP measurements. To assess the influence of selective drop-out on our results, 
we repeated our analyses with VVV only based on the first three BP measurements. To 
assess whether an association between VVV and dementia might be affected by overall 
changes in BP, we additionally adjusted for the slope in SBP over all available visits.83 To 
assess if the results of our analyses are indeed independent from hypertension at baseline 
(defined as SBP >140 mmHg, DBP >90 mmHg and/or use of antihypertensive medication) 
or mean SBP during follow-up, we additionally adjusted for these variables. In previous 
reports, adherence to antihypertensive treatment and seasonal change were identified to 
potentially influence VVV.84 The association between these variables and VVV was assessed 
with unpaired t tests. Adherence to antihypertensive treatment was operationalised as self-
reported full compliance with the prescribed medication regimen. Seasonal change was 
defined as at least two visits in different seasons. All statistical tests were two-sided with a 
p-value of <0.05 considered statistically significant. For the eight different VVV measures, 
a p-value of <0.006 was considered statistically significant after Bonferroni correction for 
multiple testing. Missing data were not imputed (Supplementary Material 1, for additional 
information on statistical analyses). Analyses were done using the Statistical Package for 
Social Sciences version 24.0 (SPSS Inc., Chicago IL, USA) and R studio version 3.3.3.42 
RESULTS
From the 3526 participants at baseline, 2305 attended three or more visits and could be 
included in the analyses (Figure 1, the compact version of the flow-diagram; Supplementary 
Figure 1, the complete flow-diagram). Baseline characteristics are shown in Table 1. 
Participants included in the analyses (i.e., those attending three to five visits) were slightly 
younger, had a lower SBP, less often a history of CVD, and had a higher MMSE at baseline 
compared to participants excluded from the analyses (Supplementary Table 1). 
Mean SBP was 154.7 mmHg (SD 20.8) at baseline and 150.6 mmHg (SD 20.9) at the final 
follow-up visit (Supplementary Figure 2). Mean DBP was 81.3 mmHg (SD 10.6) at baseline 
and 77.3 mmHg (SD 11.3) at final follow-up. Mean CV of SBP was 9.0 (13.6 [SD] / 150.1 [mean] 
× 100) (Supplementary Table 2). As an example of the level of variability in SBP over time, we 
show the course in absolute SBP of four arbitrarily chosen participants representing the four 
quartiles of VVV (Supplementary Figure 3). 
After an average follow-up of 6.4 years (SD 0.8), 110 participants (4.8%) were diagnosed with 
dementia (incidence rate: 7.0 per 1000 person-years). Of these, 82 (75%) had Alzheimer’s 
disease, six (5%) vascular dementia, five (5%) dementia from another aetiology, and in 
17 participants the type of dementia could not be classified. A higher CV of SBP was not 
associated with an increased risk of all-cause dementia (HR 1.00 per one point increase in CV 
of SBP, 95% confidence interval [CI] 0.96-1.05) (Table 2). No association with dementia risk and 
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other VVV parameters were found (Supplementary Table 2). Also when stratified according 
to different BP categories, there was no association with dementia (Supplementary Table 3). 
VVV divided into quartiles did also not reveal a non-linear association with dementia (Figure 
2A). The number of dementia cases was 30 (5.5%) in the lowest quartile of VVV, 19 (3.3%, 
HR 0.6, 95% CI 0.3-1.1) in the second quartile, 32 (5.5%, HR 1.0, 95% CI 0.6-1.6) in the third 
quartile, and 29 (5.0%, HR 0.9, 95% CI 0.5-1.5) in the highest quartile. A higher CV of SBP was 
not associated with Alzheimer’s disease (HR 1.00, 95% 0.96-1.06). 
The MMSE of participants in the highest quartile of VVV (range CV of SBP 11.3-36.0) was 0.18 
(95% CI 0.00 to 0.36) points lower at baseline and declined on average with 0.09 (95% CI 
0.01 to 0.17) points per visit more than participants in the lowest quartile of VVV (range CV 
of SBP 0.4-5.9) (Supplementary Table 4). During follow-up CVD occurred in 140 participants 
(6.1%), of which 93 had a myocardial infarction and 47 a stroke. A higher CV of SBP was 
significantly associated with more incident CVD (HR 1.07; 95% CI 1.04-1.11) (Table 2) and 
VVV divided into quartiles showed a linear association (Figure 2B). Separate analyses yielded 
comparable results for myocardial infarction (HR 1.07; 95% CI 1.03-1.12) and stroke (HR 1.08; 
95% CI 1.03-1.14). 
Figure 1 - Flow-diagram of the number of participants in- and excluded from the analyses. 
Participants were included in the analyses if they had a valid blood pressure measurement at ≥3 visits. N, number of 
participants; VVV, visit-to-visit variability; MMSE, Mini-Mental State Examination; CVD, cardiovascular disease.
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Table 1 - Baseline characteristics of participants who did or did not develop dementia
All participants 
(n=2305)
Dementia   
(n=110)
No dementia 
(n=2165)
P value
Sex (male) 1032 (44.8%) 52 (47.3%) 58 (52.7%) 0.59
Age (y) 74.2 (2.5) 74.7 (2.5) 74.1 (2.4) 0.02
Ethnicity (Caucasian) 2191 (96.5%) 105 (96.3%) 2057 (96.5%) 0.86
Education (low)* 493 (21.6%) 32 (29.9%) 453 (21.1%) 0.03
History of CVD 756 (33.0%) 44 (40.0%) 696 (32.4%) 0.10
Diabetes mellitus 437 (19.0%) 29 (26.4%) 403 (18.6%) 0.04
Antiglycemic med. 326 (14.1%) 21 (19.1%) 302 (13.9%) 0.17
Hypertension** 2049 (88.9%) 97 (88.2%) 1923 (88.8%) 0.90
Antihypertensive med. 1246 (54.1%) 66 (60.0%) 1160 (53.6%) 0.19
Systolic BP (mmHg) 154.7 (20.8) 156.1 (21.5) 154.7 (20.8) 0.50
Diastolic BP (mmHg) 81.3 (10.6) 81.5 (11.2) 81.3 (10.6) 0.85
BMI (kg/m²) 27.5 (4.2) 27.6 (4.0) 27.5 (4.1) 0.71
LDL cholesterol (mmol/L) 3.1 (1.0) 3.0 (1.0) 3.1 (1.0) 0.07
Cholesterol lowering med. 774 (33.6%) 39 (35.5%) 728 (33.7%) 0.78
Current smoker 279 (12.1%) 14 (12.7%) 258 (11.9%) 0.81
MMSE 29 [28-30] 28 [26-29] 29 [28-30] <0.01
Intervention group 1233 (53.5%) 43 (39.1%) 1010 (46.7%) 0.12
Baseline characteristics of all participants included in the analyses (i.e., present at ≥3 visits). Data are presented as 
frequencies (%), mean (SD) or median [interquartile range]. P values are calculated with a Chi-squared test, an unpaired T 
test or Mann-Whitney U test. * Low educational level defined as no education or primary education only. **Hypertension 
was defined as a systolic blood pressure at baseline ≥140 mmHg, a diastolic blood pressure at baseline ≥90 mmHg or the 
use of antihypertensive medication. CVD, cardiovascular disease; med., medication; BP, blood pressure; BMI, body mass 
index; LDL, low-density lipoprotein; MMSE, Mini-Mental State Examination.
Table 2 - Cox proportional hazards regression on the association between blood pressure variability 
and dementia or cardiovascular disease.
 
Dementia Cardiovascular disease
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
 Model 1 1.00 (0.96-1.04) 0.97 1.08 (1.04-1.11) <0.01
 Model 2 1.00 (0.96-1.05) 0.90 1.08 (1.04-1.11) <0.01
 Model 3 1.00 (0.96-1.05) 0.58 1.07 (1.04-1.11) <0.01
Cardiovascular disease includes myocardial infarction or stroke. Model 1 is the unadjusted model; in model 2 we adjusted 
for gender, age, and low educational level; and in model 3 we additionally adjusted for obesity, low-density-lipoprotein, 
smoking and diabetes. CI indicates confidence interval.
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Figure 2 - Hazard ratios of the association between quartiles of coefficient of variation of systolic 
blood pressure and dementia (A) or cardiovascular disease (B).
Analyses are unadjusted. The y-axis is shown in logarithmic scale. Quartile 1 includes CV of SBP 0.4 to 5.9; quartile 2, CV of 
SBP 5.9 to 8.4; quartile 3, CV of SBP 8.4 to 11.3; quartile 4, CV of SBP 11.3 to 36.0. At the bottom of each graph, the number 
of participants with dementia or cardiovascular disease are shown in relation to the total number of participants per 
quartile. CI, confidence interval; VVV, visit-to-visit variability; CV, coefficient of variation; SBP, systolic blood pressure; HR, 
hazard ratio; ref., reference group.
Sensitivity analysis showed that there was no association between VVV and dementia 
when taking mortality into account in the competing risk analysis (subdistribution HR 1.01; 
95% CI 0.96-1.05) (Supplementary Table 5). The predefined subgroup analyses yielded no 
apparent associations either (Table 3). No association with dementia was apparent when 
only including the first three BP measurements in the VVV measure (HR 1.01, 95% CI 0.97-
1.05). Additional adjustment for trend in BP (HR 0.95, 95% CI 0.90-1.00, P=0.06), hypertension 
at baseline (HR 1.01, 95% CI 0.96-1.05) or mean SBP during follow-up (HR 1.01, 95% CI 
0.96-1.05) did not change the association with dementia. Adherence to antihypertensive 
treatment did not significantly influence CV of SBP (adherent, n=1563, mean 9.3, SD 4.6; 
non-adherent, n=92, mean 9.2, SD 4.6; P=0.83), nor did seasonal change (BP measured in 
different seasons, n=615, mean 9.0, SD 4.4; BP measured in the same season, n=1690, mean 
9.1, SD 4.5; P=0.64).
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Table 3 - Subgroup analyses of the association between blood pressure variability and dementia.
Dementia cases    (n=, %) CV (mean, SD) HR (95% CI) P value
Intervention group 67 / 1222 (5.5%) 9.3 (4.5) 0.98 (0.91-1.06) 0.66
Control group 43 / 1053 (4.1%) 8.8 (4.3) 1.01 (0.96-1.06) 0.81
AHM at baseline 66 / 1160 (5.4%) 9.4 (4.5) 1.04 (0.97-1.11) 0.30
No AHM at baseline 44 / 1047 (4.2%) 8.6 (4.3) 0.97 (0.92-1.03) 0.36
AHM started/stopped* 32 / 579 (5.5%) 9.7 (4.7) 0.99 (0.94-1.04) 0.70
No AHM started/stopped** 78 / 1696 (4.6%) 8.8 (4.3) 1.02 (0.95-1.10) 0.58
History of CVD 44 / 740 (5.9%) 9.4 (4.8) 0.93 (0.86-1.00) 0.05
No history of CVD 66 / 1520 (4.3%) 8.9 (4.3) 1.04 (0.99-1.10) 0.11
3 BP measurements 50 / 455 (11.0%) 8.4 (4.7) 1.01 (0.96-1.07) 0.86
4 BP measurements 43 / 999 (4.3%) 9.1 (4.7) 1.01 (0.95-1.07) 0.82
5 BP measurements 17 / 851 (2.0%) 9.4 (4.0) 1.06 (0.95-1.18) 0.35
Analyses are unadjusted (model 1). *Antihypertensive medication started or stopped during follow-up. **Antihypertensive 
medication (yes or no) constant throughout study. Only the interaction term of ‘history of CVD’ and CV was significant 
(p=0.01). CV, coefficient of variation; SD, standard deviation; AHM, antihypertensive medication; CVD, cardiovascular 
disease (including myocardial infarction and stroke); CI, confidence interval.
DISCUSSION
In our study population of community-dwelling older people, VVV was not associated with 
incident, all-cause dementia after an average follow-up of 6.4 years. This result is irrespective 
of the measure of VVV applied, mean SBP, use of antihypertensive medication, or history of 
CVD. High VVV was associated with stronger decline in MMSE and with a higher incidence 
of CVD. 
The absence of an association with dementia is in contrast with findings from the Three-
City Study, in which a significant association between a higher VVV and an increased risk 
of incident dementia was found.78 This observational cohort study (n=6506 participants) is 
comparable regarding age, but had a lower systolic VVV (CV of SBP, 7.2) and cardiovascular 
risk at baseline in comparison to our study population, with a lower mean SBP and fewer 
participants with diabetes mellitus. The calculation of VVV and the follow-up duration was 
comparable to our analyses. In the Three-City study a higher incidence rate was found of 
11.8 dementia cases per 1000 person-years, possibly due to a more sensitive dementia 
assessment procedure using a neuropsychological test battery as opposed to the pragmatic 
and clinical approach used in preDIVA. However, it seems unlikely that this influenced the 
association with VVV. In a subgroup of our study population without a history of CVD, there 
was a trend towards a positive association between a higher VVV and incident dementia, 
although this effect was small. Perhaps in older people with a higher cardiovascular 
burden, cerebrovascular damage, presumed to contribute to the occurrence of cognitive 
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decline and dementia, is already too advanced to detect a significant influence of VVV on 
incident dementia.78,79 Another theoretical possibility explaining the contrast between our 
findings and those of the Three-City study is that our study was underpowered to detect 
an association. This seems unlikely since the HR for dementia was one; not suggestive of a 
small sample size as a cause of our null finding. Reproduction of these analyses in different 
study populations may be required to determine the true nature of the association between 
VVV and dementia incidence. 
One of the hypotheses on a potential association between VVV and dementia is through 
progression of cerebrovascular lesions including white matter hyperintensities, cortical 
infarcts, and cerebral microbleeds.77,79 We found an association between VVV and increased 
risk of stroke, and between VVV and decline in MMSE. It is conceivable that the 6-8 years of 
follow-up in our study was too short to detect a clinically overt effect on dementia incidence 
as a result of high VVV, or that at the age range in our study cerebrovascular damage has 
advanced too much for VVV to influence the progression. The relation between high 
VVV earlier in life (i.e., midlife or early late-life) and dementia in late life may be stronger, 
similar to the relation between absolute blood pressure in mid-life and dementia in late-
life.74 Other potential mechanisms underlying an association with dementia are that high 
VVV and cerebral amyloid-β depositions (an important neuropathological hallmark of 
Alzheimer’s disease) are the result of increased arterial stiffness.85 The neuropathological 
changes characteristic for Alzheimer’s disease might also lead to autonomic dysfunction 
and through this a higher VVV, even before any cognitive problems have occurred.26 Finally, 
a potential relation between VVV and dementia might not be causal, but both stem from a 
common underlying cause.
We found a significant association between VVV and decline in MMSE. This is in accordance 
with previous reports that found a positive association between VVV and cognitive 
deterioration.26,77,86 However, the association found in our study is probably not clinically 
relevant, as it would take approximately 18 years for the MMSE to be one point lower in the 
highest versus the lowest VVV quartile. The MMSE is not very sensitive to minor cognitive 
changes and was developed as a screening tool for dementia.64 
The association of VVV with CVD may have consequences for clinical practice. Potentially, 
antihypertensive treatment should not only be initiated and evaluated to reduce mean BP, 
but also to reduce VVV. The effect of different antihypertensive drugs on VVV is variable, and 
the lowest VVV is seen in treatment with calcium-channel blockers and non-loop diuretics.87 
The drug-class differences can partially account for the difference in stroke risk, but not 
for the difference in risk of myocardial infarction.87 Interestingly, calcium channel blockers 
belong to the class of antihypertensive drugs associated with a lower risk of dementia.41 
Strengths of our study are the large number of participants and virtually complete information 
on primary outcome. The assessment of dementia was thorough with a long follow-up and 
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validation by an independent outcome adjudication committee, since it concerned the 
primary outcome of the preDIVA study.61 We added several sensitivity analyses, including 
other VVV measures, to strengthen our findings. An important limitation of our study is 
that the number of available BP measurements is limited and the interval between BP 
measurements is relatively long. Analyses stratified for number of BP measurements showed 
that participants with only three BP measurements had on average a lower VVV (CV 8.4) 
and a non-significantly higher risk of dementia (11%). To assess whether selective drop-out 
influenced our results, we repeated our analyses with VVV based only on the first three BP 
measurements, but this did not change the results. Some participants who were excluded 
from the analyses because of <3 BP measurements had an MMSE <24 at their last visit. 
Due to the limited number of BP measurements, we are unable to assess whether these 
participants also had a relative high VVV. Another limitation of our analyses is that they are 
based on a randomized controlled trial population. The intervention may have influenced 
variability, particularly early on in the study when hypertension was newly diagnosed. 
However, in our stratified analysis the influence of randomization group appeared minimal 
and the difference in BP reduction between intervention and control groups was small. 
We did not collect data on dosage of antihypertensive medication and time of day of the 
BP measurement. We could therefore not assess the influence of these factors on VVV. We 
were, however, able to assess the influence of adherence to antihypertensive treatment 
and seasonal change. Stroke occurrence is possibly underreported in our study due to the 
fact that it was not collected separately from TIA during the early phases of the study, and 
incident cases in the first four years of follow-up were therefore not included in the analyses. 
However, these events were missing for all participants and it is unlikely that this influenced 
the association with VVV. 
In conclusion, in our study population of community-dwelling older people VVV is not 
associated with an increased risk of dementia over six years of follow-up. Future research 
is needed to confirm the findings of this study and assess whether other associations 
between VVV and incident dementia might exist including at a younger age and if followed 
over longer periods. We found a significant association with decline in MMSE, but its clinical 
relevance is uncertain. High VVV was associated with more incident CVD. 
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SUPPLEMENTARY MATERIAL
Supplement appendix 1. Statistical analysis
We used the Statistical Package for Social Sciences version 23.0 (SPSS Inc., Chicago IL, USA) 
for the Cox proportional hazards regression. R studio version 3.2 was used for the general 
linear mixed-effects model, with R-package ‘LME4’, and for the competing risk analysis, 
with R-package ‘survival’.42,88,89 For the general linear mixed-effects model we used MMSE 
as continuous variable. However, because the MMSE data were not normally distributed, 
we repeated our analyses with an individually calculated value of decrease in MMSE from 
baseline. This gave comparable results. We presented our results on the raw MMSE scores 
as these were more easy to interpret. 
Missing data 
Variables
Participants with 
missing data (number, %)
Main analyses Visit-to-visit variability 0 (0.0%)
Dementia 30 (1.3%)
Cognitive decline 0 (0.0%)
Cardiovascular disease 0 (0.0%)
Confounding variables Gender 0 (0.0%)
Age 0 (0.0%)
Education 19 (0.8%)
BMI 1 (0.0%)
LDL cholesterol 48 (2.1%)
Smoking 6 (0.3%)
Diabetes mellitus 0 (0.0%)
Sensitivity analyses Mortality 4 (0.2%)
Randomisation group 0 (0.0%)
Antihypertensive medication 2 (0.1%)
Medical adherence 650 (28.2%)
Seasonal change 0 (0.0%)
Number of participants with missing data for each variable of interest. Percentage calculated is based on all participants 
included in the analyses (n=2305). BMI indicates body-mass index; LDL, low-density lipoprotein.
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Supplement Table 1 - Baseline characteristics of participants included or excluded from analyses
Participants included in 
analyses (n=2305)
Participants excluded from 
analyses (n=1221) P value
Gender (male) 1032 (44.8%) 575 (47.1%) 0.19
Age 74.2 (2.5) 74.7 (2.5) <0.01
Low educational level 493 (21.6%) 343 (28.5%) <0.01
History of CVD 756 (33.0%) 473 (39.0%) <0.01
DM 437 (19.0%) 209 (17.1%) 0.18
Hypertension* 2049 (88.9%) 1101 (90.3%) 0.21
Antihypertensive medication 1246 (54.1%) 705 (57.9%) 0.03
Systolic BP 154.7 (20.8) 156.5 (22.3) 0.02
Diastolic BP 81.3 (10.6) 81.7 (11.8) 0.36
BMI 27.5 (4.2) 27.4 (4.1) 0.69
LDL cholesterol 3.1 (1.0) 3.1 (1.0) 0.45
Current smoker (yes) 279 (12.1%) 189 (15.5%) 0.01
MMSE 28.3 (1.6) 27.8 (1.9) <0.01
Randomisation (intervention) 1233 (53.5%) 657 (53.8%) 0.86
Data are presented as frequency (%) or mean (SD). *Hypertension was defined as a systolic blood pressure at baseline 
≥140 mmHg, a diastolic blood pressure at baseline ≥90 mmHg or the use of antihypertensive medication. CVD indicates 
cardiovascular disease; DM, diabetes mellitus; BP, blood pressure; BMI, body mass index; LDL, low-density lipoprotein; 
MMSE, mini-mental state examination.
Supplement Table 2 - Predefined visit-to-visit variability measures and their association with 
dementia
Mean (SD) Hazard ratio (95% CI) P value
SBP CV 9.0 (4.5) 1.00 (0.96-1.05) 0.85
SD 13.6 (6.9) 1.00 (0.97-1.03) 0.97
VIM 2.3 (1.1) 1.02 (0.86-1.21) 0.82
ARV 6.2 (20.6) 1.01 (1.00-1.02) 0.04
Delta 30.7 (15.9) 0.99 (0.98-1.00) 0.18
DBP CV 9.0 (4.4) 1.01 (0.97-1.06) 0.54
SD 7.1 (3.5) 1.02 (0.97-1.08) 0.46
VIM 2.8 (1.4) 1.05 (0.91-1.20) 0.53
ARV 3.8 (10.3) 1.00 (0.98-1.02) 0.88
Delta 16.0 (8.2) 0.99 (0.97-1.02) 0.44
Analyses are fully adjusted (model 3). The hazard ratio is per one point increase in CV/SD/VIM/ARV/delta. SD indicates 
standard deviation; CI, confidence interval; SBP, systolic blood pressure; CV, coefficient of variation; VIM, variation 
independent of mean; ARV, average real variability; DBP, diastolic blood pressure. A P value of <0.006 was considered 
statistically significant after Bonferroni correction.
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Supplement Table 3 - Number of patients with dementia in each predefined category 
Dementia cases (%) HR (95% CI)
Stable normotension 11 / 181 (6.1%) Ref.
Episodic moderate hypertension 58 / 1109 (5.2%) 0.76 (0.40-1.45)
Episodic severe hypertension 8   / 199 (4.0%) 0.57 (0.23-1.41)
Stable hypertension 33 / 786 (4.2%) 0.64 (0.32-1.27)
The mutually exclusive categories are based on the minimum and maximum systolic blood pressure. Stable normotension 
is defined as a maximum systolic blood pressure ≤140 mmHg; episodic moderate hypertension as a minimum systolic 
blood pressure ≤140 mmHg and maximum 140-179 mmHg; episodic severe hypertension as a minimum systolic blood 
pressure ≤140 mmHg and maximum ≥180 mmHg; and stable hypertension as a minimum systolic blood pressure >140 
mmHg. Analyses are unadjusted due to the small number of dementia cases in some groups.
Supplement Table 4 - Result of the association between visit-to-visit variability and MMSE during 
follow-up
Beta (95% CI)
Intercept (VVV Q1) 28.42 (28.29 to 28.55)
VVV Q2 -0.12 (-0.30 to 0.06)
VVV Q3 -0.05 (-0.23 to 0.13)
VVV Q4 -0.18 (-0.36 to 0.00)
Visit (VVV Q1 ×  Visit) 0.03 (-0.03 to 0.08)
VVV Q2 × Visit 0.02 (-0.06 to 0.10)
VVV Q3 × Visit -0.05 (-0.12 to 0.03)
VVV Q4 × Visit -0.09 (-0.17 to -0.01)
Visit-to-visit variability (VVV) is divided into quartiles. Quartile 1 includes CV of SBP 0.4 to 5.9; quartile 2, CV of SBP 5.9 to 
8.4; quartile 3, CV of SBP 8.4 to 11.3; quartile 4, CV of SBP 11.3 to 36.0. The intercept indicates the mean MMSE at baseline 
for quartile 1. VVV indicates the mean difference in MMSE per quartile at baseline. Visit indicates mean change in MMSE 
in quartile 1 per visit. The interaction term (Q2/3/4 * Visit) determines whether the VVV quartiles experience significant 
difference in longitudinal changes over time. Analyses are adjusted for gender, age, low educational level, obesity, low-
density-lipoprotein, smoking and diabetes. CI indicates confidence interval; VVV, visit-to-visit variability; Q, quartile.
Supplement Table 5 - Competing risk analysis
Survival
CSHR (95% CI)
Mortality
CSHR (95% CI)
Dementia
CSHR (95% CI)
Dementia
SHR (95% CI)
Model 1 0.99 (0.98-1.01) 1.01 (0.97-1.04) 1.00 (0.96-1.05) 1.00 (0.96-1.05)
Model 2 1.00 (0.99-1.01) 1.01 (0.97-1.04) 1.00 (0.96-1.05) 1.01 (0.96-1.05)
Model 3 1.00 (0.99-1.01) 1.00 (0.96-1.04) 1.00 (0.96-1.05) 1.01 (0.96-1.05)
A competing risk analysis for the association between visit-to-visit variability and dementia, while accounting for 
the competing event of mortality. The cause specific hazard ratio (CSHR) estimates the direct effect of blood pressure 
variability on the various outcomes (i.e., survival, mortality and dementia). The subdistribution hazard ratio (SHR) 
describes the risk of dementia while accounting for the competing event mortality. 
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Supplement Figure 1 - Flow-diagram of the number of participants in- and excluded from the 
analyses
The grey boxes indicate the number of participants at each follow-up visit of the complete preDIVA study population. The 
white boxes indicate the number of participant included and excluded in our analyses. Participants were included in the 
analyses if they had a valid blood pressure measurement at ≥3 visits. Participants with different intervals in between the 
blood pressure measurements were included. N indicates the number of participants; VVV, visit-to-visit variability; MMSE, 
mini-mental state examination; CVD, cardiovascular disease.
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Supplement Figure 2 - Mean (95% confidence interval) systolic blood pressure during follow-up
Mean systolic blood pressure of all participants included in the analyses. Year 6+ includes the systolic blood pressure of 
participants with a visit at eigth or six years follow-up. N indicates the number of participant at each visit.
Supplement Figure 3 - Examples of the course in systolic blood pressure during follow-up per 
quartile of visit-to-visit variability 
Visit-to-visit variability quartiles are based on the coefficient of variation (CV) of systolic blood pressure (SBP). Quartile 
1 (Q1) includes participants with a CV of SBP of 0.4-5.9, the illustrated participant has a CV of SBP of 2.4. Quartile 2 (Q2) 
includes participants with a CV of SBP of 5.9-8.4, the illustrated participant has a CV of SBP of 6.6. Quartile 3 (Q3) includes 
participants with a CV of SBP of 8.4-11.3, the illustrated participant has a CV of SBP of 8.54. Quartile 4 (Q4) includes 
participants with a CV of SBP of 11.3-36.0, the illustrated participant has a CV of SBP of 14.7. Year 6+ includes the systolic 
blood pressure of participants with a visit at eigth or six years follow-up. CV indicates coefficient of variation; SBP, systolic 
blood pressure; Q, quartile.
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ABSTRACT
Objectives To explore general practitioners’ (GPs) routines and considerations on (de)
prescribing antihypertensive medication (AHM) in older patients, their 
judgement on usability of the current guideline and needs for future support.
Design Semistructured interviews.
Setting Dutch general practice.
Participants Fifteen GPs were purposively sampled based on level of experience and 
practice characteristics until saturation was reached. 
Results GPs appeared reluctant to start AHM, especially in patient >80 years. High 
systolic blood pressure and history of cardiovascular disease or diabetes 
were enablers to start or intensify treatment. Reasons to refrain from this 
were frailty and patient preference. GPs described a tendency to continue 
AHM regimens unchanged, influenced by daily time constraints, automated 
prescription routines and anticipating discomfort when disturbing patients’ 
delicate balance. GPs were only inclined to deprescribe AHM in terminally 
ill patients or after prolonged achievement of target levels in combination 
with side effects or patient preference. Deprescription was facilitated 
when GPs had experience with patients showing increased quality of life 
after deprescription and was withheld by anticipated regret (ie, GPs’ fear 
of a stroke after deprescribing). GPs felt insufficient guidance from current 
guidelines, especially on deprescription.
Conclusions GPs are reluctant to start or deprescribe AHM in older people and have 
a propensity to continue AHM within a daily routine that insufficiently 
supports critical medication review. (De)prescription is influenced by 
patient preferences and anticipated regret and current guidelines provide 
insufficient guidance.
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INTRODUCTION
Eighty percent of older people with hypertension use antihypertensive medication (AHM).90 
However, treatment recommendations for people aged 65 and over are limited and there 
is considerable variation in treatment policy between general practitioners (GPs).31,91 The 
European guideline on cardiovascular disease (CVD) prevention states that in this older 
population AHM is still effective, but that for people over 80 years old target systolic blood 
pressure (SBP) levels may be less strict (eg, 140-150 mmHg instead of <140 mmHg).31 No 
recommendations are provided on deprescription (ie, decreasing dosage or discontinuing).
In the past, older people were mostly excluded from clinical trials on AHM and cardiovascular 
prevention. More recent studies that have included this group have presented conflicting 
results. Overall, antihypertensive treatment in the oldest old (>80 years) seems to reduce 
cardiovascular morbidity but has no effect on overall mortality.92 The Systolic Blood Pressure 
Intervention Trial (SPRINT) provided evidence that intensive blood pressure (BP) control to 
a target SBP of below 120 mmHg could prevent CVD and mortality, also in people aged 
≥75 years.93,94 This trial also showed that a low target SBP did not result in more orthostatic 
hypotension, falls or acute kidney injury, which are concerns regarding intensive BP 
treatment.95 However, it remains unclear to what extent these results are generalizable.96,97 
On the other end of the spectrum, observational studies have shown that in frail people 
>80 years old a BP below 140/90 mmHg might even be harmful as it is associated with an 
increased mortality risk.98 In these oldest old people it may therefore be recommended 
to restrict to two antihypertensive drugs and aim for a maximum reduction in SBP of 15 
mmHg.92,98 This is, however, not included in the current guidelines. 
Our primary aim was to explore GPs’ routines and considerations on prescribing and 
deprescribing AHM in older people to clarify the processes underlying current (de)
prescribing practices. Our secondary aim was to assess GPs’ judgement on usability of 
current guideline and their needs for future support in this decision-making process to help 
improve future guidelines on antihypertensive treatment in older people. 
METHODS
Participants
Between October 2015 and December 2016, 15 semi-structured interviews were performed. 
The study was granted a waiver from ethical approval by the Medical Ethics Committee of 
the Academic Medical Center (AMC) in Amsterdam. All participants gave written informed 
consent. GPs from different geographical areas in the Netherlands were invited by 
telephone or e-mail to participate in the interviews. Participants were purposively sampled 
based on years of experience, setting (rural or urban) and type of practice (small-scale vs 
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healthcare centre), presence of a practice nurse and expertise with regard to cardiovascular 
risk management. Of the 44 GPs approached, 15 agreed to participate, 13 could not be 
reached and 16 refused participation. Main reason GPs declined to participate was time 
constraint. After 15 interviews, saturation was reached as no important new (sub)themes 
emerged over the last interviews. 
Data collection
Each interview was done by one of two researchers (TvM and SI), both young female 
physicians trained in qualitative interviewing. The interviewers and interviewees had no 
prior relationship and they were aware of each other’s profession and level of experience. 
A prepiloted semistructured interview guide (box 1) was developed focused on behaviour 
and attitude in daily clinical practice to make the interview as concrete as possible and limit 
the influence of socially desirable answers.99 First, participating GPs were asked to retrieve 
recent case histories on antihypertensive treatment in older patients. They were primed for 
cases in which they recently started, increased, continued (without changes), decreased or 
discontinued AHM and were asked to elaborate on their routines and considerations in the 
treatment decision. It was left to the discretion of the GPs to decide who they considered 
an older patient. They were allowed to consult their electronic health record for further 
details. Second, their views on the value of the current guideline and needs for future 
support were discussed. The interviews were held in person, at a place that was convenient 
for the interviewed GP (at their practice or home or at the AMC or Radboud University 
Medical Center). The interviews took approximately 45 minutes, were audio-recorded and 
transcribed by the interviewer verbatim. 
Box 1 - Main topics in the interview guide
% Start or increase AHM: patient from daily practice
% Continue AHM: patient from daily practice
% Deprescribe AHM: patient from daily practice
% Current guideline
% Needs and wishes for future guideline support
AHM indicates antihypertensive medication.
Data analysis
Transcripts were thematically analysed following an inductive and iterative approach.100 
Two researchers (TvM and SI) independently coded all transcripts. After every two to four 
interviews, the researchers discussed the codes and through comparison and discussion 
a common coding system was developed. The (sub)themes derived from the codes were 
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subsequently organized within the prespecified structure on AHM (de)prescription: starting, 
intensifying, continuing and deprescribing. At multiple times during the data collection 
and analysis phase, results were discussed among a team including a practising GP and an 
expert in qualitative research. Based on these discussions, the interview guide was adapted 
by adding reflective questions to study the contrast between routine behaviour and 
conscious considerations. Also, the tilting point for (de)prescription was further specified 
and the reasons for starting AHM were further explored as this is under-represented at the 
start.
Patient and Public Involvement
By exploring GPs’ routines and views, we aim to describe daily clinical practice and the 
support necessary to improve clinical practice from a GP’s perspective.  
RESULTS
Fifteen GPs were interviewed varying in years of experience from 1 to 30 years (Table 1). 
In daily practice, (de)prescription of AHM was consciously evaluated when practice nurses 
noticed a high BP in patients with a history of CVD, or when patients actively approached 
their GP for their BP, had their BP measured for other reasons, for example when moving to 
an elderly home, or underwent a critical review on polypharmacy in collaboration with the 
pharmacist. In table 2, the main barriers and enablers that GPs mentioned when starting, 
intensifying, continuing and deprescribing AHM are presented, illustrated by four cases 
(Table 3). These barriers and enablers are further explained in the text below.
Starting treatment
In general, GPs were somewhat reluctant to start AHM in older patients. This was especially 
true for the oldest old patients (>80 years), for patients with a limited life expectancy (<1-2 
year) and for frail patients. In these cases, GPs only started AHM when SBP was higher than 
180 mmHg. GPs evaluated frailty based on their clinical impression and physical, cognitive 
and overall functioning. One GP was cautious because of the psychological impact starting 
medication could have on patients: 
“Sometimes I think that the added value (of starting AHM) in patients at older ages is minimal, 
but it does have a huge impact if I say, ‘Well you have a high BP and you need medication 
for it’. I think in some cases I am inclined to say to myself, ‘Well then just leave it’ [don’t start 
AHM].“ [GP 3, male, 5-10 years’ experience as GP]
GPs felt more inclined to start AHM in patients with a history of CVD (ie, secondary 
prevention) or diabetes and in case of a planned operation. GPs were reluctant to start 
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Table 1 - Participant characteristics 
Characteristic Population (n=15)
Sex (male) 8 (53%)
Age <40 years 7 (47%)
40-50 years 3 (20%)
>50 years 5 (33%)
Years as a GP 0-5 years 4 (27%)
5-10 years 3 (20%)
10-15 years 3 (20%)
>15 years 5 (33%)
Academically affiliated* 7 (47%)
Location Urban 8 (53%)
Rural 7 (47%)
Practice type Solo 2 (13%)
Duo 4 (27%)
Group 8 (53%)
Other** 1 (7%)
Practice nurse available 10 (67%)
Characteristics of the participating general practitioners. *Academically affiliated indicates either working at an 
academic centre for educational or research purpose or working as GP trainer. **One GP worked as locum GP in different 
practices. GP indicates general practitioner; M, male; F, female.
Table 2 - Main barriers and enablers to start, intensify, continue or deprescribe antihypertensive 
medication
Enabler Barrier
Starting AHM High SBP (>180 mmHg)
History of CVD/DM
Planned operation
Patient preference 
Age >80 years
Limited life expectancy
Frailty
Psychological impact of starting medication
Patient preference
Intensifying AHM High SBP (>140 or >160 mmHg)
Age <80 years 
History of CVD/DM
Age >80 years
≥3 antihypertensive drugs
Patient preference 
Frailty
Continuing AHM Automated prescription routines
Time constraints
Requires less justiﬁcation than 
deprescribing/intensifying
Anticipating discomfort when disturbing 
the precarious balance 
Target BP level not yet reached
Deprescribing AHM Prolonged achievement of target BP
Side eﬀects, orthostatic hypotension
Risk of falling
Patient preference
Experience with increase in quality of life
Terminal illness
Anticipated regret
Deprescribing may give the impression of 
giving up on a patient
AHM gives patients a sense of control
AHM indicates antihypertensive medication; CVD, cardiovascular disease; DM, diabetes mellitus; SBP, systolic blood 
pressure; BP, blood pressure.
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AHM when patients felt resistant towards medication or, on the contrary, were inclined to 
start AHM when patients were fearful for the consequences of a high BP:
“I have an older female who was very afraid for her high BP. She used to have an angiotensin-
converting enzyme (ACE) inhibitor which I stopped, or reduced. I strictly monitored her BP for 
6 months; during which it was always good. And then, a few months later, it went up again; 
systolic [BP] around 190 or 200. And then she became very anxious. So she wanted her ACE-
inhibitor back.” [GP 1, male, >15 years’ experience] 
Table 3 - Quotes about patient cases to illustrate antihypertensive medication (de)prescription
Start AHM “We had a woman who just moved into an elderly home and came under our care. This 
is a woman of 91 years old. She came to live there with her husband, because of her age 
and because she had mild dementia. And when she arrived at the home for elderly they 
immediately measured her BP. She had a BP of 190 over 90. And so we gave her losartan 50 
mg. […] So before that she had no AHM. Well you may think, that doesn’t do much, it isn’t 
that much. And so, we gave it. Then her BP immediately went to 140 over 80 and it remained 
there. And then she started complaining about terrible dizziness. And so I stopped it again.” 
[GP 12, female, >15 years’ experience as GP]
Intensify AHM “This is also a very ﬁt lady, but she is 86 years old. She had hydrochlorothiaizde 12.5 mg and 
we increased that to 25 mg, because she had a BP of 180 over 80. And now with 25 mg it is 
160 over 80. And she feels ﬁne, so we leave it like this.” [GP 6, female, 10-15 years’ experience]
Continue AHM “A patient of 92 years old, I think. Known with heart failure, poor mobility and COPD. She 
wants as little as possible. Also she doesn’t want to go to the hospital. And her BP is actually 
not much of an issue. Even though we know it is higher from time to time. When the edema 
increases, her legs are swollen and she gets shortness of breath on exertion, well then we 
always measure the BP to see how much room we have to increase the furosemide. And there 
is always enough room, she always has a BP of 170-180. So that is nice, that we have that. 
But it never crossed my mind, when we have treated the ﬂuid retention, to follow-up on her 
BP to say, let’s see if we should treat this structurally.” [GP 15, female, 10-15 years’ experience] 
De-prescribe AHM “Here I have the ﬁle of a 69 years old woman who has stage 4 lung cancer with progressive 
brain metastases. […] Because of a language barrier, her daughter explained that her mother 
often felt dizzy when getting up. She ﬁrst called it vertigo, but after some further questioning 
it appeared more like light headedness. […] Her BP was repeatedly around 124 over 70. And 
what I did was, ﬁrst I stopped the hydrochlorothiazide. Then her BP stayed low and she was 
still dizzy. And in the end I also stopped her losartan. […] And now her BP stays around 130 
over 80, but now without any AHM. So in hindsight I think she was severely over-treated.” [GP 
11, male, 0-5 years’ experience] 
AHM indicates antihypertensive medication; BP, blood pressure; GP, general practitioner; COPD, chronic obstructive 
pulmonary disease. 
Intensifying treatment
Intensifying treatment in patients already receiving AHM (ie, increasing dosage and/or 
supplementing by adding another antihypertensive drug) seemed relatively straightforward. 
This was proposed for a SBP higher than 140 mmHg in patients younger than 80 years or 
with a history of CVD or diabetes and for SBP readings higher than 160 mmHg in patients 
older than 80 years. GPs experienced more uncertainty when patients already used at least 
three antihypertensive drugs or when patients wished to refrain from intensifying treatment:
78
Chapter 5
“I often see that people do not want this much medication. That they just want to feel 
comfortable at home. Then (at older ages) you will look more at the person behind the 
illness.“ [GP 5, male, >15 years’ experience]
Another reason not intensify treatment was frailty: 
(Interviewer: How does frailty influence your choice with regard to AHM?) “That your target BP 
is less strict. That you will accept a BP of 165 over 95 and not give someone extra medication. 
While in the fit older patient you will think, let’s give it a go (increase AHM).“ [GP 2, female, 
10-15 years’ experience]
Continuation of treatment
Continuation of AHM with unchanged regimens was often not an active choice but a 
consequence of automated repeat prescription algorithms in the electronic health record. In 
combination with time constraints within the general practice organisation, this prompted 
swift, global checks of AHM regimens only without room for an assessment whether the 
prescribed medication was still appropriate. In some cases, GPs thought it might have been 
better if they deprescribed AHM; however, they felt that leaving the drug regimen unaltered 
would require less justification than changing things around:
“I also think that it is easier to simply continue a treatment. I feel that changing a treatment 
requires much more justification and should also be done in consultation with the patient or 
family. Sometimes it can be easier to just consent to a repeat prescription, than to repeatedly 
consider whether it is still appropriate.” [GP 8, male, 0-15 years’ experience] 
When continuation of AHM was an active choice, an important motivation for leaving 
things as they were was the perception that some patients had found a precarious balance 
and changing AHM (ie, increasing or decreasing) could increase the risk of discomfort: 
“And reducing, well I think that… it’s like ‘never change a winning team’. If someone is doing 
well and has no complaints, then you are not inclined to...(change AHM).” [GP12, female, >15 
years’ experience]
Finally, one GP thought that aiming for a certain BP target also contributed to the steady 
state in repeat AHM prescriptions, which kept her from regularly re-evaluating whether 
they were still appropriate: 
“I think that, if I look at my experience, when you have made the decision to act on a BP, I think 
that you are more inclined to continue your aim for the target BP that you have set. […] I think 
that you tend to just proceed and not use every evaluation moment to reconsider whether 
you should continue with it [treatment]. Which really would have been very appropriate. But 
I notice that I do not do that myself.” [GP 15, female, 5-10 years’ experience]
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Deprescribing treatment
Reducing or discontinuing AHM was not something that was easily decided on. It required 
clear motives apart from a prolonged period during which the BP was at or below target 
level, including side effects of AHM, orthostatic hypotension, a high risk of falling and patient 
preference. Some GPs had experience with an increase in quality of life (for example feeling 
less tired) of patients after deprescribing AHM:
“When I stop AHM in older patients they often feel much better. Then the BP rises somewhat 
and they feel less tired. Well I don’t know if it is caused by that, but sometimes I think that.” [GP 
1, male, >15 years’ experience]
In some cases, the decision of GPs was influenced by anticipated regret: the fear that a 
patient might have a stroke after deprescribing AHM:
“And it requires a sort of courage to notice that when you reduce AHM, the values, the 
indicators, increase. And you have to feel comfortable with that. If you withdraw AHM and 
someone, say after six months, has a stroke, than you suddenly feel uncomfortable.” [GP 5, 
male, >15 years’ experience]
GPs acknowledged that in the terminal phase it would be rational to discontinue AHM. 
However, they often hesitated to take this step, to avoid the impression they were giving up 
on the patient or unnecessarily deprive them of a sense of being in control with adequate 
BP measurements. They aimed to avert the risk of non-fatal stroke and the accompanying 
functional limitations in the last phase of life.
Current guideline and future support
The interviewed GPs often came to new insights and ideas during the interview, when 
provided with ample time to reflect on decisions that they had made. They stated that in 
daily practice treatment decisions were often based on intuition and that it might have 
been better if they had deprescribed AHM earlier: 
“I often do this briefly in between my consultations. And I notice, now that we are talking 
about it… it forces you to critically think about it. And then I think, oh I could do this better. 
And of course we can always do our work better; nobody knows everything. But I do think 
that, now that you mention this and we critically look at it, I should think this through more 
thoroughly.” [GP 11, male, 0-5 years’ experience] 
GPs generally felt insufficiently supported by the guidelines in their efforts to treat 
hypertension in older people:
“Yes, whom to treat and whom not to treat among the oldest old. […] The healthy you have 
to treat, because they still have a long life expectancy and therefore have much to gain 
in lowering their BP. Those with diseases, like the patients with diabetes or a myocardial 
infarction, you have to treat because they have a substantially elevated risk because of 
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their disease that we are well able to bring down. That group in between, with frail elderly, I 
followed the advice not to treat them for a while. And now I recently heard that you also have 
to treat those. I just don’t know it anymore. I would really like to have a guideline that states: 
in elderly you have pay attention to this, this and this.” [GP 9, female, 5-10 years’ experience]
A GP suggested a treatment flow diagram including more subjective factors like frailty for 
future support or indicators to start or deprescribe AHM like the Screening Tool of Older 
Person’s Prescriptions (STOPP)/Screening Tool to Alert doctors to Right Treatment (START) 
criteria.101 Another suggestion was to aid deprescription by incorporating algorithms in the 
electronic health record that aid doctors and practice nurses in observing complaints that 
are potentially related to a low BP.
DISCUSSION
For Dutch GPs, starting or intensifying antihypertensive medication is guided by the 
absolute level of SBP, history of CVD and diabetes. GPs feel reluctant to start AHM at older 
age, but when someone already receives AHM they also feel reticent in accepting a high 
BP (ie, not intensifying AHM). They may refrain from intensifying AHM in cases of frailty 
or clear patient preference. There is a propensity to continue AHM in older people within 
a daily routine that insufficiently supports critical review of prescriptions due to time 
constraints and automated prescription routines. Continuation of AHM is also supported 
by anticipating discomfort when disturbing patients’ delicate balance and the perception 
that continuing treatment requires less justification. The decision to deprescribe AHM is 
difficult, although GPs also mention a possible gain in quality of life, such as less fatigue. 
Deprescription is only considered when BP is consistently at or below the target and a 
patient experiences side effects or wants to reduce treatment. Anticipated regret  of a future 
stroke may represent an additional barrier for deprescription. GPs experience insufficient 
guidance on antihypertensive treatment for older people and would welcome a treatment 
flow diagram including specific STOPP criteria as well as more subjective factors like frailty.
An important strength of our study is the diversity of GPs that were interviewed, with a 
broad range in experience and setting. The interview guide was aimed at discussing 
examples from daily clinical practice to limit the chance of socially desirable answers. We 
followed the consolidated criteria for reporting qualitative research (COREQ) guidelines 
to improve the interpretation and reproducibility of our results.102 A limitation is that our 
study only includes Dutch GPs, which may restrict the level of generalisability. The role of 
Dutch practice nurses within the cardiovascular prevention programmes has become more 
prominent over the last years (box 2).103 This probably limits the time Dutch GPs spend on 
antihypertensive treatment and may facilitate routine continuation of AHM. Since specific 
directives on BP treatment for older people are lacking in most international guidelines, the 
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feeling of limited support is likely found in other countries as well. Relative few patient cases 
were discussed were AHM was started, due to the reluctance of GPs to start AHM in older 
patients and the notion that a lot of the older patients already received AHM. Even though 
data saturation was reached, this could have potentially limited the scope of reasons to 
start AHM. 
Box 2 - Antihypertensive treatment in Dutch general practices
% Almost all Dutch citizens are registered at a general practice. 
% In the Netherlands, general practitioners (GPs) have a gatekeeping role and are relatively easy accessible.104 
% Approximately 75-80% of medication is therefore prescribed by GPs.105 
% In 2006, the guideline on hypertensive treatment was combined into a more general guideline on 
cardiovascular risk management (CVRM).106 
% Recommendations in this guideline are similar to the European guideline, aside from the Systematic 
Coronary Risk Estimation chart which is expanded up to 70 years and the target systolic blood pressure 
for people over 80 years old which is 150-160 mmHg.31 
% With the introduction of nurse-led CVRM, over the last decade, the workload for GPs decreased and 
guideline adherence improved.107
% Specialists are mainly responsible for starting antihypertensive treatment in patients with secondary 
prevention, while general practitioners play a crucial part in primary prevention.
No other qualitative study has assessed GPs’ reasons for prescription and deprescription 
of antihypertensive medication in older patients. There are however previously reported 
studies with a broader focus on cardiovascular prevention, which have shown results 
consistent to ours.108-110 These studies stated that GPs are uncertain about many aspects 
of cardiovascular prevention, including the application of guidelines, organisation of care 
and benefit for individual patients and that they are less likely to prescribe preventive 
medication in frail older people.91,108,109 Especially when focusing on AHM, the uncertainties 
are most likely fuelled by the conflicting available evidence. There is both evidence in 
favour of intensifying treatment as well as studies that support a higher target BP.94,98 These 
uncertainties may lead to overtreatment, by unnecessary continuation of AHM regimens, 
or to undertreatment, caused by the reluctance to  initiate treatment in older people who 
are still free from AHM. As continuation also seems to be a consequence of daily routine 
influenced by time constraints and automated prescription routines, overtreatment might 
be prevented by more structural time for medication reviews. Patient preference plays a 
crucial part in (de)prescribing and should be actively taken into consideration, for example 
through use of the outcome prioritization tool.111 In addition, an estimation of frailty seems 
important which, by its subjective nature, could bring about the large variation in treatment 
intentions of GPs, which was previously described in a Belgian vignette study.112 
The reluctance to deprescribe AHM in older patient, is also noted for other drug classes.113 
This reluctance is, among other factors, induced by GPs’ anticipated regret, which has been 
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previously described as a motivator to start or continue preventive treatment.109,114 The fear 
of ‘causing’ a stroke by deprescribing AHM is unsupported by clinical evidence but might 
be instigated by results from trials like the SPRINT trial that support intensive BP lowering,94 
even though multimorbid older people are potentially under-represented in this trial and 
the generalisability of these results is uncertain.96 Also for deprescribing shared decision-
making is crucial.113 Older patients have varied attitudes and ideas about their medication 
use and clear communication is therefore crucial.115 However, given the present knowledge 
gaps, risk communication is perceived difficult by GPs.116 Until now, deprescribing AHM is 
only supported by observational studies, which have demonstrated an association between 
a low or decreasing BP and worse functional outcome, cognitive decline and increased 
mortality.117,118 The Discontinuation of Antihypertensive Treatment in Elderly People (DANTE) 
trial showed that discontinuation of AHM was safe, albeit not beneficial on cognitive, 
psychological or general daily functioning during the relative short 16-week follow-up.24 
To make a better informed decision on the deprescription of AHM, it would be useful to 
have additional evidence on the efficacy of deprescription with longer follow-up and on 
the subjective and objective impact of AHM in older people. For GPs, it would be desirable 
to add indicators for deprescription (ie, STOPP criteria) in the guideline as this is what GPs 
consider difficult. 
Dutch GPs are reluctant to start or deprescribe AHM in older people. Continuation of AHM 
is reinforced by a daily routine that insufficiently supports critical medication review and 
conflicting available evidence on efficacy of intensifying treatment. Patient preference 
appears crucial for both prescribing and deprescribing. Anticipated regret  of a future stroke 
works as a barrier for deprescription. Current guidelines provide insufficient guidance and 
clear indicators on deprescription could endorse it.
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ABSTRACT
Background Selecting high-risk participants for dementia prevention trials based on 
a modifiable dementia risk score may be advantageous, as it increases 
the opportunity for intervention. We studied whether a multi-domain 
intervention can prevent all-cause dementia and cognitive decline in 
older people across three different levels of a modifiable dementia risk 
score.
Methods Prevention of Dementia by Intensive Vascular Care (preDIVA) is a 
randomised controlled trial studying the effect of multi-domain vascular 
care during 6-8 years on incident all-cause dementia in community-
dwelling people aged 70-78 years. For this post hoc analysis, we 
stratified preDIVA participants in tertiles based on their baseline LIfestyle 
for BRAin health (LIBRA) index, a modifiable dementia risk score. With Cox 
proportional hazards regression, the intervention effect on dementia 
was assessed. The effect on cognition was measured every two years 
with the Mini-Mental State Examination and Visual Association Test. 
Results  Dementia developed in 220 of 3274 (6.7%) participants. In participants 
with a low, intermediate and high LIBRA index, the hazard ratio (HR) 
of the intervention on incident dementia was respectively 0.71 (95% 
CI 0.45-1.12), 1.06 (95% CI 0.66-1.69) and 1.02 (95% CI 0.64-1.62). Also, 
when adding the non-modifiable risk factors age, education and sex to 
the index, results were comparable (respectively; HR 0.88, 95% CI 0.54-
1.43; HR 0.91, 95% CI 0.57-1.47; HR 0.92, 95% CI 0.59-1.41). There was no 
statistically significant intervention effect on cognition during follow-
up across the LIBRA groups. 
Conclusions In the preDIVA study population aged 70-78 years, the LIBRA modifiable 
dementia risk score did not identify a (high) risk group in whom the 
multi-domain intervention was effective in preventing dementia or 
cognitive decline.
Trial registration ISRCTN, ISRCTN29711771. Registered February 14th 2006, http://www.
isrctn.com/ISRCTN29711771.
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BACKGROUND
The number of dementia cases worldwide is anticipated to double over the coming two 
decades.2,119 Up to a third of Alzheimer’s disease cases may be attributable to potentially 
modifiable risk factors, including several vascular risk factors such as diabetes mellitus, 
midlife hypertension and physical inactivity.10 This offers a window of opportunity for 
prevention strategies. However, selection of the optimal target population when designing 
a randomised controlled trial (RCT) to prevent dementia remains a challenge.28 Results from 
recent RCTs suggest that interventions may be most effective in those at increased risk 
of dementia based on the presence of one or more dementia risk factors.14-16 In such an 
at risk population the potential to improve modifiable risk factors, such as hypertension 
and physical inactivity, and thereby prevent dementia, is higher. In addition, the higher 
dementia incidence rates in high risk populations increase the study power, decreasing the 
total number of participants required to demonstrate a treatment effect. 
A dementia risk score could be a useful tool to recruit a high-risk population for prevention 
trials. Most risk scores that have been developed are, however, heavily dependent on non-
modifiable risk factors such as age, sex and education.120 The LIfestyle for BRAin health (LIBRA) 
index is the first, and so far only, validated dementia risk score predominantly supported by 
modifiable health and lifestyle factors.121 It consists of the following 12 risk and protective 
factors: depression, hypertension, obesity, smoking, hypercholesterolemia, diabetes, renal 
dysfunction, physical inactivity, coronary heart disease, low/moderate alcohol use, cognitive 
activity and adherence to the Mediterranean diet. As it reflects an individual’s potential for 
dementia prevention, it may identify those most responsive to an intervention. 
Prevention of Dementia by Intensive Vascular Care (preDIVA) is a cluster-RCT evaluating the 
effect of 6-8 years of nurse-led intensive vascular care on incident dementia in community-
dwelling older people aged 70-78 years.16 Overall, no preventive effect of the intervention 
was found. The intervention seemed more beneficial in a subgroup with untreated 
hypertension who adhered to the intervention. As the preDIVA intervention targets several 
vascular risk factors, our hypothesis was that a risk score capturing several modifiable risk 
factors may function even better at selecting those responsive to the intervention.
Hence, our aim was to study whether a multi-domain intervention can prevent all-cause 
dementia and cognitive decline in older people across three different levels of a modifiable 
dementia risk score. 
METHODS
The current study is a post hoc analysis in the preDIVA trial, which was previously published. 16 
In short, the intervention comprised four-monthly visits to a practice nurse who gave 
individually tailored lifestyle advice on smoking, diet, physical activity, weight and blood 
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pressure (BP). If indicated, pharmacological treatment was started or optimized according 
to the prevailing guidelines on cardiovascular risk management.106 The control condition 
was standard care. All community-dwelling older people aged 70-78 years registered at 
participating Dutch general practices were invited to participate. The only exclusion criteria 
were a diagnosis of dementia and/or any condition likely to hinder long-term follow-up 
(such as terminal illness or alcoholism). The trial is registered at the International Standard 
Randomized Controlled Trial Number registry (ISRCTN29711771).
LIBRA index
The LIBRA index has been designed based on a systematic review and Delphi consensus 
and has been validated in several cohorts, among which a cohort aged 70-79 years.12,121,122 
In preDIVA, ten out of 12 LIBRA factors were measured at baseline (Table 1). Similar to one 
of the previously mentioned validation studies,122 there was no information on cognitive 
activity or adherence to the Mediterranean diet. Data on medical history, medication 
use, history of smoking and alcohol use were self-reported and cross-referenced with the 
electronic medical record of the general practitioner. BP, weight and height (to calculate 
Body Mass Index [BMI]) were measured using standard protocols. A blood sample was 
drawn to measure cholesterol and creatinine levels. The 15-item Geriatric Depression Scale 
was used to measure depressive symptoms and the LASA Physical Activity Questionnaire 
for physical activity.123,124 The measures corresponding to the ten LIBRA items (Table 1) were 
aligned to the previously published validation studies.121,122 Each item was assigned the 
appropriate score (Table 1) and the sum of these items formed the LIBRA index (with a 
maximum potential range of -1.0 to +12.7). Only participants with all ten items available to 
calculate the LIBRA index were included in the analysis. For a secondary analysis, the LIBRA 
index was extended with the non-modifiable risk factors age, sex and education (Table 1), in 
order to make it more comparable to other available dementia risk indices.125 This was also 
done in the previously published studies on the LIBRA index.121,122
Primary and secondary outcomes
The primary outcome was all-cause dementia, according to the Diagnostic and Statistical 
Manual of Mental Disorders IV.3 An independent outcome adjudication committee validated 
all dementia diagnoses, including a one-year follow-up period in incident cases to assure 
there were no false positive diagnoses. Cognition was the secondary outcome measure, 
which was measured every two years with the Mini-Mental State Examination (MMSE) and 
the Visual Association Test (VAT).64,128 Participants attending at least one follow-up visit were 
included in the analyses on cognition. 
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Table 1 - Definition of risk/protective factors in the LIBRA index and corresponding scores 122
Definition Score
Modifiable risk factors
Depression Score ≥5 on the 15-item Geriatric Depression Scale +2.1
Hypertension SBP ≥140 mmHg, DBP ≥90 mmHg and/or use of antihypertensive 
medication
+1.6
Obesity BMI ≥30 +1.6
Smoking Current smoker +1.5
Hypercholesterolemia Total cholesterol ≥6.2 mmol/L or use of cholesterol lowering 
medication
+1.4
Diabetes Diabetes mellitusa +1.3
Renal dysfunction Estimated glomerular ﬁltration rate <60 ml/min/1.73 m2 b +1.1
Physical inactivity Not fulﬁlling the world health organisation criteria for physical 
activity as measured with the LASA Physical Activity Questionnairec 
+1.1
Coronary heart disease Cardiovascular disease (deﬁned as myocardial infarction, angina or 
peripheral arterial disease)a 
+1.0
Low/moderate alcohol use Alcohol use 1-14 units per week for males and 1-7 for females 126 -1.0
Non-modifiable risk factors
Age Males: 70-74 years +5.2
Male: 75-78 years +6.8
Females: 70-74 years +6.2
Female: 75-78 years +9.2
Education High ≥13 years 0
Medium 7-13 years +1.4
Low ≤7 years +2.7
a Data were self-reported and cross-checked with electronic health records. b Estimated Glomerular Filtration rate was 
calculated with the creatinine-based Chronic Kidney Disease - Epidemiology Collaboration equation 127. c The world 
health organisation criteria for physical activity are defined as ≥150 minutes/week moderate-intensity or ≥75 minutes/
week vigorous-intensity or an equivalent combination. SBP indicates systolic blood pressure; DBP, diastolic blood 
pressure; BMI, body-mass index; TIA, transient ischemic attack.
Statistical analysis
We first assessed the association between the LIBRA index in the preDIVA population 
and incident dementia with Cox proportional hazards regression. We then divided the 
study population into participants with a low, intermediate and high LIBRA index based 
on tertiles of the index.122 In each group, the crude effect of the intervention on all-cause 
dementia was assessed with Cox proportional hazards regression (model 1). The years 
from randomisation to dementia diagnosis or censoring date were used as timescale. To 
assess whether the LIBRA index is more useful as selection tool when containing both 
modifiable and major non-modifiable risk factors, we repeated our analysis with the LIBRA 
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index expanded with education (model 2) and additionally with age and sex (model 3).122 
As history of coronary heart disease is not modifiable, we removed it from the LIBRA index 
in a sensitivity analysis (model 4). Our primary analysis was crude and in a secondary analysis 
we adjusted for baseline imbalances between the intervention and control group. We also 
assessed the effect of adjusting for education as this is an important risk factor for dementia 
and is associated with many of the risk/protective factors included in the LIBRA index.10 The 
proportional hazards assumption was tested using Schoenfeld residuals and was assessed 
graphically.66 
Because of the cluster-randomised design we additionally performed a multi-level analysis 
to account for clustering within general practices and health-care centres. To account for 
competing risk of death, we assessed the intervention effect on mortality in the LIBRA 
groups, and, when appropriate, performed a competing risk analysis according to the cause-
specific hazard method.69 We added a per protocol analysis to assess whether the results 
were influenced by adherence to the intervention or control condition. In the per protocol 
analysis intervention participants were excluded who had on average less than two visits 
per year and inadvertent crossover control participants who had on average more than two 
visits per year. As the LIBRA index is more sensitive in a younger cohort,122 we performed a 
predefined subgroup analysis on age (dichotomized at the median). In the primary preDIVA 
analyses, the intervention seemed to be effective in those with untreated hypertension 
who adhered to the intervention. However, the LIBRA definition of hypertension is rather 
crude (dichotomously defined as systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg and/
or use of antihypertensive medication). Therefore, we added subgroup analyses on World 
Health Organisation hypertension grades (that is; normotension, systolic BP <140 mmHg 
and/or diastolic BP <90 mmHg; grade I hypertension, systolic BP 140-160 mmHg and/or 
diastolic BP 90-100 mmHg; grade II or III hypertension, systolic BP ≥160 mmHg and/or 
diastolic BP ≥100 mmHg) and use of antihypertensive medication.31 In the Netherlands, 
people with a history of cardiovascular disease (CVD) and diabetes visit a practice nurse 
as part of standard care, potentially diluting an intervention effect.107 We therefore added 
analyses in subgroups based on history of CVD and type 2 diabetes. To assess whether the 
intervention led to an improvement of cardiovascular risk factors, as proxy for treatment 
effect, we compared decline in systolic BP, BMI and total cholesterol between baseline and 
the last available follow-up visit, across the three LIBRA groups. 
To assess whether individual changes in cognition vary over time between treatment group, 
we used a multilevel growth model stratified for participants with a low, intermediate and 
high LIBRA index.129 In this linear mixed effect model each participant and time in years were 
considered random effects and a time*randomisation interaction variable was included. 
Since absolute values of MMSE and VAT, or logarithmic transformation of these values, 
were not normally distributed, change in MMSE/VAT since baseline, which was normally 
91
Modiﬁable dementia risk score for a prevention trial
6
distributed, was used as outcome variable in the model. We performed our analyses in R 
studio version 3.2 using the survival and nlme packages.130
RESULTS
Of the 3526 preDIVA participants at baseline, 3339 (94.7%) had all ten LIBRA items available 
at baseline and could be included in the analyses (Figure S1). Median LIBRA score at 
baseline was 3.1. Participants with the highest LIBRA index were slightly older (low 74.2 
years, intermediate 74.3 years, high 74.5 years; p-value <0.01) and more often had a low 
education level (low 19.2%, intermediate 22.1%, high 29.9%; p-value <0.01; Table 2). Systolic 
BP was highest in the intermediate LIBRA group (low 151.5 mmHg, intermediate 157.5 
mmHg, high 156.7 mmHg; p-value <0.01). The baseline characteristics of the intervention 
and control group within each LIBRA group were well balanced, except for small differences 
in total cholesterol (respectively, 5.3 versus 5.5 mmol/L; p-value 0.03) in the intermediate 
LIBRA group, and mean systolic BP (157.9 versus 155.3 mmHg; p-value 0.04) and sex (37.3% 
versus 44.2%; p-value 0.02) in the high LIBRA group (Table S1).
All-cause dementia was diagnosed in 220 (6.7%) participants; 76 of 1091 (7.0%) participants 
with a low LIBRA index, 71 of 1081 (6.6%) with an intermediate LIBRA index and 73 of 1102 
(6.6%) with a high LIBRA index. The LIBRA index (model 1) was not associated with incident 
dementia (crude hazard ratio [HR] 1.02 per point increase in LIBRA index, 95% confidence 
interval [CI] 0.96-1.09). Adding education to the LIBRA index (model 2) did not change these 
results (HR 1.06; 95% CI 0.90-1.24). The LIBRA index including education, age and sex (model 
3) was significantly associated with incident dementia (HR 1.07, 95% CI 1.02-1.12). 
The HR of the effect of intensive vascular care on incident all-cause dementia was 0.71 
(95% CI 0.45-1.12) in the low, 1.06 (95% CI 0.66-1.69) in the intermediate and 1.02 (95% CI 
0.64-1.62) in the high LIBRA group (model 1; Figure 1; Table 3). The interaction between 
randomisation and LIBRA index divided in tertiles was not significant. Also, when including 
age, sex and education (model 2 and 3) or excluding coronary heart disease (model 4) in 
the LIBRA index and stratifying our study population based on this modified LIBRA index, 
the intervention was not effective in any of the groups (Table 3). Adjustment for baseline 
imbalances or education did not significantly influence the results, nor did accounting for 
clustering within general practices and health-care centres (Table S2). The results were 
similar in the per protocol analysis (Table S2). Mortality risk increased with increasing LIBRA 
index, but the intervention effect on mortality was not significantly different in the LIBRA 
risk groups (Table S3). In all secondary analyses, the HR was lowest, albeit non-significant, in 
participants with the lowest LIBRA index (Table S2). Subgroup analyses showed a significant 
interaction (p-value 0.03) between age and randomisation in the intermediate LIBRA group 
with a lower HR in younger participants aged <74.3 years (HR 0.55; 95% 0.26-1.17) compared 
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Table 2 - Baseline characteristics by LIBRA group
Low 
LIBRA index 
Intermediate 
LIBRA index 
High 
LIBRA index 
P-value
Total number of participants 1091 1081 1102
Range in LIBRA index -1.0 to 2.6 2.6 to 4.2 4.2 to 11.6
Demographics
Age (years) 74.2 (SD 2.5) 74.3 (SD 2.5) 74.5 (SD 2.5) <0.01
Sex (male) 528 (48.4%) 519 (48.0%) 445 (40.4%) <0.01
Education <0.01
 Low (<7 years) 209 (19.2%) 239 (22.1%) 330 (29.9%)
 Medium (7-12 years) 695 (63.7%) 671 (62.1%) 660 (59.9%)
 High (>12 years) 179 (16.4%) 161 (14.9%) 101 (9.2%)
Race (white) 1057 (96.9%) 1042 (96.4%) 1054 (95.6%) <0.01
Medical history
CVD (excl. stroke or TIA) 66 (6.0%) 372 (34.4%) 526 (47.7%) <0.01
Stroke or TIA 60 (5.5%) 95 (8.8%) 169 (15.3%) <0.01
Cardiovascular risk factors
Systolic BP (mmHg) 151.5 (SD 22.0) 157.5 (SD 20.8) 156.7 (SD 20.6) <0.01
Diastolic BP (mmHg) 81.0 (SD 10.9) 82.0 (SD 10.9) 81.3 (SD 11.0) 0.09
Total cholesterol (mmol/L) 5.4 (SD 0.9) 5.4 (SD 1.1) 4.9 (SD 1.2) <0.01
LDL cholesterol (mmol/L) 3.3 (SD 0.8) 3.2 (SD 1.0) 2.8 (SD 1.0) <0.01
Body mass index (kg/m2) 25.9 (SD 3.1) 26.7 (SD 3.6) 29.6 (SD 4.6) <0.01
Type 2 diabetes 30 (2.7%) 103 (9.5%) 460 (41.7%) <0.01
Smoking (currently) 46 (4.2%) 113 (10.5%) 265 (24.0%) <0.01
Alcohol use (units/week) 3 [0-7] 4 [0-14] 0 [0-10] <0.01
Physically active (WHO) 1065 (97.6%) 990 (91.6%) 784 (71.1%) <0.01
Creatinine (umol/L) 77 [68-88] 80 [68-93] 82 [71-97] <0.01
Medication use
Antihypertensive medication 332 (30.4%) 631 (58.4%) 838 (76.0%) <0.01
Cholesterol lowering medication 77 (7.1%) 370 (34.2%) 664 (60.3%) <0.01
Disability and neuropsychiatric assessment
Mini-mental State Examination (MMSE) 29 [28-30] 28,5 [27-29] 28 [27-29] <0.01
Visual Association Test (VAT) 6 [5-6] 6 [5-6] 6 [5-6] 0.05
Geriatric Depression Scale (GDS) 1 [0-1] 1 [0-2] 2 [0-4] <0.01
Data are presented as number (percentage), mean (standard deviation) or median [interquartile range]. CVD indicates 
cardiovascular disease; excl., excluding; TIA, transient ischemic attack; BP, blood pressure; LDL, low-density lipoprotein; 
WHO, world health organisation.
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Table 3 - Intervention effect on incident all-cause dementia across the models, by LIBRA group
LIBRA group
Intervention 
(n,%)
Control 
(n,%)
Hazard ratio 
(95% CI)
p-for 
interaction
Model 1 – LIBRA index Low 33/567 (5.8%) 43/524 (8.2%) 0.71 (0.45-1.12) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.06 (0.66-1.69) 0.23
High 41/606 (6.8%) 32/496 (6.5%) 1.02 (0.64-1.62) 0.27
Model 2 – LIBRA index 
including education 
Low 28/555 (5.0%) 39/498 (7.8%) 0.64 (0.40-1.05) Ref
Intermediate 38/525 (7.2%) 31/482 (6.4%) 1.11 (0.69-1.79) 0.12
High 46/660 (7.0%) 35/525 (6.7%) 1.03 (0.66-1.59) 0.17
Model 3 – LIBRA index 
including age, sex & 
education 
Low 32/564 (5.7%) 33/515 (6.4%) 0.88 (0.54-1.43) Ref
Intermediate 35/568 (6.2%) 34/510 (6.7%) 0.91 (0.57-1.47) 0.94
High 45/608 (7.4%) 38/480 (7.9%) 0.92 (0.59-1.41) 0.92
Model 4 – LIBRA index 
excluding coronary heart 
disease 
Low 36/559 (6.0%) 45/559 (8.1%) 0.75 (0.48-1.16) Ref
Intermediate 35/570 (6.1%) 28/477 (5.9%) 1.05 (0.64-1.72) 0.32
High 42/580 (7.2%) 34/489 (7.0%) 1.01 (0.64-1.59) 0.34
CI indicates confidence interval; ref, reference category
Figure 1 -  Cumulative incidence curves of the risk of dementia comparing intervention and control 
group in participants with a low, intermediate and high LIBRA index
The line indicates the incidence and the shaded area the 95% confidence interval. The number of participants at risk at 6 
years follow-up were 791 in the low LIBRA group (408 intervention; 383 control), 756 in the intermediate LIBRA group (400 
intervention; 356 control) and 738 in the high LIBRA group (406 intervention, 332 control).
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Figure 2 - Effect of the intervention on MMSE (a) and VAT (b) change since baseline in the LIBRA 
groups 
Trajectories of change in MMSE and VAT since baseline comparing control (red line) to intervention (blue line) group in 
each LIBRA group, as predicted with the multilevel growth model. A positive value indicates an increase in MMSE/VAT 
since baseline, while a negative value indicates decrease. MMSE indicates mini-mental state examination; VAT, visual 
association test.
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to older participants (HR 1.65; 95% CI 0.88-3.09) (Table S4). We found an interaction with 
diabetes in the high LIBRA group (p-value 0.03), with a lower HR in participants with diabetes 
(HR 0.61; 95% CI 0.32-1.15) in comparison to those without (HR 1.78; 95% CI 0.87-3.64). We 
found no other interactions in the subgroup analyses. Participants with a higher LIBRA index 
had on average more decline in systolic BP (respectively in the low, intermediate and high 
LIBRA group; -2.3, -5.9, -5.8; p-value <0.01), less decline in total cholesterol (-0.3, -0.3, -0.1; 
p-value <0.01) and more decline in BMI (-0.5, -0.5, -0.9; p-value <0.01). The intervention led 
to a significant decline in systolic BP in the low (intervention vs control; -3.9 vs. -0.5; p-value 
0.03) and intermediate LIBRA group (-7.4 vs. -4.2; p-value 0.04), but not in the high LIBRA 
group (-7.1 vs. -4.3; p-value 0.09; Table S5). The intervention did not significantly reduce 
cholesterol or BMI in any of the LIBRA groups (Table S5).
2674 participants had at least one valid MMSE score and 2671 at least one valid VAT 
score after baseline and could be included in the analyses on cognitive decline (Figure 
e-1). Participants excluded from these analyses were on average older, had a higher 
cardiovascular risk and a lower baseline MMSE and VAT (Table S6). After three years, decline 
in MMSE did not significantly differ between the intervention and control group among 
participants with a low (mean difference [MD] -0.08; 95% CI -0.28 to 0.13), intermediate (MD 
0.07; 95% CI -0.14 to 0.27) or high LIBRA index (MD -0.06; 95% CI -0.30 to 0.18; Figure 2a, 
Table S7). Decline in VAT also did not differ between treatment groups in the low (MD 0.03; 
95% CI -0.09 to 0.14), intermediate (MD -0.04; 95% CI -0.16 to 0.08) or high LIBRA group (MD 
0.07; 95% CI -0.05 to 0.19; Figure 2b, Table S7).
DISCUSSION
In the preDIVA study population, aged 70-78 years, the LIBRA index did not identify a high-
risk group in whom the multi-domain intervention was effective in preventing dementia or 
cognitive decline. On the contrary, there was a trend for a preventive effect in the subgroup 
with a low LIBRA index. Results were comparable when including non-modifiable risk 
factors in the LIBRA index. 
The concept of selecting people at increased risk of dementia for preventive interventions 
to magnify the intervention effect is widely supported among experts in the field and has 
been incorporated in the design of recent multi-domain prevention trials.14,15 Our results 
do not support this strategy, and are even in contrast with this concept, at least in later life, 
suggesting a more favourable effect of the intervention in those with a low LIBRA index. 
A potential explanation for this is that the contrast between the intervention and control 
condition was too small, partly due to Hawthorne effects and improvements in the standard 
care for cardiovascular risk management during the trial.16 Although in participants with a 
higher LIBRA index a greater reduction in systolic BP could be achieved this was the case in 
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both the intervention and control group and the difference between the treatment groups 
was smallest in the high LIBRA group. Another potential explanation for our results is that 
the LIBRA index does not successfully classify dementia risk in this older population aged 
70-78 years. Indeed, our analyses did not show an association between a high LIBRA index 
and increased risk of dementia. Since preDIVA is an RCT, this could potentially (partly) be 
due to the fact that the dementia risk was influenced during the trial by the intervention 
and/or Hawthorne effects. For example systolic blood pressure decreased by approximately 
8 mmHg in the intervention group and 4 mmHg in the control group, and the decline was 
steepest in participants with hypertension at baseline.16 In one of the LIBRA validation studies, 
a higher LIBRA index was associated (at group level) with an increased risk of dementia in 
people aged 70-79 years.122 The individual predictive accuracy in late life was, however, 
poor, with a C statistic of 0.50, and seemed to decrease with increasing age. Investigating 
the utility of the LIBRA index as selection tool for prevention trials at a younger age (55-70 
years) may yield different results. A third potential explanation is that the factors in the LIBRA 
index and in other dementia risk scores are dichotomous and not designed to precisely 
quantify the magnitude of the risk/protective factor nor the room for improvement. For 
example, the potential for improvement is different for someone with a systolic BP of 125 
mmHg on antihypertensive medication compared to a person with a systolic BP of 155 
mmHg without medication, although both are weighted equally in the LIBRA index with 
the dichotomous score for hypertension (including both high BP and/or antihypertensive 
medication use). In order for a risk estimation tool to be useful for selection of high-risk 
populations for dementia prevention trials, the potential for improvement should be taken 
into account (for example by distinguishing treated or untreated hypertension). 
Regardless of the LIBRA index performance in high age populations, the concept of selecting 
people at high risk of dementia may be appropriate for younger people (that is, <70 years) 
only. In older people at high risk of dementia, cerebrovascular and neurodegenerative 
damage may already be irreversible, while those with a low risk could still benefit from 
risk factor improvement in order to maintain cognitive function. Also, several observational 
studies have shown a diminishing or even inverting association between risk factors and 
incident dementia in older people, as for example the J-shaped relation with BP.20 Therefore, 
future trials should perhaps either focus on people with lowest dementia risk in old age or 
highest dementia risk in midlife. This would, however, imply that substantially larger sample 
sizes or longer follow-up will be required, as incidence rates in these groups are lower.
A strength of this analysis is that preDIVA is, up until now, the only multi-domain prevention 
trial with dementia as primary outcome. The population-based approach with few 
exclusion criteria renders preDIVA a suitable study to test whether the LIBRA-index is a 
promising tool to select high-risk groups from the general population. A limitation is the 
overall neutral result of the preDIVA trial, perhaps limiting the possibility to detect high-
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risk groups who benefit most. However, a significant effect of the intervention was found 
in the per protocol analysis among participants with untreated hypertension at baseline 
(HR 0.54, 95% CI 0.32-0.92),16 while the results of the present analyses do not show a trend 
towards improved treatment effects in higher LIBRA groups. Another limitation is that 
no other neuropsychological tests were performed besides the MMSE and VAT to detect 
more subtle cognitive changes. We did not have information on two of the 12 LIBRA items, 
among which cognitive activity which is the strongest-weighted item in the LIBRA index.121 
These factors were, however, already identified as risk factors that need further validation in 
the systematic review and Delphi consensus used to design the LIBRA index and were also 
not included the validation study among people at late life (70-79 years).12,122 Furthermore, it 
may be argued that cognitive activity at this age is not as much a modifiable risk factor but 
rather an early indicator of developing cognitive decline and dementia.131 
CONCLUSIONS
Within our study population of community-dwelling people aged 70-78 years, a modifiable 
dementia risk score does not identify heterogeneity in treatment effect of a multi-domain 
intervention to prevent dementia or cognitive decline. It suggests that in older adults a 
high LIBRA index may not be a suitable parameter to select participants for a dementia 
prevention trial. Specific characteristics of the preDIVA study, including the overall neutral 
effect of the intervention and relatively high age-group may have contributed to the lack in 
discriminating capacity of the LIBRA index.
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Figure S1 - Flow diagram 
LIBRA indicates lifestyle for brain health; MMSE, mini-mental state examination; VAT, visual association test.
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Table S2 - Secondary analyses 
Intervention 
(n,%)
Control 
(n,%)
Hazard ratio 
(95% CI)
p-for 
interaction
Adjusting for 
total cholesterol
Low 33/567 (5.8%) 43/524 (8.2%) 0.71 (0.45-1.12) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.05 (0.66-1.68) 0.24
High 41/606 (6.8%) 32/496 (6.5%) 1.01 (0.64-1.60) 0.27
Adjusting for 
mean systolic BP
Low 33/567 (5.8%) 43/524 (8.2%) 0.72 (0.46-1.13) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.06 (0.66-1.69) 024
High 41/606 (6.8%) 32/496 (6.5%) 1.04 (0.65-1.65) 0.26
Adjusting for 
gender
Low 33/567 (5.8%) 43/524 (8.2%) 0.71 (0.45-1.12) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.06 (0.66-1.69) 0.24
High 41/606 (6.8%) 32/496 (6.5%) 1.01 (0.63-1.60) 0.27
Adjusting for 
education
Low 33/567 (5.8%) 43/524 (8.2%) 0.70 (0.44-1.10) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.03 (0.64-1.65) 0.25
High 41/606 (6.8%) 32/496 (6.5%) 105 (0.66-1.69) 0.21
Accounting for 
clustering*
Low 33/567 (5.8%) 43/524 (8.2%) 0.71 (0.45-1.13) Ref
Intermediate 39/576 (6.8%) 32/505 (6.3%) 1.06 (0.66-1.69) 0.22
High 41/606 (6.8%) 32/496 (6.5%) 1.05 (0.64-1.72) 0.26
Per-protocol 
analysis
Low 24/429 (5.6%) 41/480 (8.5%) 0.62 (0.37-1.02) Ref
Intermediate 24/452 (5.3%) 32/466 (6.9%) 0.71 (0.42-1.21) 0.73
High 30/443 (6.8) 29/463 (6.3%) 1.02 (0.61-1.71) 0.17
* Clusters were general practices and health-care centres. The p-for interaction indicates the p-value of the interaction 
variable intervention*LIBRA group. The p-for interaction for the intermediate LIBRA group compares the low with the 
intermediate LIBRA group; the p-for interaction for the high LIBRA group compares the low with the high LIBRA group. CI 
indicates confidence interval; Ref, reference category; BP, blood pressure.
Table S3 - Competing risk analysis
Dementia-free 
survival 
(CSHR, 95% CI)
Mortality 
(CSHR, 95% CI)
Dementia 
(CSHR, 95% CI)
Dementia 
(SHR, 95% CI)
Low risk 1.04 (0.91-1.19) 1.07 (0.74-1.56) 0.71 (0.45-1.12) 0.70 (0.44-1.10)
Intermediate risk 0.94 (0.83-1.08) 1.12 (0.81-1.54) 1.06 (0.66-1.69) 1.06 (0.67-1.70)
High risk 0.95 (0.83-1.09) 0.87 (0.68-1.12) 1.03 (0.65-1.63) 1.05 (0.66-1.67)
CSHR indicates cause specific hazard ratio, an estimate for the direct effect of the intervention on survival, mortality or 
dementia. SHR indicates subdistribution hazard ratio, an estimate for the risk of dementia while accounting for mortality 
as competing event. This is done by giving every participant with no diagnosis of dementia the longest follow-up duration 
instead censoring them at time of death or lost to follow-up.
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Table S6 - Baseline characteristics of participant in- and excluded in the cognitive analyses
Included in 
analyses
(N= 2674)
Excluded from 
analyses 
(N= 665)
P-value
Demographics
Age (years) 74.2 (SD 2.4) 74.8 (SD 2.5) <0.01
Sex (male) 1214 (45.4%) 310 (46.6%) 0.60
Education <0.01
 Low (<7 years) 596 (22.3%) 195 (29.3%)
 Medium (7-12 years) 1690 (63.2%) 375 (56.4%)
 High (>12 years) 367 (13.7%) 86 (12.9%)
Race (white) 2577 (96.4%) 641 (96.4%) 0.35
Medical history
CVD (excl. stroke or TIA) 763 (28.5%) 228 (34.3%) <0.01
Stroke or TIA 257 (9.6%) 76 (11.4%) 0.15
Cardiovascular risk factors
Systolic BP (mmHg) 154.7 (SD 21.0) 157.7 (SD 22.7) <0.01
Diastolic BP (mmHg) 81.3 (SD 10.7) 82.0 (SD 11.8) 0.21
Total cholesterol (mmol/L) 5.3 (SD 1.1) 5.2 (SD 1.1) 0.03
LDL cholesterol (mmol/L) 3.1 (SD 1.0) 3.0 (SD 0.9) 0.04
Body mass index (kg/m2) 27.4 (SD 4.2) 27.4 (SD 4.2) 0.96
Type 2 diabetes 502 (18.8%) 102 (15.3%) 0.04
Smoking (currently) 334 (12.5%) 105 (15.8%) 0.02
Alcohol use (units/week) 3 [0-10] 2 [0-10] 0.09
Physically active (WHO) 2353 (88%) 543 (81.7%) <0.01
Creatinine (umol/L) 79 [69-92] 81 [70-94] 0,0308
Medication use
Antihypertensive medication 1466 (54.8%) 371 (55.8%) 0.65
Cholesterol lowering medication 905 (33.8%) 228 (34.3%) 0.85
Disability and neuropsychiatric assessment
Mini-mental State Examination (MMSE) 29 [27-29] 28 [27-29] <0.01
Visual Association Test (VAT) 6 [5-6] 6 [5-6] <0.01
Geriatric Depression Scale (GDS) 1 [0-2] 1 [0-3] <0.01
Participants are excluded from the analyses on cognitive decline if they only had one MMSE/VAT. Data are presented as 
number (percentage), mean (standard deviation) or median [interquartile range]. CVD indicates cardiovascular disease; 
excl., excluding; TIA, transient ischemic attack; BP, blood pressure; LDL, low-density lipoprotein; WHO, world health 
organisation.
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Table S7 - Treatment effect on cognitive decline since baseline in the LIBRA risk groups
Low 
LIBRA index 
(beta, 95% CI)
Intermediate 
LIBRA index 
(beta, 95% CI)
High 
LIBRA index 
(beta, 95% CI)
MMSE 
decline
Intercept (at 3 years follow-up) 0.09 (-0.06 to 0.24) 0.00 (-0.15 to 0.14) 0.00 (-0.18 to 0.17)
Randomisation -0.08 (-0.28 to 0.13) 0.07 (-0.14 to 0.27) -0.06 (-0.30 to 0.18)
Time (years) -0.06 (-0.10 to -0.01) -0.04 (-0.09 to 0.01) -0.07 (-0.13 to -0.02)
Randomisation * Time 0.01 (-0.05 to 0.07) 0.01 (-0.06 to 0.07) 0.03 (-0.05 to 0.10)
VAT 
decline
Intercept (at 3 years follow-up) -0.22 (-0.30 to -0.14) -0.28 (-0.37 to -0.19) -0.25 (-0.34 to -0.16)
Randomisation -0.03 (-0.14 to 0.09) 0.04 (-0.08 to 0.16) -0.07 (-0.19 to 0.05)
Time (years) -0.09 (-0.14 to -0.05) -0.01 (-0.05 to 0.04) -0.10 (-0.16 to -0.04)
Randomisation * Time 0.05 (-0.01 to 0.12) -0.08 (-0.15 to -0.01) 0.02 (-0.06 to 0.10)
The intercept indicates the mean change in MMSE/VAT since baseline at 3 years follow-up for the control group. 
Randomisation indicates the mean difference in MMSE/VAT for the intervention compared to the control group at 
year 3 years. Time (years) indicates mean change in MMSE/VAT in the control group per year. The interaction term 
(Randomisation * Time) describes the difference in the effect of time for the intervention compared to the control group.
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ABSTRACT 
Background Randomised controlled trials (RCTs) are challenging in older populations, 
and relatively uncommon, particularly those testing eHealth interventions. 
Better understanding of older adults’ motivations for participating could 
improve recruitment and study design in future trials, thereby increasing 
their validity and facilitating intervention implementation.
Objective To explore older adults’ reasons for participating in a multinational 
eHealth prevention trial, and compare motivations between countries.
Study design  Mixed methods research using quantitative (online questionnaire) and 
and setting qualitative (semi-structured interviews) approaches in a sub-study 
conducted during the recruitment phase of an 18-month RCT testing the 
efficacy of an eHealth intervention for self-management of risk factors 
for cardiovascular disease (CVD) and cognitive decline in older adults in 
Finland, France and the Netherlands.
Subjects 343 dementia-free community-dwellers aged 65+ with basic computer 
literacy and either ≥2 cardiovascular risk factors or history of CVD/diabetes.
Results Contributing to scientific progress, wanting to improve one’s lifestyle, and 
benefiting from additional medical monitoring were the predominant 
reasons for participating. Altruistic reasons were particularly relevant in 
France, while Finnish and Dutch participants mainly emphasised the 
benefits of lifestyle changes and regular medical check-ups. During 
interviews, preventing functional dependency emerged as a key 
underlying motivation. Some trial design features also influenced the 
decision to participate.
Conclusions Altruism and personal benefits motivated older adults to participate in 
the trial; emphasising such aspects could facilitate recruitment in future 
RCTs. Additional medical monitoring may be particularly appealing when 
access to public healthcare is considered limited. 
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INTRODUCTION
Given the unprecedented ageing of the global population,132 there is an urgent need 
for strategies to encourage healthy ageing and prevent age-related disorders, such as 
cardiovascular disease (CVD) and dementia. Healthy lifestyle and successful management 
of cardiovascular risk factors are thought to play an important role in this regard,11 but 
conclusive evidence and guidelines about effective and comprehensive interventions, 
particularly for dementia, are still lacking. Self-management could be a way to improve 
guideline adherence, and, with rising Internet use in older age-groups,133 wide-reaching 
and cost-efficient eHealth interventions targeting CVD and dementia risk factors, and 
promoting a healthy lifestyle, could be an innovative tool to encourage this.17 
Randomised controlled trials (RCTs), which are needed to demonstrate the efficacy of 
interventions, are challenging in older populations, not least because of difficulties with 
recruitment, which can threaten their validity.134-136 Therefore, RCTs targeting this age-group 
are relatively uncommon,137 particularly those testing eHealth interventions,138 presumably 
because Internet use has traditionally been lower in this population.133
A better understanding of older adults’ motivations for participating in RCTs could improve 
the design and recruitment of future trials, thus increasing the validity of their findings, and 
also facilitate the implementation of interventions at the population level. However, little is 
known about their opinions on and reasons for participating in RCTs,135 particularly in the 
context of lifestyle-based prevention or eHealth trials. Furthermore, it is unclear whether 
motivations differ between countries, since previous studies have generally related to trials 
conducted in a single country.137 
The primary aim of this analysis was, therefore, to explore older adults’ reasons for participating 
in a European multinational eHealth prevention trial, and to compare motivations between 
countries. Furthermore, we aimed to specifically assess the influence of using an Internet 
intervention on the decision to participate in a prevention trial.
METHODS
Setting & participants
ACCEPT-HATICE was a mixed-methods sub-study of the ‘Healthy Ageing Through Internet 
Counselling in the Elderly’(HATICE) trial (ISRCTN48151589). Quantitative and qualitative 
approaches were used in order to explore reasons for participating among our entire 
sample, and gain a comprehensive understanding of underlying motivations in a sub-
sample. HATICE was an 18-month RCT testing the efficacy of an interactive Internet 
platform designed for older adults to improve the self-management of CVD risk factors 
for the prevention of CVD and cognitive decline.17,18 Between March 2015 and August 
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2016, 2724 dementia-free community-dwellers aged 65+ with (at least) basic computer 
literacy and either two or more CVD risk factors or history of CVD or diabetes were enrolled 
in Finland, France, and the Netherlands. Eligibility was verified during an initial screening 
visit, and a baseline visit was conducted within the next two weeks. Potential participants 
were identified and recruited primarily through: (1) a population registry (Finland), (2) 
commercial mailing lists and a prevention centre (France), and (3) general practitioners 
(GPs) (Netherlands) (Supplemental Table 1). Intervention participants had access to an 
interactive platform and the remote support of a lifestyle coach; control participants were 
offered a simplified version of the platform, with no interactive features or coach support. 
From April 2016 onwards, individuals scheduled for a HATICE screening visit (a priori eligible 
for the trial) were invited to complete the ACCEPT-HATICE questionnaire, preferably prior 
to screening, otherwise between the screening and baseline visits (Supplemental Table 
1, Figure 1). Individuals who were ultimately not included in the HATICE trial, either due 
to ineligibility or withdrawal, were excluded from this analysis. A convenience sample 
of questionnaire respondents, who agreed to be re-contacted, were invited for a semi-
structured interview within three months of their HATICE baseline visit. It was planned, given 
anticipated data saturation (due to the expected homogenous nature of study populations 
within each country), to perform approximately 15 interviews per country, and to maintain 
an equal balance between male/female and control/intervention group participants.  
HATICE and ACCEPT-HATICE were approved by the local ethics committee in each country, 
and all participants provided written informed consent.
Data Collection
An online questionnaire exploring reasons for participating in the HATICE trial (Supplementary 
Material) was adapted from a questionnaire designed for a previous study.139 Respondents 
were asked to what extent they agreed with a pre-defined list of statements relating to 
potential reasons for participating in the HATICE trial, and whether or not each statement 
was a reason why they agreed to participate. They could also specify other reasons, and 
were then asked which was their main reason for participating. Semi-structured interviews 
were carried out using a standard topic list (Supplementary Material) harmonised across 
the three countries, and covering an initial introduction of the interviewee, general 
perspectives on health and prevention, and reasons for participating in the HATICE trial. 
The topic list and recommendations for common procedures for conducting the interviews 
were based on previous experience and recent literature.139 Interviewers were not aware of 
the questionnaire responses at the time of the interviews. All interviews were recorded and 
transcribed at verbatim in their original language. 
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Data analysis
Questionnaire respondents’ baseline characteristics and reasons for participating were 
compared between countries using analysis of variance or Kruskal-Wallis tests for continuous 
variables, and chi squared or Fisher’s exact tests for categorical variables. Analyses were 
performed with Stata version 14.1 (StataCorp LP, College Station, Texas).
Structured content analysis was applied to the qualitative interview data.140 In each 
country, two independent researchers coded all interviews in the local language, using 
N.Vivo (version 11) or ATLAS.ti (version 1.6.0 (484)) software. The coding framework, initially 
based on the topic list, evolved inductively during regular meetings, held to ensure inter-
coder consistency within- and across-countries, until it captured the core themes of the 
interviews. After local researchers reached consensus, core themes and selected quotes 
were translated into English. The formal content analysis was complemented by interpretive 
and iterative analyses designed to reveal the key trends of interviewee opinions in each 
country and identify between-country differences. Quantitative and qualitative results were 
then interpreted in parallel and main themes were aligned.
RESULTS
341 participants completed the questionnaire (191 in Finland, 103 in France, 47 in the 
Netherlands), and the overall response rate was 79% (Finland: 81%, France: 72%, Netherlands: 
87%, p=0.039). Two thirds of the questionnaires were completed before the HATICE 
screening visit (Figure 1). The median age of respondents was 68.7 years, 48% were male, 
and 51% had university level education. Finnish respondents were younger than French 
and Dutch respondents, and had slightly poorer cognitive and physical performance, but 
were more physically active (Table 1). 
15, 13, and 18 participants were interviewed in Finland, France and the Netherlands, 
respectively, on average 1.7 (range: 0.2-3.2) months after their HATICE baseline visit (Figure 1). 
Most common reasons for participating in the HATICE trial
Figure 2 shows reasons for participation, based on the questionnaire results. Being interested 
in contributing to scientific progress (85% of all respondents), believing that improving 
diet and/or increasing level of physical exercise can have health benefits (84%), and the 
fact that participating would bring about additional medical monitoring (79%) were the 
three most common statements respondents agreed were reasons for participating in 
the trial. However, there were some between-country differences. Notably, significantly 
more questionnaire respondents in France (96%) and the Netherlands (94%) agreed that 
contributing to scientific progress was a reason for participation, compared to Finland (77%; 
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p<0.001), and Finnish (91%) and French (82%) respondents were more likely to agree that 
the potential health benefits of improving diet and/or increasing level of physical exercise 
were a reason for participating than Dutch respondents (62%; p<0.001) (Figure 2a).
Respondents also most frequently gave one of these three reasons as their main reason for 
participating in the HATICE trial, but while each one was cited by approximately a quarter 
of Finnish respondents, in France (51%) and the Netherlands (37%) “being interested in 
contributing to scientific progress” were the predominant main reason (Figure 2b).
These were also the most common reasons for participation evoked by interviewees. In-
depth analysis of interview data is presented below to provide further insight into these 
reasons and cross-country differences. 
Figure 1 - Study flowchart
*Two interviewees did not complete the questionnaire, but participated in HATICE together with their partner, who 
completed the questionnaire and was invited for an interview.
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Table 1 - Characteristics of questionnaire respondents, by country
Finland 
(N=191)
France 
(N=103)
Netherlands 
(N=47) p
Recruitment method
Invitation letter (pop. registry)
Invitation letter (GP patients)
Invitation letter (mailing list)
Prevention centre
Other*
191 (100.0%)
-
-
-
-
-
-
10 (9.7%)
79 (76.7%)
14 (13.6%)
-
47 (100.0%)
-
-
-
N/A
Socio-demographic characteristics
Age 67.8 [66.5-69.8] 70.5 [67.3-74.0] 69.6 [66.9-74.9] <0.001
Male 84 (44.0%) 58 (56.3%) 21 (44.7%) 0.117
University education 99 (51.8%) 56 (54.4%) 18 (38.3%) 0.170
Married/living with partner 155 (81.2%) 75 (72.8%) 32 (68.1%) 0.084
Cognition, mood and physical performance
MMSE 28 [27-29] 29 [28-29] 29 [28-30] <0.001
GDS 1 [0-3] 1 [1-4] 1 [1-2] 0.300
SPPB 11 [10-12] 12 [11-12] 12 [11-12] <0.001
Cardiovascular risk profile
Current smoker 14 (7.7%) 5 (5.1%) 1 (2.3%) 0.389
Obesity (BMI≥30) 75 (39.3%) 27 (26.2%) 18 (38.3%) 0.073
Hypertension 149 (78.0%) 75 (72.8%) 36 (76.6%) 0.606
Dyslipidaemia 182 (95.3%) 100 (97.1%) 47 (100.0%) 0.318
Diabetes mellitus 39 (20.4%) 13 (12.8%) 9 (19.2%) 0.257
<150 minutes of moderate intensity physical 
activity/week
30 (15.7%) 35 (34.0%) 11 (23.4%) 0.002
History of CVD** 35 (18.5%) 21 (20.8%) 10 (21.3%) 0.854
Data are presented as median [IQR] or N (%).* Other recruitment strategies included: word of mouth, re-contacting 
participants of previous studies, and advertisements on institutional websites and in the press. Of the 13 French 
interviewees, 12 were recruited from the prevention centre, and the other from the mass mailing list invitation letter. ** 
At least one of the following: stroke/transient ischemic attack, myocardial infarction, angina pectoris, and/or peripheral 
arterial disease. BMI: body mass index; CVD: cardiovascular disease; GDS: Geriatric depression scale (score/15, higher score 
represents more depressive symptoms); MMSE: Mini Mental Status Examination (score/30, higher score represents better 
cognition); SPPB: Short Physical Performance Battery (score/12, higher score represents better physical performance).
Contributing to science and altruism
Contribution to science and other altruistic reasons were frequently mentioned by 
interviewees in all countries as reasons to participate in the trial. Dutch and Finnish 
interviewees tended to talk about the usefulness of medical research in general terms, 
and the altruistic motives were discussed very broadly and/or in addition to other more 
important reasons, including personal benefits:
”What I just mentioned, I can learn things from that. And that can contribute to my health 
and, with the results from the complete trial, it can benefit society. That is my motive to 
participate.” [NL-10]                                                        
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Figure 2 - Reasons for participation
A) Proportion of questionnaire respondents who agreed that this was a reason for participating in the HATICE trial
B) Proportion of questionnaire respondents who stated that this was their main reason for participating in the 
HATICE trial
Asterisks indicate p-values for χ² tests (between-country comparison): *p<0.05; **p<0.01; ***p<0.001
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In Finland, many HATICE participants had previously taken part in studies and considered it 
a ‘duty’ to participate in medical research:
”Well I guess it [reason for participation] was dutifulness. When I was invited, I just thought 
‘why not’? Since I had no reason to refuse. I didn’t think about it that much. I just wondered 
how many visits there would be, and if I have time to attend all of them, but… There weren’t a 
lot of visits. I didn’t really think about it very much. (…)  It was an automatic decision.” [FI-03]
French interviewees, however, gave specific meaning to their participation in a trial targeted 
towards healthy ageing, expecting it to contribute to a better understanding of healthy 
ageing and, thus, to improve the quality of life of the oldest old– a group to which they will 
soon belong to themselves. Ageing and being dependent on others evoked anxiety and 
fear, and many interviewees reported negative experiences concerning the care of older 
adults in institutions: 
”Taking care of my mother is not easy. She is 89 and she is completely dependent. (…) We 
can’t put her in a retirement home because she doesn’t want us to, and so we have to take 
care of her ourselves. We are the last generation to do so. My daughters will not take care 
of me. They will not be able to; they will work until who knows when… We have already 
integrated the fact that for us, we will eventually end up in a retirement home. I am worried 
about ageing, and especially about being dependent. I see my completely dependent mother 
and I am projecting myself.” [FR-06]
Such interviewees were particularly prone to raise ‘contribution to science’ as their main 
reason for participation in HATICE, and to admit that they would not necessarily commit to 
other kinds of studies: 
”I want to help resolve the problem [of ageing] in general, and it also forces me to respect 
certain rules. And if it can be useful for someone else, why not? But I would say that, first and 
foremost, I am participating to advance medicine, just for that. (…) I don’t really like the fact 
that I am being made to make changes, a new lifestyle, but perhaps it will also help me, bring 
me comfort in life and in my old age, and also be useful for others.” [FR-08]
”My motivation to participate is as I said before: to see if this can help me and, through me, 
help others. (…) I volunteer in a nursing home and I tell myself that it’s not very cool to grow 
old like this. And I hope, through physical and mental well-being, that we can find ways to 
protect ourselves and stay in good health as long as possible. Because when you get into a 
retirement home, it’s not happy.” [FR-02]
Improving lifestyle
Lifestyle improvement was also frequently mentioned as a reason for participation during 
interviews, and was expanded upon in particular by Dutch and Finnish interviewees. 
Some had a specific goal in mind, such as weight reduction, increasing physical activity, 
or improving dietary habits, or had already embarked on adopting a healthier lifestyle, and 
hoped that HATICE could provide external motivation and support:
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”Interviewer: Do you have any wishes or goals for a healthy lifestyle? 
Participant: To lose weight. (…) I wish I could do liposuction. Or for someone to guide me 
and push me to do things [physical activity]. I give up too easily. I think it [physical activity] 
is boring by myself and so I would prefer to do that with someone else or an organisation.” 
[NL-09]  
Lifestyle changes were generally perceived as useful and effective for the prevention of CVD 
in all three countries; however, the purpose of and motivation towards improved lifestyle 
did not seem to be preventing CVD as such, but to improve both current and future health 
and quality of life:
”Well of course it [motivation for prevention] is to feel more comfortable. I feel more 
comfortable physically when I’m lighter, and I presume that my ailments will be milder after 
I lose some weight.” [FI-05] 
Again, preventing functional dependence was a common concern: 
”And I hope, through physical and mental well-being, that we can find ways to protect 
ourselves and stay in good health as long as possible. (...) I am not sure I will escape 
dependence, Alzheimer’s disease and other pathologies. But if I can do my best to stay active 
as long as possible, then I should do it.” [FR-02]
”Maybe it’s the thought of not wanting to be a burden to others and that others don’t need 
to take care of you. A strong constitution and condition and being healthy will help one feel 
more comfortable. (…) Some [CVD] diseases can be very mild, and they don’t have much 
impact on daily life, but others can be quite serious. (…) That’s the tricky thing: when you 
end up in a wheelchair or become dependent of others. With that in mind, one should aim to 
prevent that from happening.” [FI-14]
Furthermore, some Dutch and Finnish interviewees hoped that lifestyle improvement 
would allow them to reduce or avoid medication: 
”I am really curious to see if, as a consequence of my behavioural change due to the trial, the 
medication I use (…) maybe my blood thinners and cholesterol medication etcetera, that we 
can, well maybe not stop them, but see if I can handle a lower dosage.” [NL-10]
”Well it made me worried [when the high blood pressure and cholesterol levels were 
discovered], but I was not scared. But I thought I needed to make changes now. (…) I did not 
really have any other options but to change my lifestyle. Or to start taking anti-hypertensives 
already in the mid-1990s. (…) And the diabetes drugs and so on. I rather changed my lifestyle 
so that I did not have to start taking those medications.” [FI-04]
For some Dutch interviewees it felt like an obligation to themselves and/or their treating 
physicians to do everything in they could for a healthy lifestyle.
”You pay attention that you do enough physical exercise. I know all the risk factors. I don’t 
have high blood pressure or those kind of things. But I don’t eat a lot of salt. So I incorporate it 
in my life. And I think it would be an insult to those who have treated me if I didn’t do that. A 
piece of gratitude also. And I think that is a sort of obligation that I feel.” [NL-01] 
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Medical monitoring
Additional medical monitoring was an important reason for participating for Finnish and 
Dutch interviewees:
”Yes, I had hoped that they [from the HATICE trial] would conclude that I was very healthy 
(…), that there is nothing wrong with my arteries and heart.” [NL-07]
It attracted not only proactive individuals already monitoring their health, but also those 
who were less worried about their health or tended to postpone or avoid seeking medical 
advice. For such individuals, participation provides a free and convenient opportunity to 
ascertain good health status:
”Well, [I decided to participate] just because I’m so lazy to book an appointment or see the 
doctor. I’ve already been in so many trials, I’ve always received the medical check-up there. 
Like for example my thyroid disease that was discovered in one of these studies, I probably 
wouldn’t have seen a doctor otherwise. It is good to have regular follow-up and monitoring if 
something occurs. And it’s free of charge. And all the appointments are booked for me and I 
don’t need to… It is good that it’s so easy (…) I’m too lazy to book any appointments. In this 
trial they do all the blood tests regularly and I know exactly where I stand. ” [FI-13]
In the Netherlands, interviewees who appreciated medical monitoring often mentioned 
that they did not expect anything to be wrong; they merely felt comforted by the check-
up.  In Finland, interviewees considered medical monitoring in HATICE relevant because of 
difficulties accessing regular health care, particularly for prevention purposes, and notably 
after retirement when occupational health care services are no longer available:  
”After retirement, there are no regular follow-ups anymore. One should seek medical 
attention himself, if needed. (…) And maybe [I decided to participate] also because I’m not in 
working life anymore. One doesn’t go to the health care centre every year or even every other 
year to get the blood tests and other things done. Somehow it feels that they [healthcare 
professional]  are so busy and it’s impossible to reach them. Therefore, it just doesn’t get done. 
I just mentioned earlier to you that the health care system works well, but actually, when you 
need the services, it’s difficult to access. And then the fact that I’m not sick and I should explain 
them why I need the blood tests and why my values need to be monitored. I don’t know if 
I’ve got the right impression, but sometimes it feels like they don’t think it’s necessary at all. 
A healthy person just wants to get tested for no reason. When I found out about this trial, I 
thought that, at least for 18 months, someone will examine me.” [FI-07]
For some Finnish and Dutch interviewees, detection of CVD/memory disorders or their risk 
factors also motivated participation, particularly when there was a family history of such 
conditions: 
”My father has both heart disease and a memory disorder. Of course, I’m interested in finding 
out what my situation is.” [FI-09]
French interviewees did not spontaneously mention medical monitoring as a motive for 
118
Chapter 7
participation, but frequently mentioned having a close and trustworthy relationship with 
their own GP, and that regular health care was relatively easy to access.
Impact of Internet, and other reasons for participating in the HATICE trial
Overall, less than 5% of questionnaire respondents stated that an Internet-related factor 
was their main reason for participating (Figure 2b). The majority, however, agreed that 
using an Internet platform was a fun and/or effective way to improve health (Figure 2a). 
Other Internet-related factors influenced participation for less than 50% of respondents, 
and some between-country differences were observed (Figure 2a). Interviewees did 
not consider Internet-related factors a major influence on their decision to participate. 
However, contributing to developing an Internet health tool, and the convenience of 
having continuous access to an Internet intervention were mentioned by some:
”I said yes [to the stud] because, with Internet, it is not constraining. I can access the website 
anytime, even at night.” [FR-09]
Interviewees with more extensive computer experience, in particular, thought that Internet 
could be a useful tool to improve lifestyle, and while the Internet in general was sometimes 
considered an unreliable source of information, the HATICE platform was considered 
trustworthy as it was offered by a university:
”Well, in this kind of a study, I think that… The premise is that it (the information) is reliable. 
(…) I have learned that information and knowledge generated at the university is reliable 
(…). (Interviewer: Right. So you trust the information you read in this study?) Yes. (Interviewer: 
What about information you read online?) Yes, well that should be viewed critically.” [FI-05]
Potential barriers to participation associated with Internet use included lack of confidence 
in computer skills, although basic level of computer literacy was a prerequisite for HATICE 
participation:
”Well I thought for a second, will that work with the Internet? Just for a moment and the thought 
went away just as quickly, because it looked relatively easy. That was not too bad.” [NL-07]
Also, the importance of social interaction and communication, even in an Internet-based 
intervention trial, was emphasised. 
Several other reasons for participation emerged from the questionnaires and interviews, 
including being influenced by the invitation letter. A personalised letter, particularly for Dutch 
participants, when signed by their GP, conveyed a sense of reliability and trustworthiness: 
(Interviewer: What was the reason you agreed to participate to HATICE, when you previously 
declined to participate in other studies?) ”I think it was because of the way I was approached. 
It was just very clear and it was via my GP. Then I think, well that is probably very serious. 
That is not… someone can’t do anything crazy with that or whatever. Reliable, that is what 
I mean.” [NL-07]  
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Participants felt chosen and honoured to be asked to participate. Distance to the study 
centre and small number of study visits, occupying free time, getting a distraction during a 
stressful life period, and getting new information about CVD and memory disorders were 
also mentioned: 
”Yes, they asked us and we felt honoured. I was very proud of it. Because I said to my son and 
brother-in-law, well we are participating in a study from the AMC [University Medical Centre]. 
He says, do you have to go there every time? I said, no, they come to my GP, so it is very close.” 
[NL-04]
Furthermore, participation was considered as fun, an opportunity to interact with people, 
and a way to satisfy curiosity. The non-pharmacological nature of the intervention attracted 
some participants. 
DISCUSSION
In this cross-national, mixed-methods study, involving older European adults, altruistic 
reasons, wanting to improve one’s lifestyle, and benefiting from additional medical 
monitoring were most frequent reasons for participating in an eHealth prevention trial. 
There were, however, some between-country variations in the level of importance given 
to each reason. Maintaining autonomy and preventing functional dependency, both for 
participants themselves, and for others, emerged as a key concern. The use of an Internet 
intervention did not seem to be a major motivator for participating in this trial. 
As in previous studies,135,137 wanting to support research and help others were frequent 
reasons for participating in the HATICE trial. However, contrary to Dutch and Finnish 
interviews, French interviews suggested that, rather than pure altruism (a concern for 
others in general), participation in this trial could be considered a fruit of social identification 
(a concern for a specific group, in this case older adults).141 Traditional kinship relationships, 
attitudes and policies regarding the care of older adults vary across Europe,142 ranging from 
the Nordic public service model to the Southern European family care model,143 which 
may explain our findings. Furthermore, the French participants were recruited in South-
West France, where the traditional family care model is currently shifting towards public 
service,144,145 which may evoke fear about the changing and unfamiliar care patterns for this 
age-group, particularly given the negative experiences reported of old-age dependence 
and its management, especially in nursing homes. 
Both questionnaire and interview responses highlighted that, particularly in Finland and the 
Netherlands, improving one’s lifestyle was an important reason for participating, consistent 
with younger intervention trial participants’ view,146 but again, interviews revealed that 
the underlying motivation of lifestyle improvements in this age-group was to maintain 
functional independence. Independence in various aspects of life has previously been 
emphasised as an important issue for older adults.147 
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Consistent with previous studies,148-150 our findings also indicated that personal health 
benefits and additional medical attention frequently motivate older adults to participate in 
a lifestyle-based prevention trial. However, in this multinational trial, the emphasis given to 
medical monitoring varied between countries. Finnish older adults in particular seemed to 
be motivated to participate for this reason, potentially because satisfaction with healthcare 
and perceived access to services has decreased in Finland over time,151 and having 
unmet medical needs is more common than in other countries, including France and the 
Netherlands.152 Some Finnish and Dutch interviewees felt discouraged from seeking health 
check-ups as part of routine medical care, unless there was something specifically wrong 
with them, but expressed a need to feel reassured that they were in good health. Although 
access to healthcare is not necessarily easier in France,153 people perceive the quality of 
their care as relatively higher than in other European countries.154 Furthermore, most French 
participants felt they already received sufficient care, and that HATICE was complementary 
to existing health services.
               
The main limitations of our study relate to selection bias. First, we used different recruitment 
methods in each country (e.g. many French participants were recruited through a 
prevention, while in the Netherlands, letters were sent to all potentially eligible patients 
in GP practices), which probably affected the between-country comparability of our 
samples. However, the different settings add diversity to our findings, and all participants 
nonetheless met the same eligibility criteria for the HATICE trial. Second, our participants 
are not representative of the entire older populations in the respective countries. Indeed, 
prevention trial participants tend to be healthier and more highly educated than the general 
population,155 and selection bias could have been further increased in our study because, 
in order to be eligible, individuals had to have basic computer skills. This could also have 
influenced their views about participating in an Internet intervention. Finally, our sample 
was relatively small, and we only approached a convenience sample of HATICE participants, 
not all of whom agreed to participate in this sub-study, although response rates were high. 
Nonetheless, to our knowledge, this is the first study examining older adults’ reasons 
for participating in an eHealth prevention trial. Our work is strengthened by our mixed 
methods and cross-national approach, which highlighted the influence of differences in 
health, culture and social care systems. Additionally, our study was conducted during the 
recruitment phase of a real-life trial, rather than asking opinions about participating in a 
hypothetical trial, as in some previous studies.137
In addition to informing the design of recruitment strategies in future trials promoting 
healthy ageing, our results could also help to better tailor future intervention strategies 
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to the needs and desires of older adults, which in turn could improve recruitment. Box 1 
presents our recommendations, based on our findings, some of which reinforce previous 
results relating to the HATICE trial.156 This study focused on reasons for participation, and 
further research is required to identify potentially modifiable barriers to participation, and to 
study how reasons for participation affect retention, adherence or engagement. 
Box 1 - Recommendations for designing recruitment strategies and interventions for future trials 
promoting healthy ageing in older adults
Recruitment
When inviting older adults to participate in future trials, recruitment could be facilitated by emphasising:
% Potential personal beneﬁts, such as regular medical check-ups and contacts with healthcare professionals, 
particularly when access to them is diﬃcult in the local public healthcare system. For some older adults 
this can facilitate the early detection of health problems, while for others it can provide reassurance that 
they are in good health. However, it should be underlined that participation in a trial does not and should 
not replace regular healthcare.
% Potential societal beneﬁts, particularly those aﬀecting older adults, such as preventing loss of autonomy. 
% Inﬂuential study design features, including the involvement of respected local institutions or people (e.g. 
hospitals, universities or GPs); the logistical constraints (or lack thereof ) of taking part (e.g. the number 
and location of study visits); and the expected ease of use of any technological devices required for 
the trial (which older adults may not be familiar or conﬁdent with, or mentioning that training will be 
provided to use such devices).
Intervention design
The following ﬁndings could be incorporated into the design of future interventions:
% Health information available on the internet can be perceived as unreliable by older adults, and so 
receiving understandable and accurate information from a reliable source, particularly regarding 
cardiovascular diseases and memory disorders/dementia, would be a beneﬁt. 
% Older people seem to require speciﬁc practical advice and encouragement about making lifestyle 
changes, particularly concerning diet and exercise, even if they are already motivated to do so.
% Having real-life (i.e. in person or by telephone) social interaction and communication are important 
elements to consider when designing interventions for older adults.
% Older adults may not feel conﬁdent about participating in an internet-based intervention, even if they 
have basic computer skills. Suﬃcient emphasis should therefore be given to training and ease of use for 
such interventions.
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ACCEPT-HATICE questionnaire
I agree with this statement:
This is a reason 
why I accepted to 
participate in the 
HATICE study:
To
ta
lly
 
ag
re
e
So
m
ew
ha
t 
ag
re
e
So
m
ew
ha
t 
di
sa
gr
ee
To
ta
lly
 
di
sa
gr
ee
Yes No
1. I am interested in contributing to scientiﬁc 
progress
     
2. My family and friends encouraged me to 
participate in the HATICE study
     
3. Participating in the HATICE study will help me to 
occupy my free time
     
4. Participating in the HATICE study will help me to 
improve my diet
     
5. Participating in the HATICE study will help me to 
increase my level of physical exercise
     
6. Participating in the HATICE study will enable me to 
receive speciﬁc medical monitoring
     
7. Improving my diet and/or increasing my level of 
physical exercise can have beneﬁts on my health
     
8. I am worried about my health      
9. An internet-based programme is an eﬀective way 
to improve my health
     
10. An internet-based programme is a fun way to 
improve my health
     
11. I like using the internet      
12. Participating in the HATICE study will help me to 
improve my internet skills
     
13. Thanks to the internet, I can follow the programme 
when and where I want
     
14. Participating in an internet-based programme is a 
way to show myself that I am modern (up-to-date)
     
Please specify any other reasons you have for 
participating:
15.      
16.      
Of all of these reasons, which is the main reason why you accepted to participate in the HATICE study? Please 
write in the box belox the number (from the table above) corresponding to this reason:
The main reason why I accepted to participate in the HATICE study is the reason n° |__|__|
Would you agree to be re-contacted by a researcher to answer some further questions? 
 YES    NO
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ACCEPT-HATICE interview guide
[Examples of potential questions are given in italics]
I. Reconstruction of life-course 
Introduction: First of all, I would like you to introduce yourself and to tell me about your daily activities.
Sociodemographic data 
- Marital status, number of children & grandchildren, family and friends, geographical proximity, retirement 
Environmental and psychosocial factors related to health and quality of life 
- Perceived and actual social support  
- Social and cultural activities (leisure activities); Daily activities (domestic activities) 
- Type of personality 
Can you tell me a bit more about your family and friends? Can you tell me a bit more how you spend your time?
II. Relationship with health and perceived health status 
Introduction: I would like you to tell me about your health practices and how you react when you are faced with medical 
problems. 
Health practices: evaluation of the interviewees’ behaviour when they have a health problem
- Relationship with doctors or medical/health professionals, frequency of consultations
- Relationship with medications (e.g. preference for prescribed or over the counter medications, or 
complementary medicine)
When you have a medical problem or a question about your health, what steps do you take? (E.g. in terms of consulting 
a doctor, or taking medication)
 
Perceived and actual health status
- Coping strategies for health problems
In general, how do you cope with health problems (for example, illness)? Do you tend to look for a solution? To ask for help 
or advice? Or do you generally tend to rely only on yourself? Do you tend to focus on a problem, or avoid it? Try to forget it? 
- Causal attribution (origin and responsibility of illness) and locus of control
What do health and illness mean to you? What do you think about your health? Does it depend on you? On your doctors? 
On chance or destiny? Would you say that being ill is a punishment? 
III. Perception of cardiovascular disease (CVD) risk and prevention 
Introduction: I would like you to tell me about cardiovascular disease: what it means to you and whether/how it can be 
prevented.
Exploration of beliefs about CVD (e.g. origin/cause, quest of meaning)
Level of knowledge about risks, management, and consequences associated with CVD and risk factors
What do you know about cardiovascular disease and its management?  What does it mean to you? What can one do to 
manage this disease or prevent it worsening? 
Prevention practices for CVD and risk factors
What is your personal situation in terms of cardiovascular disease? Could you tell me what do you do to try to manage or 
prevent cardiovascular disease? And how do you find out what you should do? Do you look for information about health 
in general and about specific health problems that you may encounter?
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Perceived utility and effectiveness of prevention of CVD via dietary habits, physical activity, medication
Role of Internet and online support in promoting healthy aging and preventing CVD 
- Advantages and disadvantages of using Internet for health and prevention
- Level of credibility of information on the Internet
- Perceived effectiveness of prevention of CVD and potential risks 
Could you tell me about how you use the internet (frequency, uses, on their own or with help, etc.)? What do you think 
about prevention on the internet? In what way do you think that internet can be a useful tool for your health? 
V.  Reasons for participation in the HATICE trial 
Introduction: Could you tell me about where you are up to in the HATICE trial, and why you decided to participate?
 

ENGAGING OLDER PEOPLE 
IN AN INTERNET PLATFORM 
FOR CARDIOVASCULAR RISK 
SELF-MANAGEMENT 
A QUALITATIVE STUDY AMONG 
DUTCH HATICE PARTICIPANTS
Tessa van Middelaar
Cathrien R.L. Beishuizen
Juliette Guillemont
Mariagnese Barbera
Edo Richard
Eric P. Moll van Charante
on behalf of the HATICE consortium
BMJ Open. 2018;8(1): e019683.
128
Chapter 8
ABSTRACT
Objectives To study older peoples’ experiences with an interactive internet platform for 
cardiovascular self-management, to assess which factors influence initial and 
sustained engagement. To assess their views on future use within primary 
care. 
Design Qualitative semistructured interview study, with thematic analysis. 
Setting Primary care in the Netherlands.
Participants People ≥65 years with an increased risk of cardiovascular disease who used 
the ‘Healthy Ageing Through Internet Counselling in the Elderly’ (HATICE) 
internet platform with remote support of a coach. Participants were 
selected using a purposive sampling method based on gender, age, level 
of education, cardiovascular history, diabetes, duration of participation and 
login frequency.
Results We performed 17 interviews with 20 participants, including three couples. 
In the initial phase, platform engagement was influenced by perceived 
computer literacy of the participants, user-friendliness, acceptability and 
appropriateness of the intervention, and the initial interaction with the 
coach. Sustained platform use was mainly facilitated by a relationship of 
trust with the coach. Other facilitating factors were regular automatic and 
personal reminders, clear expectations of the platform, incorporation into 
daily routine, social support and a loyal and persistent attitude. Perceived 
lack of change in content of the platform could work both stimulating and 
discouraging. Participants supported the idea of embedding the platform 
into the primary care setting.
Conclusions Human support is crucial to initial and sustained engagement of older people 
in using an interactive internet platform for cardiovascular self-management. 
Regular reminders further facilitate sustained use, and increased tailoring to 
personal preference is recommended. Embedding the platform in primary 
health care may enhance future adoption.
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INTRODUCTION
In view of global ageing and the associated increasing burden of cardiovascular disease 
(CVD), prevention has become crucial.157 The effectiveness of preventive interventions 
is indisputable, even in old age.158,159 However, adherence to long-term lifestyle and 
medication regimens remains a daunting challenge. Average adherence rates for chronic 
illnesses are as low as 50%.160 Currently, in several countries, cardiovascular risk management 
programmes are implemented into primary care and delivered by practice nurses.161 
eHealth, that is, a method to deliver health services and information using the internet 
and related technologies, is a promising tool for delivery of prevention.162 It can enable 
self-management and improve the reach and sustainability of pre-existing preventive 
programs.163 In particular, an eHealth platform combined with human support (ie, a blended 
approach) has shown beneficial effects on cardiovascular risk factors.138 
Previous research on eHealth interventions identified several important influential factors 
of engagement; personal motivation, incorporation into personal life and quality of the 
eHealth intervention.164 However, it is unclear whether these are the same for initial and 
sustained engagement. For cardiovascular prevention, sustained engagement seems 
crucial, as the effectiveness of eHealth interventions on cardiovascular risk factors declines 
over time, especially after 1-year follow-up.138  Also, an eHealth intervention specifically 
targeted at older people should have a specific age-friendly design.165 It is important to 
assess the views of end users  of an eHealth intervention to improve its chances of successful 
implementation.166,167 
Our primary aim was to study older peoples’ experiences with an interactive internet 
platform for cardiovascular self-management, to assess which factors influence initial 
and sustained engagement.  Our secondary aim was to assess older people’s views on 
implementation of such a platform in the primary care setting. 
METHODS
Setting and participants
This qualitative study with semistructured interviews was performed among participants of 
the ‘Healthy Ageing Through Internet Counselling in the Elderly’ (HATICE, ISRCTN48151589) 
trial.17 HATICE is designed to investigate whether an internet platform for cardiovascular 
self-management can improve the cardiovascular risk profile. People ≥65 years with an 
increased risk of CVD were recruited to participate in HATICE in the Netherlands, Finland 
and France. Computer illiteracy, defined as the inability to send an email, was an exclusion 
criteria for the trial. Through a thorough design and validation process, we developed 
the internet platform for cardiovascular self-management, adapted to meet the specific 
requirements of older people.18,165 The intervention is based on Bandura’s social-cognitive 
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theory for self-management and behaviour change and incorporated Michie’s taxonomy 
for standardised definitions of behaviour change interventions.168,169 The platform offers 
blended care by remote support of a health-coach trained in motivational interviewing 
techniques and the transtheoretical (or stages of change) model.170,171 Participants can send 
messages and receive feedback from their coaches within the platform. Other functionalities 
of the platform include the ability to set lifestyle goals, record measurements (eg, blood 
pressure and weight), receive information on cardiovascular risk and healthy lifestyle and 
subscribe to lifestyle groups. The layout and navigation structure were kept simple to make 
the platform user-friendly for older people. The content was regularly updated with news 
items on relevant developments in cardiovascular prevention. The intervention was solely 
delivered via the platform, except for an initial inperson meeting with their coach at baseline, 
during which first lifestyle goals were set, and a phone call after 12 months follow-up. 
This qualitative substudy was only performed among Dutch intervention participants. They 
were purposively sampled on gender, age, level of education, history of CVD, diabetes, 
duration of participation and login frequency. Participants who prematurely ended their 
participation were also invited. Twenty out of 32 participants who were invited by telephone 
were willing to partake in the interview. Main reasons for people to decline participation 
were lack of time and too little overall use of the platform, even though we specifically 
aimed to also include these participants. All participants provided written informed consent. 
Data collection
Between July 2016 and January 2017 three researchers (TvM , CRLB  and Suzanne van 
Rhijn) held semistructured interviews following an interview guide (online supplementeray 
appendix 1), focusing on participant experiences with the platform. We iteratively 
adapted the interview guide during the data collection period. For example, we decided 
to separately address initial and sustained use as distinct phases in the engagement and 
adoption of the intervention, as sustained engagement is especially challenging in lifestyle 
interventions.138 During the interviews, participants were asked to log onto the platform to 
stimulate the discussion. The final part of the interview guide focused on the interaction 
with regular care, during which participants were asked if they preferred the platform to be 
incorporated in primary health care. The interviewers all had experience with conducting 
qualitative interviews. Two of the interviewers (TvM and CRLB) were involved in the design 
and maintenance of the platform (the participants were not made aware of this) and 
one (SvR) in the logistical support of the trial. The interviewers and participants had no 
professional relationship prior to the interview. Participants were interviewed in private 
at their homes, and the interviews lasted approximately 50 minutes. No repeat interviews 
were deemed necessary. Interviews were audiotaped and transcribed verbatim, and during 
the interviews, field notes were taken. 
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Coding and analysis
Two researchers (TvM and CRLB) thematically analysed the transcripts in an iterative 
process.100 First, each researcher independently coded transcripts following an inductive 
approach; next, the researchers discussed each other’s codes to achieve interobserver 
agreement. Subsequently, the researchers together categorized the codes to generate a 
structure of main themes and subthemes. Themes were derived from the data and were 
not hypothesized prior to data collection. At several points during the analysis process, 
results were discussed with other team members to ensure independent interpretation. 
After the first seven interviews, the interview guide was adapted based on one of these 
discussions, leading to a better distinction between initial and sustained engagement with 
the platform. Questions about initial engagement were asked to all participants and about 
sustained engagement to participants who had been in the study for at least 6 months. 
After 17 interviews, data saturation was reached as no new (sub)themes or issues emerged.
RESULTS
We performed 17 interviews with 20 participants (table 1). Three interviews took place with 
couples participating in the HATICE trial together, one of which had prematurely dropped 
out from the trial. The age of the participants ranged from 65 to 84 years. Ten (50%) 
participants had a history of CVD, and six (30%) had diabetes. Length of participation in the 
trial ranged from short (2-3 months, n=8 (40%)), intermediate (7-11 months, n=6 (30%)), to 
long (14-17 months, n=6 (30%)). 
Table 1 - Characteristics of the participants
Participant characteristics Study characteristics
Nr. Gender Age Education level* CVD DM
FU 
duration (mo)
Partner partic. 
in HATICE
Login frequency 
(per mo)
1 M 73 High + - 2.6 + 0.6
F 66 Intermediate - - 2.6 + 0.5
2 F 67 Intermediate + + 2.2 - 3.2
3 F 84 Low - - 3.2 - 2.7
4 M 71 High - - 2.4 - 4.4
5 F 67 Intermediate - - 2.3 - 0.3
6 M 68 High - - 2.3 + 0.4
F 70 Intermediate - - 2.3 + 0.7
7** F 71 Intermediate + + 10.5 + 0.7
M 74 Intermediate - - 10.3 + 0.9
8 M 65 Low + + 8.4 - 0.6
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Table 1 - Continued
Participant characteristics Study characteristics
Nr. Gender Age Education level* CVD DM
FU 
duration (mo)
Partner partic. 
in HATICE
Login frequency 
(per mo)
9 M 67 High + - 7.8 - 1.1
10 F 66 High - - 14.7 + 2.6
11 F 68 Intermediate - - 14.7 - 0.5
12 M 66 Low + + 7.1 - 1.8
13 F 74 High - - 9.4 - 4.7
14 M 65 Intermediate + + 15.8 - 0.8
15 M 67 Low + + 14.8 - 3.1
16 F 83 Intermediate + - 15.8 - 5.1
17 M 84 Low + - 16.6 - 3.2
The characteristics are divided into participant characteristics and HATICE study characteristics. *Low education level 
indicates primary education or lower secondary education; intermediate, upper secondary education and postsecondary 
non-tertiary education; high, short-cycle tertiary education. ** Interview 7 was performed with participants that had 
recently (prematurely) ended their participation in HATICE. CVD, history of cardiovascular disease; DM, diabetes mellitus; 
F, female; FU, follow-up; HATICE, Healthy Ageing Through Internet Counselling in the Elderly; M, male; mo, month; partic, 
participating. 
The main themes and subthemes of factors that influence initial and sustained platform 
engagement are presented in table 2 and further explained in the text below.
Table 2- Themes and subthemes identified in the interviews of the facilitators (+) and barriers (-) in 
initial and sustained platform use
Initial platform use Sustained platform use
User-friendliness for older people
% Layout: simplicity, attractiveness (+/-) 
% Technical diﬃculties (-)
% Perceived computer literacy (+/-)
Coach: the basis for a relationship of trust
% Inperson baseline consultation (+)
% Timing and content of messages (+) 
Usefulness and perceived beneﬁt of the intervention
% Aﬃnity with platform functionalities (including 
self-management) (+/-)
% Awareness of cardiovascular risk (+/-)
% Motivation for lifestyle change with increasing 
age (-)
Coach: long-term relationship of trust
% Personal connection (+)
% Content of messages (+/-)
% Continuity of person (-)
Reactive use of the platform* (+) 
Lifestyle change: expectations and experiences
% Expectations of platform (+/-)
% Beneﬁts of lifestyle changes (+)
% Setting a goal is burdensome (-)
% Monitoring health (+)
Incorporation into daily routine
% Incorporation into daily routine (+/-)
% Social (partner) support (+)
% Continuity of care (+/-)
% Time investment (+/-)
 Perceived lack of change in the platform (+/-)
*Reactive use indicates the preference of participants to use the platform in response to automatic or personal reminders.
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Initial platform engagement
User-friendliness for older people 
Participants found the layout of the platform clear and simple which facilitated platform 
use. However, they stated that a more attractive platform could have encouraged them to 
log in more often: 
“You should have a website that makes you think, when you have some spare time at night 
or in the afternoon, why don’t I just have a look at HATICE.” [P8]
Technical difficulties in using the platform, for example, login difficulties, discouraged 
participants. Also, the notion of being inexperienced or incompetent with a computer or 
with the internet could hamper exploration of the platform and platform use. Sometimes, 
participants, together with their coach, found creative ways to use the platform when this 
was considered difficult: 
”I’m not a computer freak. […] Once I receive a message then I answer it. And then she 
[coach] says, you should also complete it in the category that it belongs to [measurement]. 
To me it is not easy to find that […] But then later I notice that she has neatly entered it [in the 
measurement functionality]. I think that’s fine.” [P12]
People who regarded themselves as inquisitive or eager to learn said this stimulated them 
in exploring the different functionalities of the platform.
Coach: the basis for a relationship of trust
For participants, trusting the coach was a prerequisite to talk about their health behaviours 
and potential lifestyle goals. The inperson baseline consultation with their coach was much 
appreciated, and formed a basis to build a relationship of trust. If the coach responded 
quickly and adequately to messages sent after the baseline visit, this stimulated platform 
engagement: 
“At first I wanted… I really had no... I mean, I was actually curious. I did not think well this 
will… for me... At a certain moment, also because of her [coach], I immediately received a 
message back and she stimulated me, she said ‘oh well done’ and I don’t know what more. 
That made me say, OK I will continue with this.” [P12] 
Instead, if messages were not answered timely, participants became discouraged to 
continue using the platform. Some participants found personal contact through the 
messaging system insufficient to build a relationship and missed face-to-face or telephone 
contact. 
Usefulness and perceived benefit of the intervention
During their first encounter with the platform, participants tended to focus on a small 
number of functionalities that appeared useful and relevant and continued with these over 
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time. This mostly concerned the messaging and measurement functionalities: 
“When I receive an email I will go to the website and log in. And then I see what happened 
[message] and have a look. And sometimes I’m asked to complete a questionnaire and I do 
that. And other times, as is the case now, I’ll go to the practice nurse; well then I have my blood 
and urine tested, and I send those along [send results to the coach].“ [P16]
Some participants reported affinity with self-management and self-measuring of 
cardiovascular risk factors. They perceived the measurement functionality as useful and 
appropriate, facilitating platform use. Conversely, limited affinity with self-management 
could form a barrier to use this functionality: 
“And I absolutely do not want my own blood pressure monitor. I did not want that when it 
[blood pressure] was too high and I certainly do not want it now that it is too low. Because 
I get very uh… It will influence me and I don’t want that. I will not make myself crazy.“ [P3]
Participants who were aware of their cardiovascular risk status, in some cases because of 
a previous CVD, deemed the content of the platform relevant. Participants with limited 
perceived need to improve their lifestyle did not see how the platform could help them and 
tended to make limited use of it: 
“I notice that it’s about CVD. That is all fine, but I don’t have that [history of CVD], so I will not 
engage any further with it [the platform]. [..] Indeed, if I do encounter it [CVD], than I would 
do it, but at this moment…” [P5]
Participants who already frequently visited their health care professional(s) stated they 
did not expect important additional benefit. Age also played a role as one of the oldest 
participants no longer prioritised adapting a healthier lifestyle because of his old age. 
Participants rarely adjusted or replaced the goals that were set at baseline. Limited use was 
made of the suggestions for lifestyle groups; participants expressed several reservations 
related to this functionality, such as that they thought that signing up created an obligation 
to participate and that groups would be dominated by older people with very limited 
functionalities.
Sustained platform engagement
Coach: long-term relationship of trust
As mentioned above, the coach was important to stimulate initial use of the platform. The 
coach also appeared pivotal in sustained platform use. If participants felt connected to the 
coach, participants felt inclined to keep using the platform and adhere to goals for lifestyle 
changes:
“Yes, because the coach makes you try to accomplish certain things. […] That would be more 
difficult without the coach. I don’t know if… every time with the website… no, I don’t think 
that that would work on its own [platform without coach].“ [P9]
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The message content was also important; a positive and personal tone could boost 
someone’s motivation. One interviewee had experienced a change in coach during the trial. 
He stated this did not clearly change his platform use, although it did negatively impact his 
connection with the coach.
Reactive use of the platform
In many interviews, participants expressed difficulty to take initiative in using the platform, 
and found it easier to use the platform in a reactive way, for example, responding to 
automatic or personal reminders: 
“Look, I like to participate in such a study, but… Perhaps I’m a bit more passive, that I think 
even if I have to have ten visits a year, that is fine. We will have a conversation; I will complete 
lists; that is all fine. But a website is… to figure things out, and to write things down, that is 
something… [Interviewer: Maybe you can call that initiative?] Yes I suppose that could be it.” 
[P14]
Participants who considered themselves as being loyal or persistent noted this stimulated 
sustained platform use: 
“I was told to make contact once a month. And so I… It’s stated here in my iPad: remember 
HATICE, report! And so we plan to do that.“ [P11]
Lifestyle change: expectations and experiences
Being motivated for lifestyle change was a reason to continue using the platform and vice 
versa. This could be related to the reason to participate in the HATICE trial. Some participants 
were aware that the trial entailed active participation and hoped that they might benefit 
from it. Others, who participated to contribute to scientific progress, seemed to expect a 
more passive participation;that is, questionnaires or tests for which no self-initiative was 
required, and were not inclined to use the platform for self-management.  Second, if people 
managed to reach their lifestyle goals and experienced its positive effects on their health, 
this stimulated sustained participation: 
“Five kilometre laps. Yes, that is the minimum distance that I would like to walk each time. 
And I can achieve that quite nicely. And in that, I noticed that I started to feel fitter. That was 
really surprising. I always thought that I would stumble along through the rest of my life. And 
now I can... you get more fit. You have more enthusiasm to tackle things.“ [P14]
In contrast, some participants felt setting a goal was an unpleasant burden. If they did not 
manage to reach their goal, they refrained from registering this on the platform or informing 
their coach, also, because they felt embarrassed or demotivated: 
“You got sort of forced to... Because you had to make certain promises, like ‘I will make sure 
to exercise so many times a day’ and ‘I will make sure I will lose weight’. Those kinds of things. 
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Yes, that went against my gut feeling. […] You were sort of embarrassed if you said, well I 
actually did not do anything.” [P7]
Participants appreciated the automatic feedback on entered measurements as it gave a 
reassuring feeling of having their health monitored. This facilitated regular logging in.
Incorporation into daily routines
Participants said that it was easier for them to keep using the platform if they had 
incorporated their platform use into their daily or weekly routine: 
“Yes I like it. It works as a sort of support. In life you have all kinds of support systems, with your 
habits and your things, and this is one of them. It has become a part of… Yes well sometimes 
I can use it and sometimes I can’t. But it has become a part of everything.” [P2]
Disruption of daily routines, such as illnesses, negatively affected platform use. Social 
support, on the other hand, was an incentive for sustained use. This was especially true for 
couples participating in the HATICE trial together: 
“I said, ‘We should do something.’ Then I started to fill those [questionnaires] in. And I said, ‘Are 
you going to do that?’ [Response partner:] ‘Yes I will do that, but I am very busy.’ I said, ‘It will 
only take a minute.’“ [P10]
Another important factor that facilitated platform-adherence was that the platform could 
improve the perceived continuity of support in self-management. In contrast to nurse-led 
periodic consultations, which are typical of secondary cardiovascular prevention programs, 
the platform felt like a source of continuous support that they could direct to any time: 
“I already visit the practice nurse, but there is a lot of time in between [visits] and then yes… 
Of course together we assess the results, look at it and discuss it. But when I’m gone, it [the 
support] is also gone. Unless, of course, it turns out that I have to… that it’s not quite OK. But 
then it’s gone again. And this is, the continuity that you’re always working on it, that is good.” 
[P2]
Some participants found using the platform was time-consuming, which worked as a 
barrier. This could occur because of the misconception that they were obliged to regularly 
add measurements. In contrast, if participants felt the platform did not take too much of 
their time they were inclined to keep using it. 
Perceived lack of change in the platform
Most participants were not aware of any changes made to the platform content, although 
others noted that news items were regularly updated. While several participants appreciated 
the stable content, others would have liked to see more changes over time, to stimulate 
their sustained engagement: 
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“Well I read that [information on cardiovascular risk] a little in the beginning and then that 
is that. Well now… And that does not change. I’m almost certain that this is the same as it 
was 1,5 year ago. […] So that is not inviting; to keep looking if there is something new.” [P15]
The coach could influence this by varying the themes of conversation. 
Future implementation
Participants indicated that the level of incorporation into the regular health care system was 
limited, and therefore, some of them felt the platform had no clear added value on top of the 
nurse-led cardiovascular risk management they already received within the primary health 
care. Regarding future implementation, participants felt positive toward incorporation of 
the platform into the existing primary care structure. Especially if the practice nurse were 
to become their coach, thus contributing to continuity of support, and if all measurements 
performed at home, and within primary and secondary care were integrated into the 
platform:
“The visit to the practice nurse is of course the real measurement. So I feel it’s important to keep 
that, because it monitors your health, or at least a part of your health. That is important. But if all 
those measurements could be incorporated into this study, that would of course be very positive, 
because than you can compare it over several years or you can use it to look things up.” [P9]
A concern of some of the participants was that this incorporation would lead to substitution 
of valued, inperson contacts with healthcare professionals by more anonymous exchange 
of messages via the platform. A participant suggested to add regular inperson visits with 
measurements to increase motivation, as a solution.
DISCUSSION 
Summary 
We have found that the support of a coach is crucial to initiate and sustain engagement 
of older people with an interactive internet platform for cardiovascular self-management. 
Factors associated with initial platform engagement are perceived computer literacy, 
usability and anticipated benefits of the platform, with special attention to the computer skills 
and preferences of older people. Factors associated with sustained platform engagement 
are regular automatic and personal reminders, clear expectations, incorporation into 
daily routine, and social support. Incorporation into primary healthcare could facilitate 
implementation of the platform and could improve the perceived continuity of support in 
self-management. 
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Strengths and limitations
The main strength of our study is that through our purposive sampling method we included 
both participants with a short, intermediate and long follow-up duration. This contributed 
to a clear distinction in motives for initial and sustained engagement. We used an iterative 
analysis method with multiple analysis rounds and adaptation of the interview guide 
throughout the process. Also, we followed the consolidated criteria for reporting qualitative 
research (COREQ) guidelines to facilitate reproducibility of study results.102 A limitation of 
our study is that we only interviewed Dutch participants, potentially limiting the scope to 
the Dutch health care setting. Furthermore, the sample is prone to bias as our participants 
were willing to partake in both the HATICE trial and our qualitative substudy. This could have 
led to selection of people with a relative positive view on the intervention and with a high 
education level.172 We minimised this potential bias by purposively sampling participants 
on education level and login frequency. Another possible source of bias is the fact that two 
of the interviewers and researchers analysing the data were involved in the development 
and maintenance of the platform. This could have influenced the intonation of questioning 
and interpretation of the data; however, their knowledge of the platform could also have 
stimulated the discussion. Independent analysis was ensured by incorporation of several 
analysis rounds with other team members. 
Comparison with existing literature
Part of our results are in line with previous studies on engagement with eHealth interventions, 
such as on the influence of usability, perceived benefit and expectations of the intervention 
and the incorporation into personal life.164 A new finding that is especially relevant for 
eHealth interventions on cardiovascular prevention is the crucial role of continuous support 
by a coach for sustained engagement. This has previously been described in a non-digital 
multi-domain preventive intervention.148 In our study, the initial inperson contact was 
important to establish a relationship of trust between the participant and coach. For most 
people, maintenance of this relationship via a messaging system appeared to work well 
for a long-standing personal connection. The importance of this kind of blended care is 
emphasised by a meta-analysis showing a more pronounced effect on cardiovascular 
risk reduction.138 Despite the use of motivational interviewing techniques and coaches 
following the  transtheoretical model,170,171 it was difficult to engage people with a low 
perceived benefit of the intervention. In general, motivational interviewing techniques 
delivered through eHealth have proven effective in inducing behavioural changes.173 
Nevertheless, a complete inperson approach might be preferable for participants in the 
precontemplation phase, when there is no intention to change behaviour, as even reading 
information about cardiovascular risk on the platform requires some level of initiative.168 
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A reactive approach, that is, responding to automatic and personal reminders, rather 
than a proactive approach seemed to suit most participants best. Previous studies have 
shown that electronic reminders are a useful tool to increase medication adherence.174 
However, it is uncertain whether this reactive approach sufficiently supports self-efficacy.168 
In line with the degrees of self-management proposed by Schermer this might be seen 
as compliant self-management.175 Even though the interactive and flexible quality of the 
HATICE platform facilitates adoption of concordant self-management, that is, incorporation 
of the lifestyle advice into their personal life, this is not employed by everyone. Limited 
computer experience is an important barrier to platform use which may prohibit large-
scale implementation. Increasing use of internet by older people is likely to overcome this 
limitation in the near future.176 
A tailored platform
Our study shows that many aspects of multi-domain eHealth interventions rely heavily 
on personal preferences. The HATICE platform has been adjusted to the need for a 
personalised platform, by not imposing any obligations on which functionalities to use 
and giving participants the opportunity to tailor the frequency of automatic reminders to 
personal preferences. However, during the interviews, it appeared that people prefer an 
even more personalised platform. For instance, engagement was dependent on personal 
preference with regard to how much the content of the platform changes over time and 
the complexity of the platform changes, affinity with self-measurement, whether or not 
confrontation with lifestyle goals was appreciated, the ideal amount of time invested and 
the optimal frequency of reminders. As suggested by Bandura, it might be useful to tailor the 
platform content and the way it is provided based on a participants readiness to change.168 
This could, for example, be incorporated in a self-learning system that automatically tailors 
to personal characteristics, stages of change, needs and wishes.177 
Implications for practice
During the HATICE trial, the platform was offered independently from regular care. 
Participants mentioned this separation as a barrier to platform use and agreed with the 
suggestion to incorporate it into the current primary care structure. Preventive eHealth 
interventions provide the opportunity to optimize continuity in support of self-management 
and reach individual targets with limited resources. In addition, implementation may improve 
sustained engagement with such an intervention.178 Suggestions for this incorporation 
are to have the practice nurse work as coach, link measurements from electronic health 
records directly to the platform and align this with additional inperson visits for nurse-led 
cardiovascular risk management. Nevertheless, opportunities to implement the platform 
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probably differ based on the healthcare system. It is therefore crucial to properly evaluate 
the health care context and views of end users and healthcare professionals to support 
successful implementation.167 Especially in healthcare systems with long distances or low 
resources, a preventive eHealth intervention may provide opportunities to improve existing 
preventive care.179
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SUPPLEMENTARY MATERIAL
Interview guide 
Opening question: Could you tell me about your experiences with the HATICE platform?
1. Use, experiences and opinion about the platform
General
Did you ever log onto the platform? What pages do you usually visit when you are logged on? What do you use the most 
and why? What don’t you use and why? What do you think about the platform? Does the platform motivate you to 
change your lifestyle? Why?
Baseline
Why did you choose to participate in HATICE? Did your coach introduce you to the platform during the second visit? What 
did the coach mention about the platform? What was you first impression? What were you expectations of the platform? 
What was expected of you?
Initial phase
What were your first experiences with logging onto the platform? What parts of the platform did you use then? What 
appealed you to use the platform? And what repelled you to use the platform?
Adherence phase
How is that now? Do you use the platform differently now in comparison to the beginning? Why? Are there things that 
could have increased your use of the platform? If it would be possible, would you keep using the platform after the study 
ended? Why?
Coach
How do you experience the contact with your coach? What do you like? What don’t you like? Do you feel that the coach 
is of added value to the platform? Would you prefer having telephone contact with your coach?
2. Interaction with regular care
Do you feel that the platform is of added value to regular care? To what extend? Have you consulted you general 
practitioner/practice nurse about the platform (or are you going to)? Why?
Would you like it if the general practitioner/practice nurse had insight into data from your personal platform? Why? If yes, 
what data would you like to share and what not?
(If applicable) Are there advantages or disadvantages to the platform in comparison to the care of your practice nurse?
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ABSTRACT
Background  Hypertension is an important risk factor for cerebral small vessel disease 
and Purpose (SVD). We aimed to study the effect of antihypertensive medication (AHM) 
on the progression and presence of cerebral SVD MRI markers.
Methods We performed a systematic literature search of MEDLINE, EMBASE, the 
Cochrane Library and BIOSIS up to January 30th 2017 for randomized 
controlled trials on the effect of AHM on ≥1 cerebral SVD MRI markers 
(i.e. white matter hyperintensities [WMH], lacunes, microbleeds, enlarged 
perivascular spaces, acute small subcortical infarcts, and brain atrophy) after 
≥1 year. No restriction on study population was applied. The Cochrane Risk 
of Bias Tool was used to assess risk of bias and I2 statistic for heterogeneity. 
We performed a random-effects meta-analysis using standardized mean 
difference (SMD) and meta-regression. 
Results We included four trials with moderate-high level of evidence, including 
patients with stroke, with diabetes mellitus and persons ≥70 years of age. In 
the trials two MRI scans were performed with 28-47 months interval. Patients 
in the AHM group had less progression of WMH than controls (SMD -0.19; 
95% CI -0.32 to -0.06; I²=20%; n=1369) and a lower WMH volume at follow-
up (SMD -0.15; 95% CI -0.39 to 0.08; I2 67%; n=1177); although not reaching 
statistical significance. AHM had no effect on progression of brain atrophy 
(SMD -0.04; 95% CI -0.66 to 0.58; I²=86%; n=406). None of the trials reported 
on other cerebral SVD markers. Larger systolic blood pressure difference at 
follow-up in the intervention versus control group was associated with less 
WMH progression (p-value=0.05).
Conclusions  AHM has a protective effect on the progression of WMH, with a larger effect 
with increasing blood pressure lowering. We found no effect on brain 
atrophy. There are no trials on the effect of AHM on lacunes, microbleeds, 
enlarged perivascular spaces or acute small subcortical infarcts.
145
Antihypertensive medication and small vessel disease
9
INTRODUCTION
Cerebral small vessel disease (SVD) is an aggregate term for damage to the small cerebral 
vessels of various aetiologies.180 Neuroimaging correlates of SVD are white matter 
hyperintensities (WMH), lacunes, microbleeds, enlarged perivascular spaces, acute small 
subcortical infarcts, and brain atrophy.181 With increasing severity it is related to cognitive 
impairment, gait problems, mood disturbances and urinary problems.180 In addition, SVD 
is an important cause of spontaneous intracerebral hemorrhage.182 Cerebral SVD has been 
proposed as a surrogate disease marker in clinical trials,30 as it has a strong correlation with 
cognition, and its progress is measurable within a span of few years.183 
Hypertension is an important risk factor for cerebral SVD.184 The association is likely causal 
as hypertension can lead to damage to the vessel wall, thus leading to arteriolosclerosis 
and microaneurysms.180 Although antihypertensive medication (AHM) is highly effective 
in preventing large artery cerebrovascular disease and is well implemented in clinical 
practice,185 its effectiveness on SVD is yet unclear.
Our aim was to study the effect of antihypertensive medication on the progression and 
presence of MRI markers of cerebral SVD. 
METHODS
Search strategy and study selection
The protocol of this systematic review and meta-analysis is registered on PROSPERO 
(CRD42017056873) and the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines were followed.36,37 We performed a systematic literature 
search up to January 30th 2017 in the databases MEDLINE, EMBASE, the Cochrane Library 
and BIOSIS. The search contained terms relating to AHM and cerebral SVD, including 
each individual SVD marker (Supplemental methods I, the complete search strategy). We 
reviewed the reference list of all selected articles for additional relevant studies.
Two reviewers (TvM and TA) screened all articles independent of one another and selected 
the appropriate articles, first based on title and abstract and then based on full text. 
Disagreement over eligibility was resolved through discussion between the reviewers. A 
third reviewer (FS) was available for final judgement if disagreements persisted. We included 
studies if they were (1) an RCT, (2) included an intervention with AHM which lasted for at 
least one year, (3) reported on progression during, or prevalence at, follow-up of at least one 
marker of cerebral SVD on MRI. SVD markers of interest were WMH, lacunes, microbleeds, 
enlarged perivascular spaces, acute small subcortical infarcts, and brain atrophy.181 We 
included both placebo controlled RCTs and RCTs with other control conditions. We did not 
apply language restrictions nor restrictions on study population. 
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Data extraction
Two reviewers (TvM and TA) extracted the data and assessed the risk of bias independently. 
Discrepancies were resolved through discussion. We used a standardized, pre-piloted data 
extraction form to extract data on study characteristics, baseline characteristics, content 
of the intervention and control condition, MRI characteristics, outcomes of the different 
cerebral SVD markers, and funding sources. Risk of bias was assessed following the 
Cochrane Risk of Bias Tool and the overall quality with the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) system.38,39 We contacted the authors 
of the included trials in case data necessary for the meta-analysis were not available in the 
published results.
Statistical analysis
We pooled the individual cerebral SVD markers with a DerSimonian-Laird random-effects 
model. For the analyses on progression we used the difference between the baseline and 
follow-up MRI. For continuous outcomes we used a standardized mean difference (SMD) 
according to Hedges’ g effect size,38 because the included trials used different methods 
to measure and report on SVD. The SMD is calculated as the difference between the 
intervention and control group divided by the standard deviation (SD).40 We assessed 
statistical heterogeneity between the included studies using the I2 statistic.186 With a funnel 
plot we visually assessed risk of publication bias. We transformed logarithmic values before 
they were entered in the meta-analysis (Supplemental methods II, additional information 
on the logarithmic transformation).187 One of the included trials did not report on total WMH 
volume, but reported on WMH volume in the subcortical region and WMH classification in 
the periventricular region separately.188 As the results on subcortical WMH were the only 
volumetric measurement, we included these in our meta-analysis. With pre-specified meta-
regression analyses, we assessed the influence of difference in mean systolic blood pressure 
(SBP) at follow-up between the intervention and control group, mean reduction of SBP 
during follow-up in the intervention group, mean duration of the intervention, and mean 
age at baseline. We used R studio package meta for the statistical analyses and plots.130
RESULTS
The literature search resulted in 2595 individual articles (Figure 1). 27 articles were screened 
based on their full text and we included five articles in the qualitative and quantitative 
analyses reporting on four individual trials. Assessment of risk of bias in the included 
studies was low or unclear (Supplemental table I). The Action to Control Cardiovascular Risk 
in Diabetes Memory in Diabetes (ACCORD-MIND) trial had a high risk of performance bias as 
treatment allocation was not blinded to participants or treating physicians due to the study 
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design comparing a target SBP of <120 mmHg to <140 mmHg.189 The outcome assessment 
of the ACCORD-MIND trial was blinded. We assessed the meta-analyses on progression of 
WMH and WMH volume at follow-up as high level of evidence and on progression of brain 
atrophy as moderate level of evidence due to risk of publication bias (Supplemental figure 
I). Authors from the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) and 
Study on Cognition and Prognosis in the Elderly (SCOPE) trial supplied additional data for the 
meta-analysis.188,190
Figure 1 - Flowchart of study selection
The four trials included 1369 participants with available data at follow-up. Average follow-
up ranged from 28-47 months (Table 1). Only the ACCORD-MIND trial was not placebo 
controlled. The ACCORD-MIND trial included patients with diabetes mellitus and an 
increased cardiovascular risk,189 the PRoFESS and Perindopril Protection Against Recurrent 
Stroke Study (PROGRESS) trial stroke patients,188,191 and the SCOPE trial individuals aged 70-
89 years old.190 Compared to the three other trials, participants from the SCOPE trial were 
substantially older and had a higher SBP at baseline. In the intervention groups mean SBP 
was decreased by 20 mmHg in the ACCORD-MIND trial, 11 mmHg in the PRoFESS trial, 13 
mmHg in the PROGRESS trial and 26 mmHg in the SCOPE trial. 
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Cerebral SVD was a secondary outcome measure in all included trials. All four trials reported 
on WMH and two trials on brain atrophy (Table 2) as measured by automatic or manual 
measurement (Supplemental table II). The ACCORD-MIND trial published their results 
on WMH volume at final visit during the trial in a second paper which also included 
measurements after extended follow-up.192 In the PRoFESS trial WMH progression and 
presence was reported as increase in subcortical WMH diameter. In the PROGRESS trial the 
progression of WMH volume consisted of the volume of new WMH lesions during follow-
up and did not include the expansion of WMH lesions present at baseline. The SCOPE 
trial reported WMH volume as percentage of total brain volume (TBV). Brain atrophy was 
reported as volumetric measurement in the ACCORD-MIND trial and as percentage of TBV 
in the SCOPE trial. None of the trials reported on lacunes, microbleeds, enlarged perivascular 
spaces or acute small subcortical infarcts. 
Figure 2 - Forest plot on the effect of AHM on WMH and atrophy 
SD indicates standard deviation; SMD, standardised mean difference; CI, confidence interval.
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All four studies (n=1369) reported progression of WMH, with a pooled SMD of -0.19 (95% 
CI -0.32 to -0.06; I2 20%; Figure 2A). WMH volume at follow-up was reported in three studies 
(n=1177), with a SMD between the intervention and control groups of -0.15 (95% confidence 
interval [CI] -0.39 to 0.08; I2 67%; Figure 2B). The SMD for progression of brain atrophy based 
on two studies (n=406) was -0.04 (95% CI -0.66 to 0.58; I2 86%; Figure 2C). One trial reported 
on presence of brain atrophy at follow-up, with a significant lower total brain volume in the 
intervention versus the control group (Table 2). 
Trials with a larger contrast in systolic BP between the treatment groups seemed to have 
larger effects on WMH progression (beta -0.02; p-value=0.05; Figure 3A). There was no 
association between progression of WMH and decrease in SBP during follow-up in the 
intervention group (beta -0.02; p-value=0.15), duration of the intervention (beta -0.01; 
p-value=0.12) or age (beta 0.01; p-value=0.58) (Figure 3B-D). We found comparable results 
for the meta-regression analyses on WMH volume at follow-up (Supplemental figure II). 
DISCUSSION
We found that AHM is effective in slowing the progression of WMH. The preventive effect 
on progression of WMH is based on four trials with high quality of evidence, low statistical 
heterogeneity and diverse study populations with both patients with stroke, with diabetes 
and older individuals. The effect on progression of WMH is strongest in trials with a higher 
difference in SBP at follow-up between the intervention and control group and is, within the 
studied populations, independent of age. AHM is not effective in slowing the progression 
of brain atrophy, but the number of studies assessing progression of atrophy was limited 
and results were heterogeneous. None of the trials assessed the effect of AHM on lacunes, 
microbleeds, enlarged perivascular spaces or acute small subcortical infarcts.
The preventive effect of AHM on progression of WMH is in line with our hypothesis. Our 
finding that AHM had a non-significant effect on WMH volume at follow-up is probably 
due to a lack of statistical power, because the meta-analysis on WMH volume at follow-
up included one trial less than the analysis on progression. Another explanation for the 
discrepancy in significance may be a modest difference in WMH volume at baseline in favor 
of the control group in the PRoFESS trial that had the largest number of participants. The 
point-estimate for the two analyses was in the same direction supporting our hypothesis 
that AHM can slow down progression of AMH. The heterogeneous results we found on 
brain atrophy are not in line with our hypothesis. A possible explanation for this is that 
brain atrophy is modulated by several other pathologic mechanisms besides SVD, including 
neurodegeneration, on which AHM may have limited effect.193 Another explanation might 
be that a target SBP of <120 mmHg was too low in the ACCORD-MIND study population 
with diabetes and an increased cardiovascular risk. The increased cardiovascular burden 
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may have already impaired the cerebral autoregulation before the start of the trial.194 A low 
blood pressure (BP), especially a low diastolic BP (63.3 mmHg at follow-up in the ACCORD-
MIND intervention group), may then cause inadequate cerebral perfusion, which may 
contribute to neurodegeneration.194,195 
For the relation of BP with mortality, cardiovascular events and potentially also dementia, 
there appears to be a ‘J-shaped curve’, indicating that both low and high BP levels are 
associated with an increased risk of disease or death.117,196,197 Such a J-shaped association 
with BP has also been suggested for the development of WMH.198 However, the ACCORD-
MIND trial had a target SBP of <120 mmHg in the intervention group and showed the 
strongest effect on curtailing progression of WMH.189 Our meta-analysis is therefore 
suggestive for a linear and not a J-shaped association, although meta-regression with 
only 4 RCTs has to be interpreted with caution. It will be interesting to see if the recently 
completed, but not yet published, Systolic Blood Pressure Intervention Trial memory and 
cognition in decreased hypertension (SPRINT-MIND),199 which assessed the effect of a target 
SBP <120 mmHg in a population with an increased cardiovascular risk but without diabetes, 
will show comparable beneficial results on WMH and perhaps also other SVD markers.
A recently published study has shown that progression of WMH is not linear over time.200 
Instead, WMH tends to progress faster in people with a higher WMH load at baseline, 
compared to people with a lower WMH load. From a prevention perspective the ideal timing 
of AHM for the prevention of WMH seems to be early in the course of hypertension. This 
would be another argument for early treatment of hypertension in the ongoing discussion 
whether or not to start AHM in people with hypertension but a low overall cardiovascular 
risk.201 However, with slow progression rates of WMH in the early stages it may be difficult to 
prove the effectiveness of AHM within a reasonable timeframe. This is less of an issue in later 
stages of WMH progression (i.e. in older people or people with an increased cardiovascular 
risk) as more contrast in WMH volume in comparison with controls may be achieved.202 
Subgroup analysis of the PROGRESS trial showed a stronger effect of AHM in participants 
with severe WMH at baseline, supporting this last hypothesis.191 Whether an intervention in 
participants with severe WMH load leads to clinical benefit on cognition or gait is unclear. 
SVD has been suggested as surrogate outcome in trials to prevent dementia.30 In our meta-
analysis we have shown that AHM can slow the progression of WMH. We did not assess 
the predictive value of this effect on the prevention of dementia or other clinical adverse 
outcomes. In the observational extension study of the ACCORD-MIND trial no long-term 
effect on cognition was observed.192 Whether this was caused by the diminished effect of 
the intervention on BP during the observational extension period (SBP increased to ±130 
mmHg in the intervention group), selective drop-out of those with the worst cognitive 
function or the absence of a clinical effect is unclear. 
As far as we are aware, this is the first systematic review and meta-analysis assessing the 
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effect of AHM on cerebral SVD. Our thorough literature search and systematic selection 
process gives a clear overview of the level of evidence available and the knowledge 
gaps for which further research is required. There is no evidence on the effect of AHM on 
lacunes, microbleeds, enlarged perivascular spaces and acute small subcortical infarcts and 
also the effect on brain atrophy requires further study. Ultimately, an answer is needed on 
the question whether AHM leads to a lower risk of important clinical outcomes, including 
dementia and mobility. A limitation of our review is the heterogeneity of methods used 
to quantify cerebral SVD. In our meta-analysis we accounted for the heterogeneity by 
using a random-effects model and a standardized outcome measure. Generalizability of 
SVD trials may be improved if current and future researchers adhere to the definitions 
and methodological guidelines for the measurement of SVD that have been published 
previously.181,203 Unfortunately, due to the limited number of studies included, no subgroup 
analyses based on characteristics of the different study populations were possible.
CONCLUSIONS
To conclude, antihypertensive medication can limit the progression of white matter 
hyperintensities. It is not effective in slowing down the progression of brain atrophy, 
although results are heterogeneous and based on a small sample. No evidence is available 
on the effect of AHM on lacunes, microbleeds, enlarged perivascular spaces or acute small 
subcortical infarcts. The effect of AHM on the progression of WMH supports the hypothesis 
of a causal pathway between hypertension and WMH. As the effect is stronger in studies 
with a lower SBP at follow-up in the intervention versus the control group, a low target SBP 
appears most appropriate to prevent the progression of WMH. Whether the preventive 
effect on WMH also leads to prevention of cognitive decline or deterioration of gait is 
unclear. It is therefore uncertain whether WMH is an appropriate surrogate outcome for 
clinical trials. The effectivity of AHM on the progression of WMH over the course of several 
years underscores the potential of intervening in the continuing process of damage to the 
cerebrovasculature, preventing brain damage and ultimately preventing dementia. 
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SUPPLEMENTARY MATERIAL
Supplemental methods I. Search strategy 
Medline
1 (((“Lacunar stroke*” or “small vessel disease” or “Cerebral Microangiopath*” or “subcortical infarct*” or “White 
matter hyperintens*” or “Cerebral microbleed*” or “Brain atroph*” or “Small vessel cerebrovascular diseas*” 
or “Small vessel cerebrovascular disorder*” or SVD or “lacunar infarct*” or “silent brain infarct*” or “subcortical 
stroke*” or “subcortical cystic infarct*” or “cerebral lacunar lesion*” or “deep lacunar lesion*” or “subcortical 
lacunar lesion*” or “symptomatic lacunar lesion*” or “a symptomatic lacunar lesion*” or “Small vessel disease 
stroke” or “small deep infarct*” or “perforator territory infarct*” or “lacunar arteriopathy” or “white matter 
lesion*” or WML or “white matter hyperintensities” or WMH or leukoaraiosis or leucoaraiosis or “Virchow-Robin 
space*” or “etat crible” or “type 3 lacune*” or “white matter change*” or “WMC” or “changes in white matter” 
or “leukoencephalopathy” or “white matter disease” or “WMD” or “white matter damage” or (“perivascular 
space*” and (cerebr* or brain)) or (lacune* and (cerebr* or brain)) or (“deep infarct*” and (cerebr* or brain)) 
or (“deep stroke*” and (cerebr* or brain)) or microinfarct*) and (cerebr* or brain)) or “brain microbleed” or 
“chronic microbleed” or “silent microbleed” or “asymptomatic microbleed” or “cerebral microhemorrhage” or 
“cerebral microhaemorrhage” or “dot-like hemosiderin spot*” or “dot-like hemosiderin deposition” or “small 
vessel infarct*” or “small vessel stroke*” or “microscopic infarct*” or “brain volum*” or “cerebral volum*”).ti,ab,kf.
2 exp “Cerebral Small Vessel Diseases”/ or exp leukoaraiosis/
3 1 or 2
4 exp “Antihypertensive Agents”/ or exp “Hypertension”/ or exp “Sodium Potassium Chloride Symporter 
Inhibitors”/ or exp “Bumetanide”/ or exp “Ethacrynic Acid”/ or exp “Furosemide”/ or exp “Sodium Chloride 
Symporter Inhibitors”/ or exp “Hydrochlorothiazide”/ or exp “Chlorothiazide”/ or exp “Bendroﬂumethiazide”/ 
or exp “Xipamide”/ or exp “Indapamide”/ or exp “Chlorthalidone”/ or exp “Metolazone”/ or exp “Diuretics, 
Potassium Sparing”/ or exp “Amiloride”/ or exp “Triamterene”/ or exp “Dihydropyridines”/ or exp “Amlodipine”/ 
or exp “Felodipine”/ or exp “Isradipine”/ or exp “Nicardipine”/ or exp “Nifedipine”/ or exp “Nimodipine”/ or 
exp “Nitrendipine”/ or exp “Nisoldipine”/ or exp “Nitrendipine”/ or exp “Diltiazem”/ or exp “Verapamil”/ or 
exp “Angiotensin-Converting Enzyme Inhibitors”/ or exp “Captopril”/ or exp “Enalapril”/ or exp “Fosinopril”/ 
or exp “Lisinopril”/ or exp “Perindopril”/ or exp “Ramipril”/ or exp “Cilazapril”/ or exp “Angiotensin Receptor 
Antagonists”/ or exp “Losartan”/ or exp “Valsartan”/ or exp “Atenolol”/ or exp “Metoprolol”/ or exp “Nadolol”/ 
or exp “Nebivolol”/ or exp “Oxprenolol”/ or exp “Pindolol”/ or exp “Propranolol”/ or exp “Timolol”/ or exp 
“Bisoprolol”/ or exp “Acebutolol”/ or exp “Celiprolol”/ or exp “Sotalol”/ or exp “Doxazosin”/ or exp “Phentolamine”/ 
or “Indoramin”/ or exp “Phenoxybenzamine”/ or exp “Prazosin”/ or exp “Ketanserin”/ or exp “Phentolamine”/ or 
exp “Labetalol”/ or exp “Hydralazine”/ or exp “Minoxidil”/ or exp “Mineralocorticoid Receptor Antagonists”/ or 
exp “Spironolactone”/ or exp “Clonidine”/ or exp “Guanabenz”/ or exp “Guanfacine”/ or exp “Methyldopa”/ or 
exp “Guanethidine”/ or exp “Mecamylamine”/ or exp “Magnesium Sulfate”/
5 (“torsemide” or “cilnidipine” or “mepirodipine” or “lacidipine” or “aranidipine” or “azelnidipine” or “benidipine 
hydrochloride” or “clevidipine” or “darodipine” or “efonidipine” or “manidipine” or “niguldipine” or “nilvadipine” 
or “quinapril” or “trandolapril” or “benazepril” or “zofenopril” or “imidapril” or “oxodipine” or “pranidipine” or 
“candesartan” or “eprosartan” or “irbesartan” or “olmesartan” or “telmisartan” or “azilsartan” or “ﬁmasartan” or 
“esmolol” or “Terazosin” or “urapidil” or “carvedilol” or “aliskiren” or “eplerenone” or “moxonidine” or “lercanidipine”).rn.
6 (antihypertensive or “anti-hypertensive” or beta-blocker* or betablocker* or angiotensin* or “loop 
diuretic*” or “bumetanide ethacrynic acid” or furosemide or torsemide or “thiazide diuretic*” or epitizide or 
hydrochlorothiazide or chlorothiazide or bendroﬂumethiazide or xipamide or indapamide or chlorthalidone 
or metolazone or amiloride or triamterene or amlodipine or cilnidipine or felodipine or isradipine or 
lercanidipine or levamlodipine or nicardipine or nifedipine or nimodipine or nitrendipine or barnidipine 
or lacidipine or aranidipine or azelnidipine or benidipine or clevidipine or darodipine or efonidipine or 
manidipine or niguldipine or nilvadipine or nisoldipine or nitrendipine or oxodipine or pranidipine or 
diltiazem or verapamil or “ACE-inhibitor*” or captopril or enalapril or fosinopril or lisinopril or perindopril 
or quinapril or ramipril or trandolapril or benazepril or zofenopril or imidapril or cilazapril or candesartan 
or eprosartan or irbesartan or losartan or olmesartan or telmisartan or valsartan or azilsartan or ﬁmasartan 
or atenolol or metoprolol or nadolol or nebivolol or oxprenolol or pindolol or propranolol or timolol or 
bisoprolol or acebutolol or celiprolol or esmolol or sotalol or doxazosin or phentolamine or indoramin or 
phenoxybenzamine or prazosin or terazosin or tolazolin or ketanserin or urapidil or fentolamin or carvedilol or 
labetalol or hydralazine or minoxidil or aliskiren or eplerenone or spironolactone or clonidine or guanabenz 
or guanfacine or methyldopa or moxonidine or guanethidine or mecamylamine or magnesium sulfate or 
((pharmacolog* or nonpharmacolog* or non-pharmacolog*) adj5 (intervention* or treatment* or therap* or 
management or strateg*))).ti,ab,kf.
7 4 or 5 or 6
8 3 and 7
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Embase
1 (exp “cerebrovascular disease”/ and (white matter lesion/ or vascular lesion/)) or exp leukoaraiosis/
2 (((“Lacunar stroke*” or “small vessel disease” or “Cerebral Microangiopath*” or “subcortical infarct*” or “White 
matter hyperintens*” or “Cerebral microbleed*” or “Brain atroph*” or “Small vessel cerebrovascular diseas*” or 
“Small vessel cerebrovascular disorder*” or SVD or “lacunar infarct*” or “silent brain infarct*” or “subcortical 
stroke*” or “subcortical cystic infarct*” or “cerebral lacunar lesion*” or “deep lacunar lesion*” or “subcortical 
lacunar lesion*” or “symptomatic lacunar lesion*” or “a symptomatic lacunar lesion*” or “Small vessel disease 
stroke” or “small deep infarct*” or “perforator territory infarct*” or “lacunar arteriopathy” or “white matter 
lesion*” or WML or “white matter hyperintensities” or WMH or leukoaraiosis or leucoaraiosis or “Virchow-Robin 
space*” or “etat crible” or “type 3 lacune*” or “white matter change*” or “WMC” or “changes in white matter” 
or “leukoencephalopathy” or “white matter disease” or “WMD” or “white matter damage” or (“perivascular 
space*” and (cerebr* or brain)) or (lacune* and (cerebr* or brain)) or (“deep infarct*” and (cerebr* or brain)) 
or (“deep stroke*” and (cerebr* or brain)) or microinfarct*) and (cerebr* or brain)) or “brain microbleed” or 
“chronic microbleed” or “silent microbleed” or “asymptomatic microbleed” or “cerebral microhemorrhage” or 
“cerebral microhaemorrhage” or “dot-like hemosiderin spot*” or “dot-like hemosiderin deposition” or “small 
vessel infarct*” or “small vessel stroke*” or “microscopic infarct*” or “brain volum*” or “cerebral volum*”).ti,ab,kw.
3 (“torsemide” or “cilnidipine” or “mepirodipine” or “lacidipine” or “aranidipine” or “azelnidipine” or “benidipine 
hydrochloride” or “clevidipine” or “darodipine” or “efonidipine” or “manidipine” or “niguldipine” or “nilvadipine” 
or “quinapril” or “trandolapril” or “benazepril” or “zofenopril” or “imidapril” or “oxodipine” or “pranidipine” or 
“candesartan” or “eprosartan” or “irbesartan” or “olmesartan” or “telmisartan” or “azilsartan” or “ﬁmasartan” or 
“esmolol” or “Terazosin” or “urapidil” or “carvedilol” or “aliskiren” or “eplerenone” or “moxonidine” or “lercanidipine”).rn.
4 exp *antihypertensive agent/ or exp *hypertension/ or exp *loop diuretic agent/ or exp *thiazide diuretic 
agent/ or exp *potassium sparing diuretic agent/
5 (antihypertensive or “anti-hypertensive” or beta-blocker* or betablocker* or angiotensin* or “loop 
diuretic*” or “bumetanide ethacrynic acid” or furosemide or torsemide or “thiazide diuretic*” or epitizide or 
hydrochlorothiazide or chlorothiazide or bendroﬂumethiazide or xipamide or indapamide or chlorthalidone 
or metolazone or amiloride or triamterene or amlodipine or cilnidipine or felodipine or isradipine or 
lercanidipine or levamlodipine or nicardipine or nifedipine or nimodipine or nitrendipine or barnidipine 
or lacidipine or aranidipine or azelnidipine or benidipine or clevidipine or darodipine or efonidipine or 
manidipine or niguldipine or nilvadipine or nisoldipine or nitrendipine or oxodipine or pranidipine or 
diltiazem or verapamil or “ACE-inhibitor*” or captopril or enalapril or fosinopril or lisinopril or perindopril 
or quinapril or ramipril or trandolapril or benazepril or zofenopril or imidapril or cilazapril or candesartan 
or eprosartan or irbesartan or losartan or olmesartan or telmisartan or valsartan or azilsartan or ﬁmasartan 
or atenolol or metoprolol or nadolol or nebivolol or oxprenolol or pindolol or propranolol or timolol or 
bisoprolol or acebutolol or celiprolol or esmolol or sotalol or doxazosin or phentolamine or indoramin or 
phenoxybenzamine or prazosin or terazosin or tolazolin or ketanserin or urapidil or fentolamin or carvedilol 
or labetalol or hydralazine or minoxidil or aliskiren or eplerenone or spironolactone or clonidine or guanabenz 
or guanfacine or methyldopa or moxonidine or guanethidine or mecamylamine or magnesium sulfate or 
((pharmacolog* or nonpharmacolog* or non-pharmacolog*) adj5 (intervention* or treatment* or therap* or 
management or strateg*))).ti,ab,kw.
6 1 or 2
7 3 or 4 or 5
8 6 and 7
9 (embase or elsevier or canadian).cr.
10 8 and 9
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The Cochrane Library
#1 ([mh “Cerebral Small Vessel Diseases”] or [mh leukoaraiosis]) 
#2 (Lacunar stroke* or small vessel disease or Cerebral Microangiopath* or subcortical infarct* or White matter 
hyperintens* or Cerebral microbleed* or Brain atroph* or Small vessel cerebrovascular diseas* or Small 
vessel cerebrovascular disorder* or SVD or lacunar infarct* or silent brain infarct* or subcortical stroke* or 
subcortical cystic infarct* or cerebral lacunar lesion* or deep lacunar lesion* or subcortical lacunar lesion* 
or symptomatic lacunar lesion* or asymptomatic lacunar lesion* or Small vessel disease stroke or small 
deep infarct* or perforator territory infarct* or lacunar arteriopathy or white matter lesion* or WML or white 
matter hyperintensities or WMH or leukoaraiosis or leucoaraiosis or Virchow-Robin space* or etat crible or 
type 3 lacune* or white matter change* or WMC or changes in white matter or leukoencephalopathy or 
white matter disease or WMD or white matter damage or (perivascular space* and (cerebr* or brain)) or 
(lacune* and (cerebr* or brain)) or (deep infarct* and (cerebr* or brain)) or (deep stroke* and (cerebr* or 
brain)) or microinfarct* and (cerebr* or brain) or brain microbleed or chronic microbleed or silent microbleed 
or asymptomatic microbleed or cerebral microhemorrhage or cerebral microhaemorrhage or dot-like 
hemosiderin spot* or dot-like hemosiderin deposition or small vessel infarct* or small vessel stroke* or 
microscopic infarct* or brain volum* or cerebral volum*):ti,ab 
#3 #1 or #2 
#4 ([mh “Antihypertensive Agents”] or [mh Hypertension] or [mh “Sodium Potassium Chloride Symporter 
Inhibitors”] or [mh Bumetanide] or [mh “Ethacrynic Acid”] or [mh Furosemide] or [mh “Sodium Chloride 
Symporter Inhibitors”] or [mh Hydrochlorothiazide] or [mh Chlorothiazide] or [mh Bendroﬂumethiazide] 
or [mh Xipamide] or [mh Indapamide] or [mh Chlorthalidone] or [mh Metolazone] or [mh “Diuretics, 
Potassium Sparing”] or [mh Amiloride] or [mh Triamterene] or [mh Dihydropyridines] or [mh Amlodipine] 
or [mh Felodipine] or [mh Isradipine] or [mh Nicardipine] or [mh Nifedipine] or [mh Nimodipine] or 
[mh Nitrendipine] or [mh Nisoldipine] or [mh Nitrendipine] or [mh Diltiazem] or [mh Verapamil] or [mh 
“Angiotensin-Converting Enzyme Inhibitors”] or [mh Captopril] or [mh Enalapril] or [mh Fosinopril] or [mh 
Lisinopril] or [mh Perindopril] or [mh Ramipril] or [mh Cilazapril] or [mh “Angiotensin Receptor Antagonists”] 
or [mh Losartan] or [mh Valsartan] or [mh Atenolol] or [mh Metoprolol] or [mh Nadolol] or [mh Nebivolol] or 
[mh Oxprenolol] or [mh Pindolol] or [mh Propranolol] or [mh Timolol] or [mh Bisoprolol] or [mh Acebutolol] 
or [mh Celiprolol] or [mh Sotalol] or [mh Doxazosin] or [mh Phentolamine] or [mh Indoramin] or [mh 
Phenoxybenzamine] or [mh Prazosin] or [mh Ketanserin] or [mh Phentolamine] or [mh Labetalol] or [mh 
Hydralazine] or [mh Minoxidil] or [mh “Mineralocorticoid Receptor Antagonists”] or [mh Spironolactone] or 
[mh Clonidine] or [mh Guanabenz] or [mh Guanfacine] or [mh Methyldopa] or [mh Guanethidine] or [mh 
Mecamylamine] or [mh “Magnesium Sulfate”]) 
#5 (antihypertensive or anti-hypertensive or beta-blocker* or betablocker* or angiotensin* or loop 
diuretic* or bumetanide ethacrynic acid or furosemide or torsemide or thiazide diuretic* or epitizide or 
hydrochlorothiazide or chlorothiazide or bendroﬂumethiazide or xipamide or indapamide or chlorthalidone 
or metolazone or amiloride or triamterene or amlodipine or cilnidipine or felodipine or isradipine or 
lercanidipine or levamlodipine or nicardipine or nifedipine or nimodipine or nitrendipine or barnidipine 
or lacidipine or aranidipine or azelnidipine or benidipine or clevidipine or darodipine or efonidipine or 
manidipine or niguldipine or nilvadipine or nisoldipine or nitrendipine or oxodipine or pranidipine or 
diltiazem or verapamil or ACE-inhibitor* or captopril or enalapril or fosinopril or lisinopril or perindopril or 
quinapril or ramipril or trandolapril or benazepril or zofenopril or imidapril or cilazapril or candesartan or 
eprosartan or irbesartan or losartan or olmesartan or telmisartan or valsartan or azilsartan or ﬁmasartan 
or atenolol or metoprolol or nadolol or nebivolol or oxprenolol or pindolol or propranolol or timolol or 
bisoprolol or acebutolol or celiprolol or esmolol or sotalol or doxazosin or phentolamine or indoramin or 
phenoxybenzamine or prazosin or terazosin or tolazolin or ketanserin or urapidil or fentolamin or carvedilol 
or labetalol or hydralazine or minoxidil or aliskiren or eplerenone or spironolactone or clonidine or guanabenz 
or guanfacine or methyldopa or moxonidine or guanethidine or mecamylamine or magnesium sulfate or 
((pharmacolog* or nonpharmacolog* or non-pharmacolog*) Adj5 (intervention* or treatment* or therap* 
or management or strateg*))):ti,ab 
#6 #4 or #5 
#7 #3 and #6 
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BIOSIS
1 (((Lacunar stroke* or small vessel disease or Cerebral Microangiopath* or subcortical infarct* or White matter 
hyperintens* or Cerebral microbleed* or Brain atroph* or Small vessel cerebrovascular diseas* or Small 
vessel cerebrovascular disorder* or SVD or lacunar infarct* or silent brain infarct* or subcortical stroke* or 
subcortical cystic infarct* or cerebral lacunar lesion* or deep lacunar lesion* or subcortical lacunar lesion* 
or symptomatic lacunar lesion* or asymptomatic lacunar lesion* or Small vessel disease stroke or small 
deep infarct* or perforator territory infarct* or lacunar arteriopathy or white matter lesion* or WML or white 
matter hyperintensities or WMH or leukoaraiosis or leucoaraiosis or Virchow-Robin space* or etat crible 
or type 3 lacune* or white matter change* or WMC or changes in white matter or leukoencephalopathy 
or white matter disease or WMD or white matter damage or (perivascular space* and (cerebr* or brain)) 
or (lacune* and (cerebr* or brain)) or (deep infarct* and (cerebr* or brain)) or (deep stroke* and (cerebr* 
or brain)) or microinfarct*) and (cerebr* or brain)) or brain microbleed or chronic microbleed or silent 
microbleed or asymptomatic microbleed or cerebral microhemorrhage or cerebral microhaemorrhage or 
dot-like hemosiderin spot* or dot-like hemosiderin deposition or small vessel infarct* or small vessel stroke* 
or microscopic infarct* or brain volum* or cerebral volum*).ti,ab,kw.
2 (antihypertensive or anti-hypertensive or beta-blocker* or betablocker* or angiotensin* or loop 
diuretic* or bumetanide ethacrynic acid or furosemide or torsemide or thiazide diuretic* or epitizide or 
hydrochlorothiazide or chlorothiazide or bendroﬂumethiazide or xipamide or indapamide or chlorthalidone 
or metolazone or amiloride or triamterene or amlodipine or cilnidipine or felodipine or isradipine or 
lercanidipine or levamlodipine or nicardipine or nifedipine or nimodipine or nitrendipine or barnidipine 
or lacidipine or aranidipine or azelnidipine or benidipine or clevidipine or darodipine or efonidipine or 
manidipine or niguldipine or nilvadipine or nisoldipine or nitrendipine or oxodipine or pranidipine or 
diltiazem or verapamil or ACE-inhibitor* or captopril or enalapril or fosinopril or lisinopril or perindopril or 
quinapril or ramipril or trandolapril or benazepril or zofenopril or imidapril or cilazapril or candesartan or 
eprosartan or irbesartan or losartan or olmesartan or telmisartan or valsartan or azilsartan or ﬁmasartan 
or atenolol or metoprolol or nadolol or nebivolol or oxprenolol or pindolol or propranolol or timolol or 
bisoprolol or acebutolol or celiprolol or esmolol or sotalol or doxazosin or phentolamine or indoramin or 
phenoxybenzamine or prazosin or terazosin or tolazolin or ketanserin or urapidil or fentolamin or carvedilol 
or labetalol or hydralazine or minoxidil or aliskiren or eplerenone or spironolactone or clonidine or guanabenz 
or guanfacine or methyldopa or moxonidine or guanethidine or mecamylamine or magnesium sulfate or 
((pharmacolog* or nonpharmacolog* or non-pharmacolog*) adj5 (intervention* or treatment* or therap* or 
management or strateg*))).ti,ab,kw.
3 1 and 2
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Supplemental methods II. Logarithmic transformation
For a meta-analysis the raw data in each study does not need to be normally distributed. Only the distribution 
of the mean should be normally distributed. Any logarithmic mean and variability measures should therefore be 
transformed to the raw data. This can be done with the following formula:187
x indicates the raw mean; z, logarithmic mean; s, raw SD; z, logarithmic SD.
This formula led to the following transformation of data on white matter hyperintensities (WMH) at follow-up and 
progression during follow-up from the ACCORD trial:
Mean WMH at follow-up, intervention: exp (0.62 + (0.412/2))= 2.02
SD WMH at follow-up, intervention: (exp(0.412 − 1) × exp(2 × 0.62 + 0.412)) = 0.87
Mean WMH at follow-up, control: exp (0.77 + (0.422/2))= 2.36
SD WMH at follow-up, control:  (exp(0.422 − 1) × exp(2 × 0.77 + 0.422)) = 1.04
Mean WMH progression, intervention: exp (0.53 + (0.412/2))= 1.85
SD WMH progression, intervention: (exp(0.412 − 1) × exp(2 × 0.53 + 0.412)) = 0.79
Mean WMH progression, control: exp (0.68 + (0.422/2))= 2.16
SD WMH progression, control: (exp(0.422 − 1) × exp(2 × 0.68 + 0.422)) = 0.95
Supplemental table I - Cochrane risk of bias assessment 
A
CCO
RD
PRoFESS
PRO
G
RESS
SCO
PE
Random sequence generation (selection bias) + + + +
Allocation concealment (selection bias) + + + +
Blinding of participants and personnel (performance bias) - + + +
Blinding of outcome assessment (detection bias) + + + ?
Incomplete outcome data (attrition bias) + ? + +
Selective reporting (reporting bias) ? + + ?
Other bias + + + ?
The green plus-signs indicate a low risk of bias, the yellow question mark-signs indicate an unclear risk of bias, and 
the red minus-sign indicates a high risk of bias. In the ACCORD trial participants and treating physicians could not be 
blinded.189,192 This was inherent to the design of the intervention; i.e. intensive blood pressure (BP) control with a target 
SBP <120 mmHg. In the PRoFESS trial no explanation was given for the participants that were lost to follow-up thereby 
increasing the risk of attrition bias.188 In the SCOPE trial no selection criteria for the MRI substudy were given, no declaration 
of interest was presented and it was unclear whether the outcome assessment was blinded to treatment allocation.190 
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9
Supplemental figure I - Funnel plot on progression of WMH (A), WMH volume at follow-up (B), and 
progression of brain atrophy (C)
WMH indicates white matter hyperintensities.
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This thesis focuses on blood pressure (BP) management to prevent dementia. In part I 
I studied the relation between BP in late life and dementia, with a meta-analysis on 
the preventive effect of BP-lowering interventions and analyses on specific classes of 
antihypertensive medication (AHM) and visit-to-visit BP variability. In addition, I performed 
interviews with general practitioners (GPs) on (de)prescription of AHM. In part II I explored 
several methodological aspects in dementia prevention trials. This includes analyses 
on the usability of a modifiable dementia risk score as tool to select an optimal target 
population. I interviewed trial participants on reasons for participation in a prevention trial 
and engagement with an interactive internet platform. Finally, I completed a meta-analysis 
on the effect of AHM on progression of cerebral small vessel disease (SVD), to assess its 
usefulness as intermediate outcome. In this chapter I will discuss the findings within the 
framework of other relevant research and discuss its’ implications for clinical practice and 
future research.
PART I – BLOOD PRESSURE IN LATE LIFE AND DEMENTIA
Historical perspective 
Until half a century ago BP and dementia were not known to be associated and were viewed 
as two separate domains. To better understand developments leading to the research 
questions addressed in this thesis, I briefly shed some light on the historical context of both 
domains. 
The ancient Egyptians already described the concept of dementia around 2000 B.C. Until 
the early eighteenth century many different terms were used to describe dementia, such 
as imbecility, senility or simplicity; reflecting the view of society, that long considered 
dementia a psychosocial problem.204 The term dementia is derived from the Latin term 
demens, which loosely translated means ‘without mind’.204 In the 17th century, Thomas 
Willis described a correlation between stroke and dementia, knowledge that later led 
to the concept of vascular dementia.205 Alzheimer’s disease was introduced much later, 
in 1910, with the clinical and pathological descriptions made by Alois Alzheimer on his 
patient, mrs. Auguste D.206 She presented with severe cognitive impairment, delusions 
and hallucinations, and, at autopsy of the brain, had loss of neurons and the presence of 
senile plaques and neurofibrillary tangles. These distinct features were later considered to 
characterize Alzheimer’s disease. 
The research field on BP is relatively young. Until the early twentieth century a progressive 
increase in BP was considered part of normal aging.207 After the death of Franklin D. 
Roosevelt in 1945 due to a haemorrhagic stroke, with a BP of 300/190 mmHg, the United 
States government declared high BP a threat to national health.208 The first observational 
studies and trials in the subsequent years focused on the detrimental effects of a high 
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diastolic BP. Twenty years later, trials on high systolic BP followed. 
Both research domains merged in 1947 with the first case studies linking hypertension to 
cognitive function.209 Several cross-sectional and later also prospective descriptive studies 
followed. These studies first focussed on the association of BP with vascular dementia, but 
in the 1990s also an association with Alzheimer’s disease became apparent.210 
Antihypertensive medication classes
Even though the association between midlife hypertension and dementia is strong, in 
chapter two we have shown that randomised controlled trails (RCTs) have not conclusively 
proven that lowering BP by AHM and/or lifestyle changes can prevent dementia. Our results 
in chapter three indicate that there might be an AHM class-specific effect in preventing 
dementia, with lower risks in participants using calcium channel blockers (CCBs) and/or 
angiotensin receptor blockers (ARBs). However, we could not confirm this class-specific 
effect in our systematic review (chapter two). A network meta-analysis was deemed 
unreliable, as there were too few trials for the different AHM classes and these were all 
placebo-controlled, limiting the possibilities of indirect comparisons. Paired meta-analysis 
(including only direct comparisons) did not indicate a favourable AHM class, aside from one 
trial on CCBs with a high risk of publication bias. 
There are several cerebrovascular and neurodegenerative mechanisms that could explain 
the class-specific effect described in chapter three (further elaborated on in the subsequent 
paragraph).59 Another hypothesis for the observed association is that it is not based on a 
physiological class-difference, but rather a difference in the stability of BP control.67 A way 
of assessing this is with visit-to-visit BP variability. However, we did not find an association 
between a higher BP variability and an increased risk of dementia (chapter four). In a 
French cohort study, which found an association between visit-to-visit variability and risk 
of dementia, the AHM class effect appeared independent of BP variability.67,78 Another way 
to define BP control is by looking at the biological half-life of different AHM, as drugs with 
a longer biological half-life probably give a more stable BP control and this may potentially 
lower the risk of dementia.211 We have assessed this within the Prevention of Dementia by 
Intensive Vascular Care (preDIVA) study population with AHM at baseline, by comparing 
participants using AHM with a longer half-life, to participants using AHM with a shorter 
half-life (divided at the median half-life). Participants using AHM with a longer half-life did 
not have a lower risk of dementia (hazard ratio 0.96, 95% confidence interval 0.66-1.39; 
unpublished data). Based on these findings, the association between CCBs and/or ARBs and 
dementia does not appear to be the consequence of a difference in stability of BP control, 
thereby increasing the likelihood that there is indeed a physiological class effect. 
Currently, researchers study the class-specific effect of AHM on dementia and cognitive 
decline with a systematic review and harmonised meta-analysis of observational studies 
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and RCTs.212 This meta-analysis will address class-specific effects in a larger and more diverse 
study population. However, confounding by indication is still an important potential source 
of bias, as mainly observational studies are included.213 An RCT on potential AHM class effects 
on dementia risk is required to make conclusive recommendations for clinical practice (as 
described in further detail in the final paragraph of this chapter). 
MRI characteristics as intermediate marker
Cerebral SVD has been identified as mediator in the association between hypertension and 
cognitive impairment via atherosclerosis.214 Contrary to the previously mentioned neutral 
findings of BP-lowering interventions to prevent dementia (chapter two), we found 
that AHM could prevent progression of white matter hyperintensities (WMH), one of the 
markers of cerebral SVD (chapter nine). An effect of AHM on brain atrophy could not be 
found and no trials assessed the effect on the other markers of SVD (lacunes, microbleeds, 
enlarged perivascular spaces and acute small subcortical infarcts). A similar WMH-dementia 
mismatch  was seen in the Evaluation of Vascular Care in Alzheimer’s Disease (EVA) trial,215 with 
a beneficial effect of vascular care on WMH progression in patients with early Alzheimer’s 
disease and cerebrovascular lesions, but no effect on cognition or disability. Results from 
the preDIVA magnetic resonance imaging (MRI) sub-study (preDIVA-M) were in line with 
the primary results of the preDIVA trial, showing no effect of the intervention on WMH 
progression.202 Secondary analyses in preDIVA-M suggested that treatment effect was 
larger in participants with higher WMH volume at baseline. 
It is intriguing that despite the effect of AHM on (one of) the mediator(s) no effect on 
dementia was found. Perhaps influencing only one marker of cerebrovascular pathology 
is not sufficient to yield a clinical effect, especially since dementia in older persons is 
often associated with mixed neurodegenerative and cerebrovascular pathology. In our 
systematic review in chapter two many trials had an intervention duration <5 years, which 
may be too short to detect an effect on dementia, while a two to four year follow-up seems 
adequate to detect an effect on WMH (chapter nine). Finally, competing risk of death may 
have influenced the results on dementia more than on WMH. BP-lowering interventions 
decrease the risk of mortality and therefore cause an imbalance in the number, and possibly 
also the age and cardiovascular risk, of people at risk of dementia or WMH progression. 
This selective dropout may have a stronger effect on the dementia analysis as this requires 
longer follow-up. 
The preDIVA-M substudy provides the opportunity to explore some of our hypothesized 
mechanisms proposed in chapter three and four on the association of dementia with 
different AHM-classes and visit-to-visit BP variability. One of the pathways that potentially 
accounts for the association between CCBs and/or ARBs and dementia in chapter three is 
an increase in cerebrovascular perfusion.59 With the MRI data of preDIVA-M we were able to 
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assess the level of cerebral perfusion in participants with specific AHM-classes. Although the 
number of participants using CCBs or ARBs was small (n=35), a substantially higher cerebral 
perfusion was found in comparison to participants using other AHM (unpublished). CCBs 
and ARBs are also suggested to influence amyloid β depositions. A brain autopsy study 
showed that ARB use was associated with less amyloid depositions.216 Similar autopsy 
studies are not available for CCBs.59 In chapter four we found that high visit-to-visit BP 
variability was not associated with a higher risk of incident dementia. Our results are in 
contrast with two other observational studies where an association between visit-to-visit 
or day-to-day BP variability and dementia was found.78,217 One of the potential pathways 
of this association would be that BP variability causes microvascular damage which leads 
to atherosclerosis and ultimately (progression of) cerebral SVD. Within the preDIVA-M sub-
study, we found an association between visit-to-visit BP variability and WMH progression (β 
0.04; 95% CI 0.01-0.07; p-value<0.01; unpublished data). Another possible explanation may 
be that arterial stiffness causes a higher BP variability and higher risk of dementia, as it is 
associated with amyloid β depositions.85
Potential disadvantages of a low or declining BP
Observational studies indicate a J-shaped association between BP and several measures of 
poor outcome, such as cardiovascular disease (CVD), cognitive decline and mortality (see 
also chapter one, Figure 1).20,207,218 Whether a low BP is indeed causally related to a higher 
risk of poor outcome, is only known for diastolic BP and ischemic coronary heart disease; 
this is conceivable, as coronary perfusion occurs mainly during diastole.207 It is less evident 
whether such a causal relation is also present for systolic BP or with different outcome 
measures. A recent individual participant data (IPD) meta-analysis based on two RCTs 
among almost 14 thousand participants, showed that people treated with a target systolic 
BP <120 mmHg had a lower risk of CVD within three years than those with a target systolic 
BP <140 mmHg.219 Interestingly, the investigators found that the extent of the deviation 
from the target BP was an important marker for CVD in both treatment arms. This supports 
the reverse causality-hypothesis, which states that a low or declining BP is a marker of 
unfavourable patient characteristics and, with that, marker of poor outcome. The reverse 
causality-hypothesis is also supported by studies on BP trajectories, which show that BP 
already declined 14 to 18 years prior to death or dementia.75,220 It is not yet known whether 
such a decline is still amenable to treatment. 
The optimal BP treatment for people in late life is unknown. Trials have shown that AHM 
can still prevent CVD and mortality in older people and that a target systolic BP as low as 
<120 mmHg may be preferable.92,94 However, the generalizability of these trial populations 
to the general population, including multi-morbid and frail people, is questionable as it is 
often a selection of healthier older people.221 Also, with increasing age, treatment priorities 
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shift from preventing morbidity and mortality to maintaining quality of life and functional 
independence.222 To study how GPs deal with the uncertainties regarding optimal BP 
treatment for people in late life, we interviewed fifteen Dutch GPs (chapter five). We explored 
their routines and considerations when prescribing and deprescribing (decreasing dosages 
or discontinuing) AHM. GPs indicated that they often continued AHM and felt restrained 
in deprescribing. Factors that influenced this restrained approach in reducing AHM were 
anticipated regret (that is, fear to ‘cause’ a stroke by deprescribing) and the feeling that 
continuation of treatment required less justification. GPs felt insufficient guidance from 
current guidelines and they would appreciate clear indicators for deprescription. 
The evidence to deprescribe AHM remains limited. A trial published in the 1990’s showed 
that discontinuation of long-term diuretic use increases the risk of heart failure within six 
months.223 In the 20 years thereafter no new trials were published, until 2015 when the 
Discontinuation of Antihypertensive Treatment in Elderly People (DANTE) trial was published.24 
In this RCT AHM was discontinued or continued among people 75 years and older with 
mild cognitive deficits. Within a relative short follow-up period of 16 weeks, no benefit on 
cognitive, psychological, or general daily functioning was seen, but overall deprescription 
was safe during the short study period. A recent Cochrane review confirmed the limited 
available evidence on the effectiveness of AHM withdrawal on cognitive decline.23 For 
clearer directives, a deprescription trial with a longer follow-up duration and careful event 
and outcome monitoring is required. Such a trial could, for example, include frail older 
adults or older people with a decreasing BP despite stable AHM use. Deprescription in 
combination with lifestyle advice seems preferable.224 Outcome measures such as those 
used in the DANTE trial are probably most appropriate, as cognitive, psychological and 
physical functioning are of increasing importance with increasing age and they can be 
affected by a cardiovascular event. 
Clinical implications
Our two systematic reviews on the efficacy of BP-lowering interventions to prevent dementia 
(chapter two) and cerebral SVD (chapter nine) will not directly change clinical practice, as 
BP-lowering interventions are already widely implemented to prevent CVD and mortality. 
More guidance is required on the indication, intensity and method of BP treatment for older 
people (chapter five). The current cardiovascular risk management guideline for Dutch 
GPs supports diuretics or CCBs as first choice treatment for older people.106 The results as 
presented in chapter three may suggest CCBs should be favoured over diuretics. However, 
as this result is based on an observational study and there is also observational evidence in 
favour of diuretics,67 there appears to be insufficient evidence to recommend changes to the 
current guideline. A trial with head-to-head comparison of AHM classes among older people 
could yield more evidence for a better-balanced choice for either AHM class (as described 
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in further detail in the final paragraph of this chapter). Evidence on the association between 
high visit-to-visit BP variability and an increased risk of CVD (chapter four) is consistent 
in current literature.27 Although a causal relation is not yet established, taking visit-to-visit 
variations in BP into account to minimize variability appears rational. Such an approach could 
also alert physicians to a declining BP, which is associated with poor outcome. BP variability 
or a declining BP are currently not taken into account by Dutch GPs when (de)prescribing 
AHM (unpublished data from the interviews presented in chapter five). In chapter five we 
showed that the uncertainty about the net benefit of AHM deprescription, GPs’ propensity 
to continue prescribing unchanged fuelled. As approximately a third of people in late 
life receive potentially inappropriate medication,225 more support in making the decision 
to reduce AHM is necessary. While an AHM deprescription trial with longer follow-up is 
needed to provide clearer evidence on the advantages and disadvantage of deprescribing, 
clinical practice could already benefit from increased awareness of the possibility to reduce 
AHM among doctors and patients. A step in this direction is the recently published Dutch 
guideline that states deprescription in frail older adults should be considered in case of 
possible side-effects or limited life expectancy.226 Shared decision making can aid in making 
better-informed decisions, by discussing the pros and cons of treatment with the patient 
and inquiring patients’ wishes and priorities. Patients have indicated to appreciate such an 
open conversation about medication use.227 
PART II – METHODOLOGICAL CHALLENGES IN PREVENTION TRIALS
Methodological considerations in the preDIVA trial
In the preDIVA trial no overall beneficial effect was found of intensive vascular care, among 
community-dwelling older people, on the primary outcome dementia and secondary 
clinical outcomes CVD and mortality.16 One potential explanation for the neutral result is 
limited contrast between the intervention and control group. In particular, a pronounced 
decrease in systolic BP of 15-20 mmHg after baseline was observed in both treatment groups. 
This could have been caused by an improvement in the standard level of cardiovascular 
care during the trial, with a stronger focus on primary prevention after the 2011 guideline 
update.106 Another explanation for the pronounced BP decline was that GPs were notified 
when a high BP was observed, which was the case in approximately three quarters of 
the participants at baseline,62 and they probably acted accordingly. As it is considered 
unethical to not notify participants and/or their physician when an un(der)treated risk 
factor is detected, the only way to avert this is by not measuring BP at baseline. Hawthorne 
effects could have also influenced the results, which indicates that participants and health 
care providers could have changed their behaviour simply because they participated in a 
study.228 Additionally, the preDIVA population could have been too old for the intervention 
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to have a preventive effect. The optimal timing for a dementia prevention trial is unclear. 
The window of opportunity decreases with increasing age, while the incidence of dementia 
increases.28 
Another potential explanation for the neutral result of preDIVA is the unselected population 
at baseline, including participants with a low and high dementia risk. Although this is a 
pragmatic choice that improves generalizability and opportunities for implementation, it 
reduces the preventive room for improvement, as it is not possible to substantially reduce 
a risk that is already low. In a predefined subgroup analysis, a significant beneficial effect 
of the intervention on dementia incidence was found among participants with untreated 
hypertension at baseline who were adherent to the subsequent intervention.16 In chapter 
six we assessed whether we could also find such a responsive group by selecting 
participants based a dementia risk score with multiple modifiable risk factors, the LIfestyle 
for BRAin health (LIBRA) index.12 Contrary to our hypothesis, we found a trend towards a 
beneficial effect in participants with a low LIBRA index. Certainly this small effect should not 
be over-interpreted, but an interesting hypothesis may be that a high modifiable risk does 
not necessarily mean there is a high potential for change. A score designed as selection 
tool for prevention trials should combine a risk estimation with an estimation on whether 
adequate care is given for those risk factors (that is, their potential for change). That way a 
person with a systolic BP of 130 mmHg while using AHM, will less likely be recruited than a 
person with un(der)treated hypertension with a systolic BP of 160 mmHg, who may have a 
greater potential to benefit from the intervention. 
In chapter three and four we studied the preDIVA dataset as if it were an observational 
cohort. As preDIVA is an RCT, these analyses may have suffered from various forms 
of bias. In general, external validity of RCTs is weaker than observational studies due to 
more pronounced selection bias at recruitment.172 This seems to be of limited influence 
on preDIVA due to the general population approach and limited exclusion criteria, which 
resulted in a 52% participation rate of those who were invited. Comparison of preDIVA 
characteristics at baseline with national (cohort) data suggests that the preDIVA population 
is largely representative of the Dutch general population aged 70-78 years.72 What could 
have affected the external validity of our results was selective drop-out of frail or cognitively 
impaired participants. As dementia was defined as clinical diagnosis and information on this 
outcome was available for 3454 (98%) participants,229 it is unlikely that this drop-out affected 
our primary outcome much. However, it could have influenced results on cognition and 
selection of participants for the BP variability analyses, as we could only include participants 
who were present at ≥3 visits to reliably estimate variability. This could have led to a selection 
of relatively healthy participants. Another potential source of bias is that the natural disease 
course of dementia may have been altered by the intensive vascular care and/or Hawthorne 
effect, potentially influencing the association of dementia with AHM class or BP variability. 
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Pre-defined subgroup analyses did not show any differences in the association based on 
randomisation group. However, this may be because of the limited contrast between the 
intervention and control group. 
Methodological considerations in the HATICE trial
As part of the Healthy Ageing Through Internet Counselling in the Elderly (HATICE) project, an 
international RCT assessing the effect of an interactive internet platform for cardiovascular 
self-management has taken place.17 As primary outcome the intervention effect on 
cardiovascular risk will be assessed and as one of the secondary outcomes the effect on 
cognition. In contrast to the general population approach used in the preDIVA trial, in 
the HATICE trial high-risk participants have been recruited based on the presence of ≥2 
cardiovascular risk factors (such as hypertension or lack of physical exercise), and/or a history 
of CVD, and/or a diagnosis of diabetes.17 The generalizability of the trial is strengthened 
by recruiting participants from three European countries; the Netherlands, Finland and 
France. We explored the reasons for participation in HATICE to improve recruitment of 
future trials in chapter seven.  The main reasons for participation were altruism, to improve 
one’s lifestyle and to benefit from additional medical monitoring. The interviews revealed 
interesting cross-country differences in views on health care and how this influenced the 
decision to participate. For example, Finnish participants expressed low satisfaction with 
the availability of preventive primary health care and, potentially as a result, considered the 
medical monitoring aspect of HATICE highly relevant. French participants were concerned 
for their own wellbeing with increasing age, as they viewed care for, and quality of life of, 
the oldest of old below standard. They participated in HATICE to improve the overall care 
for oldest of old. As shown in chapter eight the reason for participation was often related 
to expectations of the platform and level of initiative in using the platform, with altruistic 
participants expecting fewer personal benefits and showing a tendency to use the platform 
in a more reactive way. These and other factors that influence engagement with the 
HATICE platform were further explored in chapter eight with semi-structured interviews 
among Dutch HATICE intervention participants. For both initial and sustained engagement, 
personal contact with the coach appeared pivotal. Comparable results were also found 
in a qualitative study among preDIVA participants.148 While striving for concordant self-
management (that is, when a person is enabled to maintain a healthy lifestyle independent 
from additional support) we noticed a reactive use of the HATICE platform in response to 
emails or reminders. This could imply a level of dependence on the platform and/or their 
coach. That may not be ideal, but perhaps inevitable and could still evoke lifestyle changes 
and potentially lower the cardiovascular risk. The final end visits in the HATICE trial have 
been completed in February 2018.
175
General discussion
10
Ongoing BP trials to prevent dementia
The systematic review presented in chapter two provides a clear overview of the published 
BP trials with dementia as primary or secondary outcome. To make well-informed 
recommendations for future research we should also take into consideration the knowledge 
that will be acquired in currently ongoing trials. An important ongoing BP management 
trial with dementia, cognition and cerebral SVD as outcomes is the Systolic Blood Pressure 
Intervention Trial Memory and Cognition in Decreased Hypertension (SPRINT MIND).199 The 
SPRINT trial showed a beneficial effect of intensive BP lowering (target systolic BP <120 
mmHg versus <140 mmHg) on incident CVD and mortality in 9361 people with a systolic 
BP ≥130 mmHg at baseline and an increased cardiovascular risk, but without diabetes. 
Of all SPRINT participants data on incident dementia over five years will be gathered. In 
a subgroup also the rate of global cognitive decline and cerebral SVD progression will 
be measured.199 Intensive BP control could potentially prevent dementia, but, given the 
J-shaped association, a reverse outcome is also imaginable. It will be interesting to see if 
the results on dementia, cognition and SVD are in line with one another or present an SVD-
dementia mismatch (as previously discussed). The mixed pathology of dementia could still 
cause a mismatch, but the influence of competing risk of death might be smaller due to the 
relative young study population (mean age of 68 years at baseline). An ongoing trial that 
combines target BP with a multi-domain approach is the European Society of Hypertension-
Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial.230 This is a 3 × 
2 factorial design comparing three systolic BP targets (<125 mmHg, 125-135 mmHg and 
135-145 mmHg) and two low-density lipoprotein cholesterol targets (<1.8 mmol/L and 
1.8-2.8 mmol/L). 7500 patients aged ≥65 years with hypertension and a recent stroke or 
transient ischemic attack will be included. The primary outcome is stroke after four years 
and secondary outcomes are dementia and cognitive decline. An ongoing trial that might 
give more insight into the class-specific effect of CCBs is the Nimodipine Preventing Cognitive 
Impairment in Ischemic Cerebrovascular Events (NICE) trial.231 This Chinese trial assesses the 
effect of nimodipine in the acute phase after an ischemic stroke to prevent mild cognitive 
impairment at six months. Their hypothesis is that nimodipine can increase cerebral 
perfusion and thereby reduce neurological deficits after acute ischemia. This may, however, 
not be the same protective mechanism as that in the general population of older people. 
Intermediate outcome measures
PreDIVA is the first prevention trial with dementia as primary outcome. This is generally 
deemed too challenging as, due to the slow disease process of dementia, such trials need 
a relative long follow-up duration and large sample size to detect an effect. Most of the 
ongoing and future trials will therefore only include dementia as secondary outcome 
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measure and will most likely be underpowered to demonstrate an effect. Therefore, to 
come to more robust conclusions on the effects of cardiovascular prevention on dementia 
incidence, combining the data of several trials in a meta-analysis, preferably an IPD meta-
analysis, may be the best way forward. The HATICE consortium has laid the groundwork for 
such an IPD by creating a shared data platform with preDIVA, Finnish Geriatric Intervention 
Study to Prevent Cognitive Impairment and Disability (FINGER) and Multidomain Alzheimer 
Preventive Trial (MAPT).14,15,232 When long-term follow-up on dementia becomes available 
from FINGER and MAPT, the first IPD meta-analysis on prevention of dementia can be 
performed. In such an IPD meta-analysis a competing risk analysis can be performed to give 
more insight into competing risk of death as potential source of bias, which we were not 
able to do in our meta-analysis with aggregated data (chapter two).
Given the restrictions on using dementia as primary outcome, researchers have the difficult 
task of choosing an intermediate outcome measure for prevention trials with relatively short 
follow-up periods. In the HATICE trial a composite score including systolic BP, body-mass 
index and low-density lipoprotein cholesterol was chosen as primary outcome measure.17 
Arguments in favour of choosing this composite score are that it captures the intervention 
targets that are objectively measurable, no existing cardiovascular risk score was deemed 
appropriate for this population, and an intervention effect could be measurable within 18 
months. This in contrast to, for example, an effect on CVD which would be a clinically more 
relevant endpoint. Another, more often used, intermediate outcome is cognitive function. 
As cognitive decline is one of the core symptoms preceding dementia, it seems rational to 
use this as an intermediate outcome measure, but interpretation can be challenging due to 
a poor signal to noise ratio or learning effects, especially when cognitive training is included 
in the intervention. In addition it is unclear which cognitive tests are best suited for dementia 
prevention trials. Cognition can be measured with short, global tests such as the Mini-
Mental State Examination (MMSE), however the MMSE is designed as screening instrument 
rather than a test to measure change of cognition over time and is not very specific. Use 
of the MMSE in more sensitive analyses, such as the linear mixed-models used in chapter 
four and six, can show small differences that may be statistically significant but are likely 
not clinically relevant.64 An extensive neuropsychological test battery is time consuming 
and could be considered burdensome. To limit the burden on participants a composite 
score could be used including only a few cognitive tests sensitive to early symptoms of 
dementia.233 Finally, markers of cerebral SVD have been proposed as intermediate outcome. 
As the causal pathway of cardiovascular risk reduction to prevent dementia is likely mediated 
by cerebrovascular lesions, it would seem plausible to use cerebral SVD as intermediate 
outcome. In chapter nine we have shown that AHM can prevent progression of WMH. 
Before WMH can be reliably used as intermediate outcome measure, it should be confirmed 
that an effect on WMH progression is a proxy for an effect on dementia. Additionally, as an 
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MRI scan is not always easily available, is costly and can be a burden on participants, one of 
the other more pragmatic outcome measures might be preferable.
Towards a future prevention trial
I would like to conclude this chapter by making recommendations for the design of a future 
dementia prevention trial, based on the knowledge acquired in this thesis. In my opinion an 
RCT studying the class-specific effect of CCBs would be most valuable. Assessing the effect 
of CCBs instead of ARBs seems more feasible and relevant to daily practice, as the preferred 
first-choice AHM classes for older people without a history of CVD are diuretics or CCBs 
(based on the Dutch cardiovascular risk management guideline).106 In clinical practice Dutch 
GPs do not appear to have clear preference for a specific AHM class and treatment choices 
are mainly based on previous experiences with specific drugs (unpublished data from the 
interviews presented in chapter five). A randomised intervention with CCBs, therefore, seems 
achievable. As dihydropyridine CCBs, such as amlodipine and nifedipine, can effectively 
penetrate the blood-brain barrier these would be preferable to a non-dihydropyridine CCB 
such as verapamil.70 Choice of the control condition is more difficult. An option is to take any 
other AHM as control condition and leave it up to the treating physician which AHM class 
(other than CCBs) to choose, as the clinically most relevant question is what the preferred 
AHM class would be when AHM is indicated. This will probably most often be diuretics, as 
these are equal in rank to CCBs from the perspective of hypertension treatment. However, as 
diuretics have also been associated with a lower risk of dementia in observational studies,67 
this may limit the contrast between the intervention and control group. A different option 
would be to select another AHM class as control condition, such as angiotensin converting 
enzyme (ACE) inhibitors, as these are the recommended second choice AHM class and 
have comparable effectiveness in preventing cardiovascular events.106,234 Even though, 
the preDIVA and HATICE trial both assessed the efficacy of a multi-domain intervention 
targeting multiple cardiovascular risk factors, I would propose to restrict this intervention 
to this single-domain. The rationale behind a multi-domain intervention is that dementia is 
a multi-factorial disorder, lifestyle interventions for the different cardiovascular risk factors 
largely overlap, and the different components might have synergistic effects. The proposed 
CCB trial is, however, not a lifestyle intervention and there are no theoretical grounds that 
indicate a synergistic effect. With a single-domain intervention we will be able to draw firm 
conclusions on the presence of a class-effect and not have a ‘black box’ problem of not 
knowing what part of the intervention was effective. 
With regard to the choice of the target population, I would recommend to stay as close to 
clinical practice as possible. In this case that would be to include both people who use AHM 
and for whom addition of a new antihypertensive drug is indicated, as well as people who 
have an indication to start AHM. This could be people with or without a history of CVD as, on 
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the one hand, selection of a high-risk group in a dementia prevention trial is recommended, 
but on the other hand our subgroup analyses in chapter three showed more benefit of 
CCBs in people without a history of CVD. The exact age range to apply as inclusion criteria is 
arbitrary. Most AHM class evidence is available for older people,58 although any intervention 
effect will probably decrease with increasing age.28 For optimal comparison, it may be 
rational to align the age range of this CCB trial to the range used in the preDIVA trial (70-78 
years), as this is the population were we found our association with CCBs (chapter three). 
A somewhat younger population (65-75 years) may also be appropriate as we assessed 
AHM classes in participants who probably already used their AHM for several years. The only 
exclusion criteria for the trial would be the presence of dementia or another disorder likely 
to hinder successful follow-up. As GPs prescribe the vast majority of medication for primary 
and secondary prevention,235 recruitment via GP practices would be preferable. Recruitment 
dependent on the active cooperation of the treating physician is known to be difficult, 
mainly due to time constraints, and can be facilitated by a study nurse.236 Recruitment in 
different countries could be considered to enhance generalizability, although this may be 
difficult to achieve due to large differences in cross-country primary care systems. 
Incident all-cause dementia remains the preferred primary outcome measure for trials 
aimed at reducing cardiovascular risk to prevent dementia. A minimal follow-up period of 
five years is probably required to demonstrate any impact on the slow disease process of 
dementia.51 If we base a sample calculation on the treatment effect, population age, follow-
up duration and lost to follow-up of preDIVA (with 80% power and a significance level of 
0.05%) we would have to include approximately 1450 participants. However, if you lower 
the population age to 65-75 years the required sample size increases to approximately 
4300 participants, as mean incidence rates are much lower in this age group (1-3 per 
1000 person-years).73 If such a follow-up length and/or large sample size is not possible, 
an intermediate outcome measure should be chosen. Based on this thesis WMH would 
seem like a useful intermediate outcome for prevention trials. However, as the causal 
pathway of the beneficial effect of CCBs is via cerebral perfusion, production of amyloid 
β or neurofibrillary tangles, or neuronal cell death, for this CCB trial WMH as intermediate 
outcome would not make sense.59 In the ongoing Nilvadipine in Mild-to-Moderate Alzheimer’s 
disease (NILVAD) trial the effect of the CCB nilvadipine in patients with mild to moderate 
Alzheimer’s disease on cognition is studied.237 One of the secondary outcome measures of 
this trial is cerebral blood flow.238 This trial will provide information on whether the use of 
CCBs can influence cerebral blood flow in this population and whether this, in turn, leads to 
an effect on cognition. Whether this result is then also applicable for older people without 
Alzheimer’s disease, and thus if cerebral blood flow can be used as intermediate outcome 
measure in a primary prevention setting, needs to be assessed. Likewise a z-score of BP 
decline (comparable to the composite score used in HATICE) would not be useful, as the 
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theoretical benefit of CCBs lies beyond their BP lowering capacities. If projected incidence 
rates for dementia are too low to acquire sufficient power, the clinically most appropriate 
intermediate outcome would therefore probably be a composite cognitive score. 
In summary, based on the knowledge acquired in this thesis, I conclude that an RCT is 
warranted on the effect of CCB versus any other AHM or ACE-inhibitors on the prevention 
of dementia (or cognitive decline) in older, primary care patients. 
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With the projected increase in the number of dementia cases there is an urgent need for 
prevention. Midlife hypertension is one of the most influential risk factors for dementia 
for which a widely implemented and effective treatment is available. Blood pressure (BP) 
management could provide a good tool for prevention, but is not yet proven effective. 
In addition, the relation between BP in late life and dementia is less clear. This thesis is 
therefore focused on BP management to prevent dementia. In part I I assess the complex 
relation between BP in late life and dementia and in part II I study several methodological 
issues in dementia prevention trials. 
Several chapters in this thesis are based on the following two multi-domain prevention 
trials. Prevention of Dementia by Intensive Vascular Care (preDIVA) is a Dutch randomised 
controlled trial (RCT) on the preventive effect of intensive vascular care during six to eight 
years on incident dementia among community-dwelling people aged 70-78 years. Healthy 
Ageing Through Internet Counselling in the Elderly (HATICE) is an RCT on the effect of an 
interactive internet platform for cardiovascular self-management on the cardiovascular risk 
profile among people aged 65 years and older with an increased cardiovascular risk. 
PART I – BLOOD PRESSURE IN LATE LIFE AND DEMENTIA
In chapter two we present the results of a systematic review and meta-analysis on the effect 
of BP-lowering interventions to prevent incident dementia. We could include nine RCTs with 
a high level of evidence. Seven of the trials focused  on antihypertensive medication (AHM) 
and two on a lifestyle or combined intervention. Collectively, the RCTs reported on 57682 
participants. Among the participants receiving a BP-lowering intervention 1041 (3.6%) got 
diagnosed with dementia versus 1090 (3.8%) of the control participants, resulting in a risk 
ratio of 0.93 (95% confidence interval [CI] 0.84-1.02). BP-lowering interventions were also 
not effective when specifying dementia into the subtypes Alzheimer’s disease or vascular 
dementia. The effect was not influenced by duration of the intervention, age or systolic BP. 
An important methodological limitation is that only one trial performed a competing risk 
analysis and we could therefore not reliable assess the influence of competing risk of death 
on our results. 
We investigated whether there might be a class-specific beneficial effect of AHM in chapter 
three among the 1951 preDIVA participants with AHM at baseline. Twenty-six of the 522 
(5.1%) participant using calcium channel blockers (CCBs) got diagnosed with dementia, 
which was significantly lower than the 98 (8.5%) participants that got diagnosed with 
dementia among those using other AHM classes (hazard ratio [HR] 0.56, 95% CI 0.36-0.87). 
In addition, the number of participants using angiotensin receptor blockers (ARBs) that 
got diagnosed with dementia (20 out of 389, 5.1%) was significantly lower (HR 0.60, 95% 
CI 0.37-0.98). Use of diuretics, angiotensin converting enzyme inhibitors or beta-blockers 
was not associated with a significantly lower or higher dementia risk. The association with 
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CCBs was most evident in participants without a history of cardiovascular disease and with 
uncontrolled hypertension. Systolic BP was not significantly lower in participants using 
CCBs or ARBs. 
In chapter four we assessed the association between visit-to-visit BP variability and incident 
dementia. For this analysis we included preDIVA participants with three to five 2-yearly 
BP measurements. We could not find an association between visit-to-visit BP variability 
and all-cause dementia (HR 1.00, 95% CI 0.96-1.05). We did find that participants with the 
highest BP variability had significantly more decline in Mini-Mental State Examination 
(MMSE; beta -0.09, 95% CI -0.17 to -0.01). The clinical relevance of this small difference in 
MMSE is, however, uncertain. A higher visit-to-visit BP variability was also associated with an 
increased risk of cardiovascular disease (HR 1.07, 95% CI 1.04-1.11). 
The guidelines on BP management in older people are limited, as the optimal BP treatment 
in this population is not yet know. In chapter five we studied how Dutch general 
practitioners (GPs) deal with these indistinct directives by inquiring their routines and 
considerations on prescribing and deprescribing of AHM in older patients. During 15 semi-
structured interviews it appeared that GPs have a propensity to continue AHM and that 
they experience several constraints in starting and stopping or reducing the dosage. This is 
a consequence of daily routine influenced by time constraints and automated prescription 
routines. The reluctance in deprescribing AHM was among others influenced by GPs’ 
anticipated regret for a stroke. GPs feel current guidelines provide insufficient guidance. 
PART II – METHODOLOGICAL CHALLENGES  
IN DEMENTIA PREVENTION TRIALS
It is deemed suitable to select people with an increased dementia risk to participate in 
dementia prevention trials. The best tool to select such an at risk population is, however, 
unclear. In chapter six we assess whether a modifiable dementia risk score is a useful 
selection tool, by studying whether stratifying the preDIVA study population on LIfestyle 
for BRAin health (LIBRA) index at baseline selects those susceptible to the intervention. Our 
study showed that the intervention was not more effective in preventing dementia among 
people with a low (HR 0.71, 95% CI 0.45-1.12), intermediate (HR 1.06, 95% CI 0.66-1.69) or 
high (HR 1.02, 95% CI 0.64-1.62) LIBRA index. This did not improve when including the non-
modifiable risk factors age, education and sex to the LIBRA index. The intervention was also 
not effective in preventing cognitive decline in people with a low, intermediate or high 
modifiable dementia risk. 
In chapter seven we explored the reasons for participating in HATICE. With a mixed-method 
approach we combined quantitative data from online questionnaires with qualitative data 
from semi-structured interviews. Participants indicated their main motives for participation 
were wanting to benefit science, wanting to improve one’s lifestyle and benefiting from 
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additional medical monitoring. Interesting cross-country differences became apparent 
influenced by societal and healthcare differences. The underlying motivation to participate 
was preventing dependency.
Long-term adherence to lifestyle changes is difficult to attain and is crucial for cardiovascular 
prevention. In chapter eight we present results of a qualitative study among Dutch 
intervention participants of the HATICE trial. During 17 semi-structured interviews we 
have explored older people’s experiences with initial and sustained use of the HATICE 
platform. Participants indicated that human support of their coach was crucial for initial and 
sustained engagement. Regular automatic and personal reminders also facilitated platform 
use, however it is unclear whether this also leads to sustained self-management. Increased 
tailoring of the platform to personal preference could further facilitate engagement. 
Implementation of such an eHealth intervention is likely most successful if incorporated in 
the existing cardiovascular prevention programs in primary care.
Cerebral small vessel disease (SVD) has been proposed as intermediate outcome 
measure in dementia prevention trials, as it is a mediator in the causal pathway between 
hypertension and dementia. Cerebral SVD is an aggregate term for the neuroradiological 
markers white matter hyperintensities (WMH), lacunes, microbleeds, enlarged perivascular 
spaces, acute small subcortical infarcts and brain atrophy. To assess whether AHM can 
prevent (progression of) cerebral SVD we performed a systematic review and meta-analysis 
(chapter nine). Four trials including 1369 participants found a significantly beneficial effect 
of AHM on the progression of WMH (standardised mean difference -0.19; 95% CI -0.32 to 
-0.06). The two trials that assessed the effect of AHM on brain atrophy found no consistent 
effect (standardised mean difference -0.04; 95% CI -0.66 to 0.58). None of the trials reported 
on the other SVD markers. WMH progression might be a useful intermediate outcome 
for dementia prevention trials. However, before WMH can reliable be used as outcome 
measure, an effect on relevant clinical outcomes should be established. 
CONCLUSION
The studies in this thesis have shown that BP-lowering interventions, with AHM and/or 
lifestyle changes, do not significantly reduce the risk of dementia. Specific classes of AHM 
(namely, calcium channel blockers and angiotensin receptor blockers) are associated with 
a lower risk of dementia. A high BP variability is not associated with an increased risk of 
dementia. Dutch GPs have a tendency to continue AHM and are reluctant in starting and 
deprescribing. There are many methodological challenges in dementia prevention trials. 
We have shown that selecting participants based on a modifiable dementia risk score may 
not be useful. For long-term adherence to an eHealth lifestyle intervention, human support 
by a coach is crucial. AHM can effectively prevent progression of WMH, a marker of cerebral 
SVD. 
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Preventie van dementie, ook wel het vóórkomen van dementie, is urgent door de verwachte 
toename in het aantal mensen met dementie. Hypertensie (een te hoge bloeddruk) op 
middelbare leeftijd is een van de belangrijkste risicofactoren voor dementie, waarvoor een 
effectieve en wereldwijd toepasbare behandeling beschikbaar is. Bloeddruk behandeling 
zou dan ook een geschikte manier kunnen zijn voor de preventie van dementie, maar 
dit is nog niet bewezen. Daarnaast is de relatie tussen bloeddruk op oudere leeftijd en 
dementie minder duidelijk. Dit proefschrift gaat over bloeddruk behandeling ter preventie 
van dementie. In deel I heb ik me gericht op de complexe relatie tussen bloeddruk op 
oudere leeftijd en dementie en in deel II op verschillende methodologische problemen in 
dementie preventie onderzoek.
Enkele hoofdstukken in dit proefschrift zijn gebaseerd op de wetenschappelijke onderzoeken 
PreDIVA (“Prevention of Dementia by Intensive Vascular Care”) en HATICE (“Healthy Ageing 
Through Internet Counselling in the Elderly”). Voor deze onderzoeken worden deelnemers 
gerandomiseerd (geloot) tot een groep waarbij risicofactoren op hart- en vaatziekten (HVZ), 
zoals hoge bloeddruk en overgewicht, verbeterd worden of tot een controle groep die 
deze behandeling niet krijgt. PreDIVA is een Nederlands onderzoek onder mensen tussen 
70 en 78 jaar waar de behandeling bestaat uit een bezoek aan een praktijkondersteuner 
elke drie maanden. Na zes tot acht jaar is er gekeken of er in de behandelde groep minder 
deelnemers dement zijn geworden. HATICE is een onderzoek in Finland, Frankrijk en 
Nederland waar de behandeling het gebruik van een interactief internet platform is met als 
doel het verbeteren van de leefstijl gedurende 1,5 jaar. 
DEEL I – BLOEDDRUK OP OUDERE LEEFTIJD EN DEMENTIE
In hoofdstuk twee beschrijven we een systematische review en meta-analyse naar het 
effect van bloeddruk verlagende behandeling ter preventie van dementie. Hiervoor 
konden negen gerandomiseerde onderzoeken meegenomen worden in de analyses. 
Zeven onderzoeken keken naar het effect van bloeddruk verlagende medicatie (ook wel 
antihypertensiva genoemd) en twee naar een leefstijl of gecombineerde behandeling. De 
negen onderzoeken tezamen hadden bijna 58 duizend deelnemers. In de groep deelnemers 
die de bloeddruk verlagende behandeling kreeg werd 3.6% dement en van de controle 
groep 3.8%. Dit verschil was niet statistisch significant, en kan dus op kans berusten. Ook 
zagen we geen effect van bloeddruk verlagende behandeling op de specifieke subtypen 
van dementie, de ziekte van Alzheimer of vasculaire dementie. Het effect werd niet 
beïnvloed door de duur van het onderzoek, leeftijd van de deelnemers of hoogte van de 
bloeddruk. Een belangrijk methodologisch bezwaar van de meta-analyse is dat we geen 
rekening hebben kunnen houden met het concurrerend risico op overlijden. Bloeddruk 
verlagende behandeling kan immers het risico op overlijden verlagen, maar daardoor zijn 
er in die groep wel meer mensen in leven die dement kunnen worden.  
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In hoofdstuk drie hebben we bekeken of het op het dementie risico uitmaakt welk 
soort antihypertensivum iemand krijgt. De meeste antihypertensiva vallen binnen één 
van de volgende vijf klassen: diuretica, β-blokkers, calcium antagonisten, ACE-remmers 
en angiotensine receptor blokkers. Deze onderzoeksvraag hebben we onderzocht onder 
1951 preDIVA deelnemers met antihypertensiva. Van de 522 deelnemers met calcium 
antagonisten kreeg 5% dementie, terwijl dit 8% was onder de deelnemers met een ander 
type antihypertensivum. Dit verschil was statistisch significant. Het percentage mensen met 
dementie was ook significant lager onder de 389 deelnemers die angiotensine receptor 
blokkers gebruikten (5%). De associatie met calcium antagonisten was het sterkste onder 
deelnemers zonder voorgeschiedenis HVZ en met niet goed gecontroleerde hypertensie. De 
gemiddelde bloeddruk van deelnemers met calcium antagonisten of angiotensine receptor 
blokkers was gelijk aan de bloeddruk van deelnemers met een ander antihypertensivum. 
In hoofdstuk vier hebben we bekeken of het risico op dementie hoger is onder mensen 
met veel wisselingen in bloeddruk, wat ook wel bloeddruk variabiliteit wordt genoemd. 
Deze vraag hebben we bekeken onder preDIVA deelnemers met drie tot vijf 2-jaarlijkse 
bloeddruk metingen. Binnen deze groep konden we geen verband tussen bloeddruk 
variabiliteit en dementie vinden. We vonden wel dat mensen met een hoge bloeddruk 
variabiliteit een sterkere afname in cognitie (geheugen, denken etc.) hadden. Dit was echter 
maar een klein verschil op een vrij grove test. Het is dan ook de vraag of dit significante 
verschil ook relevant is voor het individu. Er was een verband tussen een hogere bloeddruk 
variabiliteit een hoger risico op HVZ. 
De richtlijnen voor bloeddruk behandeling van ouderen zijn beperkt, omdat het nog niet 
bekend is hoe je deze groep het beste kan behandelen. In hoofdstuk vijf onderzochten 
we hoe Nederlandse huisartsen met deze onduidelijkheid omgaan in de dagelijkse 
praktijk door ze te vragen naar hun routines en overwegingen bij het voorschrijven van 
antihypertensiva. Met behulp van 15 interviews werd duidelijk dat huisartsen een neiging 
hebben om antihypertensiva voor te blijven schrijven en dat ze terughoudend zijn in het 
starten en afbouwen of stoppen. Dit is een gevolg van de dagelijkse routine met beperkte 
tijd en geautomatiseerde voorschrijf routines. De terughoudendheid in het afbouwen van 
antihypertensiva werd onder andere beïnvloed door verwachte spijt voor het ‘veroorzaken’ 
van een beroerte door medicatie af te bouwen. Huisartsen voelen zich onvoldoende 
gesteund door de huidige richtlijnen. 
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DEEL II – METHODOLOGISCHE UITDAGINGEN  
IN DEMENTIE PREVENTIE ONDERZOEK
Voor een gerandomiseerd onderzoek naar de preventie van dementie is het nuttig om 
deelnemers te selecteren met een verhoogd risico op dementie. Het is alleen nog niet 
bekend wat voor selectiemiddel hiervoor het meest geschikt is. In hoofdstuk zes hebben 
we bekeken of een dementie risico score op basis van modificeerbare risicofactoren 
(risicofactoren waar we iets aan kunnen doen) een goed selectiemiddel is. Hiervoor hebben 
we preDIVA deelnemers in drie groepen verdeeld; deelnemers met een laag, gemiddeld en 
hoog risico op dementie. Het effect van intensieve vaatzorg op de preventie van dementie 
verschilde niet in de drie groepen. Het leek zelfs zo dat de vaatzorg effectiever was in de laag 
risico groep, al was dat verschil niet significant. Het maakte hierbij niet uit of de risicoscore 
alleen modificeerbare risicofactoren bevatte of ook de niet-modificeerbare risicofactoren 
leeftijd, geslacht en opleidingsniveau. Intensieve vaatzorg was ook niet effectief in het 
vóórkomen van cognitieve achteruitgang in de drie groepen. 
In hoofdstuk zeven hebben we de redenen voor deelname aan HATICE onderzocht. 
Hiervoor hebben we resultaten van online vragenlijsten gecombineerd met interviews 
onder Finse, Franse en Nederlandse HATICE deelnemers.  De deelnemers gaven aan dat 
een bijdrage aan wetenschappelijk onderzoek, de wens om hun leefstijl te verbeteren en 
aanvullende medische monitoring belangrijke redenen waren om mee te doen aan het 
onderzoek. Verschillen tussen de drie landen werden beïnvloed door maatschappelijk 
verschillen en verschillen in gezondheidszorg. Een onderliggende motivator voor deelname 
was vermijden dat ze afhankelijkheid zouden worden van anderen.
Eén van de grootste uitdagingen van behandelingen ter verbetering van de leefstijl is 
het langdurig volhouden van een goede leefstijl. In hoofdstuk acht presenteren we de 
resultaten van een interviewonderzoek onder Nederlandse HATICE deelnemers die het 
interactieve platform gebruikten. Tijdens 17 interviews hebben we deelnemers gevraagd 
naar hun ervaringen met het internet platform en wat voor hen het platform gebruik 
stimuleerde of beperkte. De deelnemers gaven aan dat met name de ondersteuning door 
de coach cruciaal was voor verbintenis aan het platform, zowel aan het begin van het 
onderzoek als op langere termijn. Ook regelmatige automatische en persoonlijke berichten 
ondersteunden het platformgebruik. Het is alleen onduidelijk of dit ook tot een verbetering 
van leefstijl kan leiden. Het platform zou kunnen verbeteren door het nog beter aan te 
passen aan individuele wensen. Deelnemers dachten dat het platform de meeste kans van 
slagen had als het opgenomen zou worden in de huidige preventie programma’s in de 
huisartspraktijk. 
Onderzoek naar de preventie van dementie wordt bemoeilijkt doordat het enkele jaren 
duurt voordat dementie zich ontwikkelt en het dus lang duurt voordat je weet of een 
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behandeling effectief is. Een goede vroege uitkomstmaat zou schade aan de kleine vaten 
in de hersenen (in het Engels ‘cerebral small vessel disease’) kunnen zijn. Die schade kan 
je zien op een scan van de hersenen door witte stof afwijkingen, kleine herseninfarcten 
en bloedingen, en afname van het hersenvolume. In hoofdstuk negen hebben we 
door middel van een systematische review en meta-analyse gekeken of antihypertensiva 
toename van dit soort schade kan vóórkomen. Vier gerandomiseerde onderzoeken met 
meer dan duizend deelnemers hebben hier naar gekeken en konden we in onze meta-
analyse meenemen. De onderzoeken lieten zien dat het gebruik van antihypertensiva de 
toename van witte stof afwijkingen kan vóórkomen. De twee onderzoeken die naar afname 
in hersenvolume hadden gekeken konden echter geen effect van antihypertensiva vinden. 
De andere kenmerken van schade aan de kleine vaten waren niet onderzocht. Voordat 
witte stof afwijkingen als vroegtijdige uitkomstmaat voor dementie preventie onderzoek 
gebruikt kan worden, moet echter wel aangetoond worden dat het preventieve effect op 
witte stof afwijkingen ook leidt tot een effect op dementie.  
CONCLUSIE
De onderzoeken in dit proefschrift hebben laten zien dat bloeddruk behandeling, door 
middel van medicatie en/of leefstijlverandering, het risico op dementie niet verlaagt. 
Wel zijn specifieke klassen antihypertensiva (calcium antagonisten en angiotensine 
receptor blokkers) geassocieerd met een lager risico op dementie. Bloeddruk variabiliteit 
is niet geassocieerd met een hoger risico op dementie. Huisartsen hebben de neiging 
antihypertensiva door te blijven schrijven in plaats van de afweging te maken om ze af te 
bouwen. Er zijn verschillende uitdagingen in het doen van dementie preventie onderzoek. 
We hebben laten zien dat het selecteren van deelnemers op basis van een dementie 
risicoscore met modificeerbare risicofactoren niet effectief is. Voor langdurige motivatie 
voor een leefstijlbehandeling via het internet is ondersteuning door een coach cruciaal. 
Antihypertensiva zijn effectief in het vóórkomen van toename in witte stof afwijkingen, een 
kenmerk van schade aan kleine vaten in de hersenen. 
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members of the research group. The data is not yet made openly available, as currently 
several secondary analyses are still ongoing. 
Qualitative data
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